Global Clinical Development -General Medicine 
LCZ696/Entresto®
Clinical Trial Protocol CLCZ696B2319 / [STUDY_ID_REMOVED]
Multicenter, open -label, study to ev aluate safety, 
tolerability , pharmacokinetics and, pharmacodynamics of 
LCZ696 follow ed by a 52-week randomized, double -blind, 
parallel group, activ e-controlled study
 to ev aluate the 
efficac y and safety of LCZ696 compared w ith enalapril in 
pediatric patients from 1 month to < 18 y ears of age w ith 
hear t failure due to sy stemic left v entricle sy stolic 
dysfunction
Document type: Amended Clinical Trial Protocol
EUDRACT number: 2015 -004207 -22, PIP02 -11-M05
Version number: 07 (Clean )
Clinical trial phase: II/III
Release date: 15-Nov-2021
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 03(August 2015)

Novartis Confidential Page 2
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 6
List of figures ...................................................................................................................... 7
List of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 11
Amendment 7 ........................................................................................................................... 12
Amendment 6 ........................................................................................................................... 14
Amendment 5 .................................................................................................................... 16
Amendment 4 .................................................................................................................... 20
Amendment 3 .................................................................................................................... 22
Amendment 2 .................................................................................................................... 24
Amendment 1 .................................................................................................................... 24
Protocol summary .............................................................................................................. 27
1Introduction ....................................................................................................................... 32
1.1 Background ............................................................................................................ 32
1.2 Purpose .................................................................................................................. 34
2Study  objectives and endpoints ......................................................................................... 34
2.1 Primary  objectives ................................................................................................. 34
2.2 Secondary  objectives ............................................................................................. 34
35
2.4 Objectives and related endpoints ........................................................................... 35
3Investigational plan ........................................................................................................... 39
3.1 Study  design ........................................................................................................... 39
3.2 Rationale for stud y design ..................................................................................... 50
3.3 Rationale for Global Rank primary  endpoint ................................ ........................ 50
3.4 Rationale for patient population ............................................................................ 54
3.5
Rationale for dose/regimen, route of administration and duration of treatment ....55
3.6 Rationale for choice of comparator ....................................................................... 57
3.7 Purpose and timing of interim anal yses/design adaptati ons
.................................. 58
3.8 Risks and benefits .................................................................................................. 58
4Population ................................ ................................ ................................ .......................... 60
4.1 Inclusion criteria .................................................................................................... 61
4.2 Exclusion criteria ................................................................................................... 61
5Treatment ................................ ................................ ................................ ........................... 63
5.1 Study  treatment ...................................................................................................... 63

Novartis Confidential Page 3
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
5.1.1 Investigational and control drugs .......................................................... 63
5.1.2 Additional treatment .............................................................................. 66
5.2 Treatment arms ...................................................................................................... 66
5.3
Treatment assignment and randomization............................................................. 67
5.4 Treatment blinding ................................................................................................. 67
5.5 Treating the patient ................................................................................................ 68
5.5.1
Patient numbering ................................................................................. 68
5.5.2 Dispensing the stud y drug ..................................................................... 68
5.5.3 Handling of study  and additional treatment .......................................... 69
5.5.4 Instructions for prescribing and taking stud y treatment ........................ 69
5.5.5 Permitted dose adjustments and interruptions of study  treatment ........ 70
5.5.6
Rescue medication ................................................................................ 72
5.5.7
Concomitant medication ....................................................................... 72
5.5.8 Prohib ited medication ........................................................................... 73
5.5.9 Emergency  breaking of assigned treatment code .................................. 73
5.6 Study  completion and discontinuation ................................................................... 74
5.6.1 Study  completion and post -study  treatment .......................................... 74
5.6.2 Discontinuation of study  treatment ....................................................... 74
5.6.3 Withdrawal of informed consent ........................................................... 75
5.6.4 Loss to follow -
up .................................................................................. 75
5.6.5 Early study termination by the sponsor ................................................. 76
6
Visit schedule and assessments ......................................................................................... 76
6.1 Information to be collected on screening failures .................................................. 86
6.2 Patient demographics/other baseline char acteristics ............................................. 86
6.3 Treatment exposure and compliance ..................................................................... 86
6.4 Efficacy .................................................................................................................. 87
6.4.1 Efficacy  assessment .............................................................................. 87
6.4.2 Secondary  efficacy  endpoints ............................................................... 90
90
6.5 Safety ..................................................................................................................... 90
6.5.1 Physical examination ............................................................................ 91
6.5.2 Vital signs .............................................................................................. 91
6.5.3 Height/length, head circumference and weight ..................................... 92
6.5.4 Laboratory  evaluations .......................................................................... 92
6.5.5 Electrocardiogram (ECG) ..................................................................... 96

Novartis Confidential Page 4
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
6.5.6 Left ventricular ejection fraction (LVEF) or fractional shorte ning 
assessments ........................................................................................... 96
6.5.7 Pregnancy  and assessments of fertility ................................................. 97
6.5.8 Angioedema .......................................................................................... 97
6.5.9 Appropriateness of safety  measurements .............................................. 98
6.6 Other assessments .................................................................................................. 98
6.6.1 Clinical outcome assessments (COAs) ................................................. 98
6.6.2 Pharmacokinetics ................................................................................ 101
7Safety  monitoring ............................................................................................................ 103
7.1 Adverse events ..................................................................................................... 103
7.2 Serious adverse events ......................................................................................... 105
7.2.1 Definition of SAE ............................................................................... 105
7.2.2 SAE reporting
...................................................................................... 106
7.3 Protocol specific unblinding rules ....................................................................... 107
7.3.1 Adverse events that are commonly  seen in the study  population .......107
7.4 Liver safety  monitoring ....................................................................................... 108
7.5 Renal safet y monitoring ....................................................................................... 109
7.6 Reporting of stud y treatment errors including misuse/abuse .............................. 109
7.7 Pregnancy  reporting ............................................................................................. 109
8Data review and database management ........................................................................... 110
8.1
Data collection..................................................................................................... 111
8.2 Database management and quality  control .......................................................... 111
8.3 Data monitoring committee (DMC) .................................................................... 111
8.4
Adjudication committee....................................................................................... 112
8.5 Part 1 PK/PD data review
.................................................................................... 112
9Data analy sis................................ ................................ ................................ .................... 113
9.1 Analy sis sets ........................................................................................................ 113
9.2
Patient demographics and other baseline characteristics..................................... 114
9.3 Treatments ........................................................................................................... 114
9.4 Analy sis of the primary  variable(s) ..................................................................... 115
9.4.1 Variable (s)........................................................................................... 115
9.4.2 Statistical model, hy pothesis, and method of anal ysis........................ 116
9.4.3 Handling of missing values/censoring/discontinuations ..................... 116
9.4.4 Sensitivity  analy ses............................................................................. 117
9.4.5 Supportive analy ses............................................................................. 117
9.5 Analy sis of secondary  variables
.......................................................................... 117

Novartis Confidential Page 5
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
9.5.1 Efficacy  variables................................................................................ 117
9.5.2 Safety
 variables ................................................................................... 118
119
9.5.4 PK/PD ................................................................................................. 119
119
9.6 Interim anal yses................................................................................................... 120
9.7
Sample size calculation........................................................................................ 121
10Ethical considerations ...................................................................................................... 123
10.1 Regulatory
 and ethical compliance ...................................................................... 123
10.2 Informed consent procedures
............................................................................... 124
10.3 Responsibilities of the I nvestigator and IRB/ IEC............................................... 124
10.4 Publication of study  protocol and results ............................................................. 124
11Protocol adherence .......................................................................................................... 125
11.1 Protocol amendments ........................................................................................... 125
12References ....................................................................................................................... 125
13Appendix 1: Clinically  notable laboratory  values and vital signs ................................... 129
14Appendix 2: L iver event a
nd laboratory  trigger definitions and follow -up 
requirements .................................................................................................................... 131
15Appendix 3: Specific renal alert criteria and actions ................................ ....................... 133
15.1 Guidelines for the management of renal dy sfunction .......................................... 134
16Appendix 4: American heart association (AHA) pedi
atric advanced life support
(PAL S) guidelines ........................................................................................................... 135
16.1
Guidelines for the management of blood pressure .............................................. 136
17Appendix 5: Treatment guidelines for elev ated potassium and hy perkalemia (serum 
potassium greater than or equal to 5.3 mmol/L )
.............................................................. 137
18Appendix 6: Reference table -blood volume by  weight ................................ ................. 139
19 Appendix 7: NYHA/Ross classification.......................................................................... 141
20
Appendix 8: Patient global impression o f severit y (PGI S)............................................. 142
143
21.1 Teen report (ages 13 -
18)...................................................................................... 143
145
21.3 Child report (ages 8 -12)....................................................................................... 147
149
21.5
Young child report (ages 5 -7).............................................................................. 151
153
155
157

Novartis Confidential Page 6
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
21.9 160
22Appendix 10: GF R by  age............................................................................................... 163
164
 
166
166
167
168
.168
.168
25Appen dix 13: Safety  Monitoring for Age Group 3 patients ............................................ 170
25.1 Safety  Monitoring for Age Group 3 patients: ...................................................... 170
26Appendix 14: Up
-titration dosing instructions for patients in Age Group 3 (1 month 
to <1 y ear at randomization) who turn 1 y ear old during Part 2 ..................................... 171
26.1 Up-titration instructions for Age Group 3 patients who turn one y ear old 
during Part 2 ........................................................................................................ 171
27Appendix 15: Urgent safety  measure (USM) .................................................................. 172
27.1 Instructions for patients impacted b y the USM ................................................... 172
27.2 USM impli cations regarding data collection and study  results ........................... 173
List of tables
Table 2
-1 Objectives and related endpoints ................................ .......................... 35
Table 3-1 Part 1: PK/PD - Minimum required pre -study  body -weight 
normalized daily  doses of commonly  prescribed ACEI s or ARBs 
that should be tolerated prior to the L CZ696 1.6 mg /kg and 3.1 
mg/kg single dose PK/PD assessment ................................ ................... 42
Table 3-2 Part 1 (PK/PD) - Visit 101, 201, and UNS PK/PD blood and urine 
sample collection ................................ ................................ ................... 44
Table 3-3 Safety  monitoring criteria for initiation/up -titration of study  drug .......46
Table 3-4 Part 2 (Efficacy ): Total daily  dose levels of commonly  prescribed 
ACEI /ARBs to guide selection of the study  medication starting 
dose ....................................................................................................... 47

Novartis Confidential Page 7
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Table 3-5 Part 2 (Effica cy): Study  drug dose levels for double -blind enalapril 
and L CZ696 for age groups 1 and 2 ...................................................... 49
Table 3
-6 Part 2(Efficacy ): Study  drug dose levels for double -blind enal april 
and L CZ696 for age group 3 ................................................................. 49
Table 5
-1 LCZ696 drug suppl y for Part 1 (PK/PD) and Part 2 (Efficacy )............ 65
Table 5-2 Enalapril drug suppl y for Part 2 (Efficacy) ........................................... 66
Table 5
-3 Prohibited treatment by  medication class ............................................. 73
Table 6
-1 Part 1 Assessment Schedule .................................................................. 78
Table 6
-2 Part 2 Asses sment Schedule .................................................................. 81
Table 6
-3 Primary  endpoint algorithm using ranked anal ysis............................... 87
Table 6-4 Laboratory  examinations ....................................................................... 93
Table 6
-5 Sparse PK Assessment Schedule Part 2 Group 2 Subset .................... 102
Table 7-1 Adverse events (AEs) com monly  seen in study  population ................ 107
Table 7-2 Guidance for capturing the study  treatment errors including 
misuse/abuse ....................................................................................... 109
Table 9
-1 Assumed percentage of patients in each category  of the primary  
efficacy  endpoint in Part 2 by  treatment group at Month 8 (Week 
32) ....................................................................................................... 122
Table 9
-2 Assumed percentage of patients in each category  of the primary  
efficacy  endpoint in Part 2 by  treatment group at Month 12 (Week 
52) ....................................................................................................... 123
Table 13
-1 Clinically  notable laboratory  values .................................................... 129
Table 13
-2 Criteria for clinically  notable vital signs ............................................. 130
Table 14
-1 Liver event and laboratory  trigger definitions .................................... 131
Table 14
-2 Follow up requirements for liver events and laboratory  triggers ........ 131
Table 15-1 Specific renal alert criteria and actions ............................................... 133
Table 16-1 5thpercentile systolic blood pressure table ......................................... 135
Table 18
-1 Reference table –blood collection volumes by  body  weight (kg) ......139
Table 22-1 GFR b y age for initiation/up -titration and exclusion criteria .............. 163
Table 26-1 Part 2 (Efficacy ): Study  drug dose level for double -blind enalapril 
and L CZ696 for Age Group 3 patients who turn 1 year old during 
the study .............................................................................................. 171
List of figures
Figure 3-1 Study  design .......................................................................................... 41
Figure 3 -
2 Global rank endpoint categories 3, 4, 5 ................................................. 53

Novartis Confidential Page 8
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
List of abbreviations
γGT Gamma -glutam yl transferase
ACEI Angiotensin converting enzy me inhibitor
AE Adverse Events
AHA American heart association
Alb Albumin
ALT Alanine aminotransferase 
ARB Angiotensin receptor blockers 
AST Aspartate aminotransferase
AT1 Angiotensin type 1
AUC Area under the curve
bid Twice a day
BMI Body mass index
BNP B-type natriuretic peptide
BP Blood pressure
BUN Blood urea nitrogen
CCB Calcium channel blocker
CEC Clinical Endpoint Committee 
CFR Code of Federal Regulations
cGMP Cyclic guanosine monophosphate
CHBP Child- bearing potential (female)
CHF Chronic heart failure
CI Confidence interval
CL or CL/F Clearance
ClinRO Clinician reported outcome
Cmax Maximum drug concentration
COA Clinical outcome assessments
CPO Countr y pharma organization
CRF Case report form
CV Cardiovascular 
CV% Coefficient of variation%
DAR Dose administration record
DMC Data monitoring committee
EC Ethics committee
ECG Electrocardiogram
ECHO Echocardiogram
ECMO Extracorporeal membrane oxygenation
EDC Electronic data capture
EF Ejection fraction
eGFR Estimated glomerular filtration rate
EMA European Medicines Agency
ENA Enalapril

Novartis Confidential Page 9
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
EU European Union
FAS Full analy sis set
FS Fractional shortening
FDA Food and Drug Administration
GMR Geometric mean ratio
HF Heart failure
HFH Heart failure hospitalization
HFrEF Heart failure reduced ejection fraction
IB Investigator brochure
ICH International Conference on Harmonisation
ICU Intensive care unit
IEC
IMPIndependent ethics committee
Investigational medicinal product
IN Investigator notification
INR International normalised ratio
IRB Institutional review board
IRT Interactive response technology
ISHLT International society for heart and lung transplantation
IUD Intrauterine device
IUS Intrauterine system
IV Intravenous
LBQ657 Active metabolite of AHU377(sacubitril)
LFT Liver function test
LOCF Last observation carried forward
LLOQ Lowest limit of quantification
LVEF Left ventricular ejection fraction
MCHC Mean corpuscular hem oglobin concentration
MCV Mean corpuscular volume
MMRM Mixed model for repeated measures
MRI Magnetic resonance imaging
MUGA Multi gated acquisition scan
NEP Neprilysin
NP Natriuretic peptide
NTproBNP N-terminal pro -brain natriuretic peptide
NYHA New York Heart Association
PBPK Physiologically based pharmacokinetic
PCR Protein -creatinine ratio
PD Pharmacodynamics
PDCO Paediatric Committee
PedsQL Pediatric Quality of Life Inventor y
PGIS Patient Global Impression of Severity
PIP Paediatric investigation plan

Novartis Confidential Page 10
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
PK Pharmacokinetics
PP Per protocol
PRO Patient reported outcome
PSD Premature subject/patient discontinuation
PT Preferred term
PVR Peripheral vascular resistance
RAAS Renin angiotensin aldosterone s ystem
RAS Renin -angiotensin system
RDW Red blood cell distribution width
SAE Serious adverse events
SAF Safety population
SAP Statistical Analysis Plan
SBP Systolic blood pressure
SUSAR Suspected unexpected serious adverse reaction
T1/2 Time required for drug concentration to decrease by half
TBL Total bilirubin
ULN Upper limits of normal
UNOS United Network for Organ Sharing
ULOQ Upper limit of quantification
UNS Unscheduled
UNS TD Unscheduled study treatment discontinuation
US United States
USM Urgent Safety Measure
VAD Ventricular assist device
WHF Worsening heart failure
WHO World Health Organization

Novartis Confidential Page 11
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Glossary  of terms
Cohort A specific group of patients/subjects fulfilling certain criteria
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug
Dosage Dose of the study treatment given to the patien t in a time unit ( e.g.100 
mg once a day, 75 mg twice a day)
Enrollment Point/time of patient entry into the study at which informe d consent 
must be obtained ( e.g. prior to starting any of the procedures 
described in the protocol)
Epoch A portion of the study which serves a specific purpose. T ypical epochs 
are: screening/recruitment, wash -out, treatment, and follow -up
Investigational drug The drug whose properties are being tested in the study; this definition 
is consistent with US CFR 2 1 Section 312.3 and is s ynon ymous with 
“investigational new drug” or “investigational medicinal product.”
Medication pack number A unique identifier on the label of each investigational drug package
Part A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: 
a single dose part and a multiple dose part, or a part in 
patients/subjects with established disease and in those wi th newly -
diagnosed disease.
Patient/subject ID A unique number assigned to each patient upon signing the informed 
consent 
Personal Data Subject information collected by the Investigator that is transferred to 
Novartis for the purpose of the clinical tr ial. This data includes subject 
identifier information, study information and biological samples.
Randomization number A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Study drug/ treatment Anysingle drug or combination of drugs administered to the patient as 
part of the required study procedures ; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy
Study Treatment 
Discontinuation (TD)When the patient permanently stops taking study treatment prior to the 
defined study treatment completion date 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being 
tested in the study
Withdrawal of consent 
(WoC)Withdrawal of study consent: Withdrawal of consent from the study 
occurs only when a subject does not want to participate in the study 
any longer, and does not allow any further collection of personal data .

Novartis Confidential Page 12
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Amendment 7
Amendment rationale
An urgent safet y measure (USM) has been implemented, effective 26October 2021, in 
consideration of a qualit y event affecting the active comparator (Enalapril) used in this study in
order to maintain the safety  of the patients and the integrit y of th isongoing study .
Recruitment closed in January  2021 and 339 of 375 randomized patients who received study 
drug, have completed or were discontinued from the study at the time the USM was issued. The 
study  is expected to be completed by earl y January 2022. Thirty -six (36) patients were ongoing 
as of 26 October 2021, of whom 5 had discontinued study  medication . Thirty
-one (31) patients 
were taking study  medication at the start of the USM .As of 31 October 2021, all patients had 
to discontinue study  drug treatment and be change dto local standard of care, respecting required 
washout periods .The changes included in this amendment in the context of the USM are 
intended to maintain the scientific integr ity of the study .
This amendment is to reflect the action taken under the USM and revise the primar y anal ysis to 
account for the USM. 
Changes to the protocol
The following changes have been made:
Section 27 Appendix 15Urgent safet y measure (USM) :Details regarding the USM , instructions 
for patient s impacted by the USM a nd USM implications regarding data collection and study 
results, are included in this Appendix.
Section
6, Table 6-2Part 2 Assessment Schedule: Changes made to assessments done at visits 
UNS/TD (Unscheduled/ Treatment discontinuation) , UNS and 416/499 for patients impacted by 
the USM ,areincluded . Two addition al footnotes, 18 and 19,have been added to clarify what 
assessments need to be done at these visits for these patients.
References to Section 27 Appendix 15Urgent safety  measure (USM) and/orSection 6, Table 
6-2Part 2 Assessment Schedule have been made in multiple sections of the protocol ,including 
the following: 
-Section 3.1 Study  design 
-Section 3.3 Rationale f or
Global R ankprimary  endpoint
-Section 6.4.1 Efficacy  Assessment 
-Section 6.6.1.2 Patient reported outcomes (PRO)
-Section 6.6.2 Pharmacokinetics, Part 2 (Efficacy )
Section 7.2.2 SAE reporting :Revised text regarding SAE reporting asrequired by  BfArM HA 
for all protocols and amendments submitted for sites in German y
Section 
9.4.2 Statistical model, hypothesis, and method of analysis: Added t ext related to USM
Section 9.4.3 Handling of missing values/censoring/discontinuations Part 2 (Efficacy ): Added 
text related to USM

Novartis Confidential Page 13
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Section 9.4.4 Sensitivity  anal yses: Added text related to USM
Section 9.5.1 Efficacy  variables Part 2 (Efficacy ): Added text related to USM
Section 9.5.3 Biomarkers: Added text related to US M 
Updates have been made to the L ist of abbreviations. 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRB/EC
A copy of this amended protocol will be sent to the Institutional Revi ew Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities.
This amendment isrequired for patient safet y(i.e.,necessary  to eliminate immediate hazards 
to the trial subjects ICH GCP 3.3.8). Therefore ,it will be implemented prior to IRB/IEC
approval , but will be sent for approval as well.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Summary  of previous amendments 
Amendment 6 (08 -Oct-2020)
Amendment 5 (18 -Sep- 2020
Amendment 4 (04 -Feb-2019)
Amendment 3 (01 -Oct
-2018)
Amendment 2- JP (05 -Sep-2017)
Amendment 2 (10 -Jul-
2017)
Amendment 1 (08 -Aug-2016)
Original protocol (19 -Nov-2015)

Novartis Confidential Page 14
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Amendment 6
Amendment rationale
The reason for this amendment is 
1)to correct a t ypographical error in the dosing regimen for enalapril for Age Group 3.
2)to align study  medication starting dose selection for Age Group 3 with Age Group s 1 
and 2, based on pr ior ACEI /ARB use.
3)to align contraception language with the current LCZ696 I nvestigator’s Brochure
4)to qualify  the follow up duration for the babies of study  participants who become 
pregnant during stud y participation
This study  is ongoing. Age Groups 1, 2 and 3 in Part 1 have been completed. In Part 2, 
recruitment is ongoing for Age Groups 1 and 2, and approximately  335 patients have been 
enrolled in the study , thus far. These change s arenot expected to influence the patient 
population or the study  results.
Changes to the protocol
The following change s have been made:
In the “Changes to the protocol ” Section of Amendmdnt 5, a further description of the 
changes that were made to the protocol with Amendment 5, is provided .
Section 3.1 Study  Design, Part 2 (Efficacy) -Randomized treatment epoch (Visit 401 to 
Visit 416/499) Table 3-4Total daily  dose levels of commonly  prescribed ACEI /ARBs 
to guide selection of the study  medication starting dose: Clarified “low”and “higher ”
ACEI /ARB doses in the text. Removed dose levels 1x through 4x of commonly 
prescribed ACEI/ARBs from Table 3
-4.
Section 3.1 Study  Design, Table 3 -6Part 2(Efficacy )Study  drug dose levels for double -
blind enalapril and LCZ6 96 for age group 3: The enalapril dose for Dose Level 2x has 
been corrected to 0.075mg/kg bid.
Section 4.2 Exclusion Criteria, Exclusion Criterion 19: Expanded contraception 
requirements per the current LCZ696 Investigator’s Brochure (i.e. contraception to 
continue for 7 day s after discontinuation of study  drug).
Section 7.7 Pregnancy Reporting: Added revised follow up requir ement (i.e. 12 months) 
after birth of the baby for participants who become pregnant during the study .
Section 10.2 Informed consent procedures: Expanded contraception requirements per 
the current LCZ 696 Investigator’s Brochure (i.e. contraception to continue for 7 days 
after discontinuation of study  drug)
Updates have been made to the List of abbreviations. Typographical and grammatical errors 
have also been corrected in various sections.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.

Novartis Confidential Page 15
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
IRB/EC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 
Summary  of previous amendments 
Amendment 5 (18 -Sep- 2020
Amendment 4 (04 -Feb-2019)
Amendment 3 (01 -Oct
-2018)
Amendment 2- JP (05 -Sep-2017)
Amendment 2 (10 -Jul-
2017)
Amendment 1 (08 -Aug-2016)
Original protocol (19 -Nov-2015)

Novartis Confidential Page 16
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Amendment 5 
Amendment rationale
The main reasons for this amendment are as follows:
Based on review of Part 1 Age Group 3 PK/PD/Safet y data, this amendment defines the 
target dose and dose regimen for Part 2 Age Group 3 to enable enrol lment into Part 2 
for Age Group 3. The planned target dose of LCZ696 2.3 mg/kg bid for Part 2 Age 
Group 3 together with the implementation of additional hy potension safet y monitoring 
for Part 2 Age Group 3during the initial up-titration phase is supported by the DMC 
and has been added to the protocol with this amendment. The DMC also supports the 
protocol changes with this amendment that enables Age Group 3 
patients who turn 1 
year old during Part 2 of the study  and who are safel y tolerating the LCZ696/placebo 
2.3mg/kg bid dose, to be able to up-titrate to LCZ696/placebo 3.1 mg/kg bid dose (the 
target dose for Age Group 2), if it is in the patient’s best interest as assessed by the 
Investigator . 
Based upon agreement with the EMA/PDCO (PIP M04) to align the age groups with 
the ICH E11 guidelines on pediatric subsets, modified age groups that will be included 
in the anal ysis.
The enrollment target of 25% ACEI /ARB naïve patients has been removed, as it is 
considered not attainable given that patients in this study  population are often initiall y 
treated with some form of RAS inhibition when first diagnosed. Ninet ypercent (90%) 
of the patients have 
been randomized thus far and only a small percentage 
(approximately  5%) of these patients are ACEI/ARB naïve.
The requirement to include 20% randomized patients per age group in the analysis of 
Part 2 has been removed
. Given the challenges of recruiting patients 1 month to  <1 year 
old (Age Group 3), it is considered not feasible to enroll 72 patients (20% of 360 patients) 
in this age group. The requirement for 80 patients with an event in Category  1 or 2 has 
also been removed. The study  is sufficiently  powered based on the Global Rank 
Endpoint and the number of patients expected to have a Category  1 or 2 event.
 
 
Patients in Age Group 2 will be required to be Ross class II or higher at randomization. 
This is based on the lower event rate observed in Age Group 2 patients vs. Age Group 
1 patients.
Measur ement of height has been clarified with a statement recommending use of a 
stadiometer for standing height measurements.
Text has been added to the protocol in order tobe able toaddress health authority 
requests for data if required for an ongoing marketing authorization application 
regulatory  review.

Novartis Confidential Page 17
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Based upon Health Authority  agreement, the rationale for collecting race and ethnicity 
data has been added to the protocol.
This study  is ongoing. Age Groups 1, 2 and 3 in Part 1 have been completed. In Part 2, 
recruitment is ongoing for Age Groups 1 and 2, and approximately  325 patients have been 
enrolled in the study , thus far.
Changes to the protocol
The following changes have been made:
Protocol Summary : Treatment Section: Added target dose level(Dose Level 4x) for Age 
Group 3. Added statement enabling Age Group 3 patients that turn 1 year old during the 
study , to be up -titrated to Group 3 Dose Level 5x(LCZ696 3.1 mg/kg bid / enalapril 0.2 
mg/kg bid). Data Anal ysis Section: Clarified age groups for Part 1 analy sis. Added 
modified age groups for Part 2 
analysis.
 
Section 3.1 Study  design: Removed enrollment target of 25% ACEI /ARB naïve patients. 
Removed requirement for 20% of the total n of 360 (72 patients) to be randomized and 
included for analysis in each age group. Removed required number of patients (80) with 
an event in Category  1 or 2 (in two places in this section). Clarified Part 1 age groups. 
Clarified target dose for Age Groups 1 and 2 (Dose Level 4)and a dded target dose level
(Dose Level 4x) for Age Group 3. Modified Table s 3-4, 3 -5 and3-6. Added safet y 
monitoring requirements for Part 2 Age Group 3 patients. Added details enabling Age 
Group 3 patients that turn 1 year old during the study, to be up -titrated to Group 3 Dose 
Level 5x (LCZ696 3.1 mg/kg bid/ enalapril 0.2 mg/kg bid). Also added a statement 
indicating that a scheduled or unscheduled visit may  be used for these up -titrations and 
added detailed criteria for up-titration . Note: References to dose level s 1 through 4
throughout the protocol have 
been changed to dose levels 1x to 4x for Age Group 3 
patients.
Section 3.1 Part 2 (Efficacy) Table 3 -4: Total dail y dose levels of commonl y prescribed 
ACEI /ARBs for purpose of comparing to dose levels of study  drug: Added Part 2 Age 
Group 3 dose levels 1x through 4x comparative ACE I/ARB doses.
Section 
3.8Risks and Benefits: Added text describing data from Part 1 Age Group 3 
and additional safet y monitoring requirements for Age Group 3 patients in Part 2.
Section 4 Population: Clarified age groups and NYHA/Ross class group for Part 2 
stratification. Removed requirement for 20% of the total n of 360 (72 patients) to be 
rando mized and included for anal ysis in each age group.
Section 4.1 Inclusion criteria: Removed the e nrollment target of 25% ACEI /ARB naïve 
patients. Removed the option for Age Group 2 patients (with a prior history  of Ross 
class II or higher) to be Ross class I at randomization. Age Group 2 patients must be 
Ross class II or higher at randomization.

Novartis Confidential Page 18
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Section 5.1.1 Study  treatment –Investigational and control drugs, Table 5-2: Added 
blister as packaging option for e nalapril tablets (2.5 mg) .
Section 
5.3Treatment assignment and randomization : Clarified age groups and 
NYHA/Ross class group for Part 2 stratification.
Section 5.5.4 Instructions for prescribing and taking study  treatment, Part 2: Clarified 
Part 2 study  drug supplies.
Section 
5.5.5 Permitted dose adjustments and interruptions of study  treatment: Clarified 
target dose for Age Groups 1 and 2 (Dose Level 4) and added target dose for Age Group 
3 (Dose Level 4x). Added safet y monitoring requirements for Age Group 3 patients in 
Part 2. 
Section 6, Table 6-2Part 2 Assessment Schedule: Footnote 6, clarified requirements 
regarding use of a Central Laboratory for laboratory  analyses. Footnote 7, added text 
clarify ing abbreviated labs for vi sits 402 and 404; added text with regard to abbreviated 
labs for Part 2 Group 3 patients who turn1 year old during the study , who are up-titrated ; 
Footnote 17, added text with regard to additional vital signs monitoring for Part 2 Group 
3 patients at the initial dose for each dose level up
-titration .
Section 6.2 Patient demographics /other baseline characteristics: Added note regarding 
rationale for coll ecting race and ethnicity  data .
Section 6.5.2 Vital Signs: Added instructions regarding additional vital sign 
meas urement requirements for Part 2 Group 3 patients
Section 6.5.3 Height/length head circumference and weight : Clarification added 
regarding measur ement of height .
Section 6.5.4 Laboratory Evaluations: added text clarify ing abbreviated labs for visits 
402 and 404 
Section 6.5.4.3 Estimated GFR: Corrected text stating that change in estimated GFR 
will be calculated from screening for local labs and from randomization for central labs.
Section 
6.5.9 Appropriateness of safet y measurements: Correction: ICH E12 should 
have been ICH E11 ( correct in the Refere nce section) .
Section 8.3 Data Monitoring Committee: Noted thatdata may be provided to Health 
Authorities, if required for an ongoing marketing authorization application regulatory 
review and Novartis w ill inform the DMC should this occur .
Section 9.2 Patient demographics and other baseline characteristics: Added modified 
age groups for anal ysis.
Section 9.3 Treatments Part 1 (PK/PD) and Treatments Part 2 (Efficacy ): Minor 
clarifications to analy sis text .
Section 9.4.1 Analy sis of the primary  variable(s) , Variables, Part 1 (PK/PD): Clarified 
PK/PD model analy sis desc ription text .

Novartis Confidential Page 19
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Section 9.4.2 Statistical model, hypothesis and method of analy sis: Added modified age 
groups and NYHA/Ross class groups andnoted that thenumber and percentage of 
patients in each categor y will be provided by  treatment group for each age group, each 
modified age group, and for overall.
Section 9.5 Anal ysis of secondary  variables : Added modified age groups for anal ysisto 
multiple subsect ions in this section and clarified the efficacy anal ysis text.
Section 12: References have been updated .
Section 
13 Appendix 1Table 13-2 Criteria for clinically  notable vital signs : Clarified 
criteria for 
clinicall y notable vital signs with the addition of missing < and ≥ signs .
Section 
25Appendix 13 Safet y Monitoring forPart 2 Age Group 3 patients: New 
Appendix added (Appendix 13)
Section 26 Appendix 14 Up-titration dosing instructions for patients in Age Group 3 (1 
month to <1 year at randomization) who turn 1 year old during Part 2: New Appendix 
added (Appendix 14 )
.
Updates have been made to the List of abbreviations. T ypographical errors have also 
been corrected in variou s sections .
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC and Health Authority 
approval according to local regulations prior to implemen tation. 
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 
Summary  of previous amendments 
Amendment 4 (04-Feb-2019)
Amendment 3 (01 -Oct-2018)
Amendment 2- JP (05 -Sep-2017)
Amendment 2 (10 -Jul-
2017)
Amendment 1 (08 -Aug-2016)
Original protocol (19 -Nov-2015)

Novartis Confidential Page 20
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Amendment 4
Amendment rationale
 
 
 
 
 
In addition, clarification is provided in this amendment regarding location alternatives if local 
requirements do not allow home urine pregnancy  testing
This study  is ongoing. In Part 1of the study , Age Groups 1 and 2 have been completed and Age 
Group 3 is ongoing. In Part 2 of the study ,approximately  144 patients have been randomized , 
thus far.
These changes will not influence the study  population or results of the study  and will not impact 
patient safet y.
Changes to the protocol
The following changes have been made:

  
  

Section 6 Visit schedule and assessments : removed the words “at home” as it relates to urine 
pregnancy  testing given the clarification added to Table 6 -2 Part 2
Table 6 -2Part 2 Assessment Schedule : Clarified footnote 5 providing location alternatives 
if local requirements do not allow home urine pregnancy  testing 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underl ined for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities.
The changes described in this amended protocol are non-substantial and do not require IRB/IEC
approval prior to implementation.

Novartis Confidential Page 21
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
The changes herei n related to the clarification regarding location alternatives for urine 
pregnancy  testing, affect the Informed Consent. Sites are required to update and submit for 
approval a revised Infor med Consent that takes into account the changes described in this 
protocol amendment. 
Summary  of previous amendments 
Amendment 3 (01 October 2018)
Amendment 2- JP (05 September 2017)
Amendment 2 (10 July  2017)
Amendment 1 (08 August 2016)
Original protoco l (19 November 2015)

Novartis Confidential Page 22
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Amendment 3
Purpose of the amendment
The main purposes of this amendment are to:
expand the examination of the exposure -response relationship for Group 3 (i.e. 1 month to 
< 1 y ear) in the Part 1 pharmacokinetic (PK)/pharmacody namic (PD) assessment. (This 
will be done by  evaluating two dose levels of LCZ696, specificall y LCZ696 0.4 mg/kg 
and L CZ696 1.6 mg/kg in Part 1 Group 3.)
add the target dose level for Group 3 in Part 2 
add sparse PK assessment at steady  state in a subset of patients in Part 2 Age Group 2 to 
further confirm the target dose for this age group
modify  the left ventricular ejection fraction (LVEF) and the fractional shortening (FS) 
inclusion threshold to expand the eligibility  range for patients
  
This study  is ongoing. Age Grou p 1 and Group 2 in Part 1 have been completed. In Part 2 
approximately  86 patients have been enrolled in the study , thus far.
These changes are not expected to influence the results of the study  or to impact patient safet y.
Changes to the protocol
The foll owing changes have been made:
For Part 1 Group 3 patients, removed the single dose level of LCZ696 0.8 mg/kg and 
replaced it with two dose levels: LCZ696 0.4 mg/kg and LCZ696 1.6 mg/kg. Inclusion 
criterion 7 has been modified accordingly . Total of approximately  4 observations per dose 
(approximately  8 in total) and a minimum of 4 patients is planned for Group 3 in Part 1.
Added the target dose level for Group 3 in Part 2 ( Table 3-6).
Updated “Exclu sion 4” and “Exclusion 7” to clarify  the applicability  only to Part 2. 
Modified “Inclusion 5"regarding left ventricular ejection fraction and the fractional 
shortening as described in 
Section 4.1.
Added “Exclusion 26” to exclude a patient that is breast fed by a mother that is using an 
ACE I. 
Updated “Exclusion 19” to clarify  the methods of contraception.
Additional pregnancy  testing (monthly ) that must be done for women of child- bearing 
potential for studie s that include study  medication where highl y effective contraception is 
required, has been added.
Changed the Abbreviated laborator yevaluation sat week s 2 and 6 from required to optional 
(seeTable 6 -2).

Novartis Confidential Page 23
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Added to Part 2 of the study , astead y-state Sparse PK blood collection visit, applicable to 
a subset of patients in Group 2 (approximately 24 patients of whom approximately  12 
patients are expected to be randomized to LCZ696 ) who agree to participate .  
 
 
 
 
 
Applies to sites in Japan only: Added a n extra clinic visit to Part 2 of the protocol at week 
1 (Visit 401JPN) in Table 6-2. 
Clarified and updated language around ACEI /ARB dosing prior to the dosing with LCZ696 
for Part 1.
Clarified and updated language around the weight measurement and visit schedule in Part 
1.
Added clarification to Section 3.1regarding additional patients in Part 1 Group 3 tobe 
evaluated if needed for dose determination for P art 2.
Added instructions regarding “plasma potassium” in Section 6.5.4.
Removed Endpoint collection from the Assessment Table for Part 1 ( Table 6
-1). E ndpoints
from Part 1 (open -label, single dose PK/PD) are not part of the efficacy  analysisand will 
not be adjudicated .
Added instructions regarding countries where blood samples cannot be shipped out of the 
country
 due to local regulations (Table 6-2).
Made c hanges to “Glossary  of Terms” and Section 5.6.3 to align with the new “Withdrawal 
of Consent” language. Corrected t ypographical errors in various sections.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using 
strike through font for deletions and underlined for insertions.
A copy of this protocol amendment will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) for all sites and Health Authorities.
The changes described in this protocol amendment require IRB/ IEC approval prior to 
implementation. In addition, as the changes herein affect the Informed Consent, sites are 
required to submit for approval an Informed Consent that takes into account the changes 
described in this amended protocol.

Novartis Confidential Page 24
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Amendment 2
Purpose of the amendment
Themain purpose of this amendment is to remove technical details pertaining to the preparation 
of liquid formulation of the st udy drugs, LCZ696 and enalapril .
These changes will not influence the study  population orresults of the study  and will not impact 
patient safet y.
Changes to the protocol
Deleted information related to liquid formulation of L CZ696 and enalapril in Part 1 and 
Part 2.
Clarified that instructions for the preparation of the liquid study  drugs are provided in the 
Pharmacy  Manual which is provided to the site/pharmacy  as a separate document .
Other clarification: Clarified the earl y stud y termination procedure ( Section 5.6.5 ) 
according to the “Detailed Guidance from the European Commission, CT -1, 4.2.2- 163”.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using 
strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol are non-substantial and do not require IRB/IEC 
approval prior to implementation.
In addition, details regarding compounding the liquid formulation will be removed from the 
Informed Consent. Sites should update and submit for approval a revised Informed Consent that 
takes into account the changes described in this amended protocol.
Amendment 1
Purpose of the amendment
All of the amendment changes are made prior to enrolling patients into the study . 
The main purpose of this amendment is to examine the exposure -response relationship for 
Groups 1 (6 to < 18 years) and 2 (1 to < 6 years) by the addition of a second (and lower )dose 
of LCZ696 (0.8 mg/kg) to the LCZ696 (3.1 mg/kg) Part 1 pharmacokinetic 
(PK)/pharmacod ynamic (PD) assessment. 
In addition, to ensure an adequate number of clinical endpoints are included in the Global Rank 
primary  endpoint in Part 2, the study  will stop when at least 80 patients have an event in 
Category  1 or 2.  
For the Global Rank primary  endpoint determination, the Pediatric Quality  of Life inventory 
(PedsQL )Physical Functioning domain will be used only for Group 1 (ages 6 to < 18 years), 

Novartis Confidential Page 25
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
since Group 1 is the only age group where all the patients will be doing a patient self-report 
PedsQL .
This amendment also adds a number of other clarification changes to the PK, PD biomarkers, 
and blood collection information; updated information about study  drugs LCZ696 and enalapril; 
updates to endpoint and adjudication information. Ther e are other changes included to add 
clarity , enhance readability , correct ty pographical errors and provide further details.
Changes to the protocol
The f ollowing changes have been made:
Added second dose to Part 1 study  design and other relevant sections. Assessment 
schedule ,Safety , PK, and PD data review ha vebeen revi sedaccordingl y. 
Total of six patients per dose for each age group is planned .  Two doses are being assessed 
in Groups 1 and 2, and o ne dose is being assessed in Group 3.
Added plasma B-type natriuretic peptide (BNP )to Part 1.  Relevant changes have been 
made to biomarker data and blood collection details.  
Detailed information about PK blood sample handling was moved to the laboratory  
manual.
Added urine cGMP (cyclic guanosine monoph osphate )collection at baseline pre -dose for 
PD assessment in Part 1.
Updated and corrected blood volumes for PK and PD sampling in Part 1.
Added information about at least 80 patients with events in Category  1 or 2.
Added safety  and tolerability  Secondary objective in Part 1.
For the PedsQL scale, the chronic version (one month recall period) was replaced with the 
acute version (7 day s recall period). 
The reason for this change is that the patient reported 
assessment of 7 day s is considered more appropriat e compared to 1 month for pediatric 
heart failure patients. Added text indicating that t he PedsQL Phy sical Functioning module 
will be used for the primary  Global Rank endpoint only  for Group 1 (6 to <18 y ears old) 
(Section 3.3 and Section 6.4.1 ).
Updated Patient Global Impression of Severit y (PGIS) age range to consistently  state 5 to 
< 7 y ears and 7 to < 18 years old, and changed ‘Very  Mild’ to ‘None’ fo r the PGI S scale.
 
Secondary  objective was clarified for “delay ing” for time to first occurrence of event.
Inclusion and exclusion criteria updated to provide further infor mation and clarity .
Added that a confirmatory serum pregnancy  test should be performed when urine 
pregnancy  test is positive ,and added serum pregnancy  test at Visit 416/499. 
Deleted biomarkers from the list of the safet y parameters in Section 6.5 as biomarkers are 
not a safet y parameter in this study .
Reference table for blood volume by  weight was updated (Appendix 6 ,Table 18-1).
Clinical events and adjudication information updated in Sections 6.4.1 andSection 9.7.

Novartis Confidential Page 26
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Added s ystolic BP 5thpercentile information for patients with age of 1 month to < 1 year 
(Appendix 4, Table 16-1) and ≥ 30% mean GFR (glomerular filtration rat e)by age table 
(Appendix 10, Table 22-1).
Updated renal safety  monitoring Section 7.5.
Added reference for FDA guidance in Section 7.3.1 for safety  reporting.
Clarified and updated language around management of study
 drug .
Typographical errors were corrected in various sections.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.

Novartis Confidential Page 27
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Protocol summary
Protocol numberCLCZ696B2319
Title Multicenter, open -label, study to evaluate safety, tolerability , 
pharmacokinetics and,pharmacodynamics of LCZ696 followed by a 52 -
week randomized, double- blind, parallel group, active -controlled study to 
evaluate the efficacy  and safety of LCZ696 compared withenalapril in 
pediatric pa tients from 1 month to < 18 years of age with heart failure due 
to systemic left ventricle systolic dysfunction
Brief title Pharmacokinetics (PK), pharmacodynamics (PD), safety and efficacy  
study of LCZ696 in children (1 month to < 18 years) with heart failure due 
to systemic left ventricle systolic dysfunction
Sponsor and clinical 
phaseNovartis; Phase 2/3 
Investigation typeDrug
Study typeInterventional 
Purpose and rationaleThe purpose of this study is to determine whether pediatric heart failure 
(HF) patients (1 month to < 18 years old) will derive greater clinical 
treatment benefit with LCZ696 compared to enalapril over 52 weeks 
treatment duration. This study includes two p arts. Part 1 will determine 
the dose for Part 2. Part 2 will assess the efficacy  and safety of LCZ696 
compared to enalapril.
Primary objective(s)Part 1: The primary  objective is to determine the 
pharmacokinetics (PK) and pharmacodynamics (PD) of LCZ696 
in pediatric HF patients
Part 2: The primary  objective is to determine whether LCZ696 is 
superior to enalapril for treatment of heart failure as assessed 
using a global rank en dpoint in pediatric HF patients
Secondary o bjectives Part 1: To assess the safety and tolerability of LCZ696 in 
pediatric patients with HF
Part 2: To determine whether LCZ696 is superior to enalapril in 
delaying time to first occurrence of the composite of either
Category 1 or2 events (e.g . death ,worsening HF)
Part 2: To determine whether LCZ696 is superior to enalapril for 
improving NYHA (New York Heart A ssociation )/Ross functional 
class
Part 2: To determine whether LCZ696 is superior to enalapril for 
improving the Patient Global Impression of Severity (PGIS) 
score
Part 2: To characterize the population PK of LCZ696 exposur e 
in pediatric patients with HF ,including an assessment of steady -
state sparse PK data in a subset of Group 2 patients
Part 2: To assess the safety and tolerability of LCZ696 
compared to enalapri l in p ediatric patients with HF
Study designThis is a multi -center study in pediatric patients (1 month to <18 years) 
with HF ( i.e. LVEF/fractional shortening criteria as describe din Inclusion 
Criterion Number 5). This study uses a seamless design which consists 
of two parts: 

Novartis Confidential Page 28
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Part 1: This is a multi -center, open -label study to characterize 
the PK and PD of LCZ696. This information will enable the 
prediction of multiple dose PK exposure and support dosage 
determin ation for Part 2 of this stu dy
Part 2: This is a 52 -week randomized, double blind, parallel -
group, active controlled, study to evaluate the efficacy, safety, 
and tolerability of LCZ696 compared to enalapril in addition to 
conventional HF treatment in pediatric patients with HF
Popul ationThe study population consists of pediatric HF patients 1 month to <18 
years, inpatient or outpatient, with s ystemic left ventricle systolic 
dysfunction; and includes at least 18 patients in Part 1 ;and randomizes 
360 patients in Part 2 at cente rs wor ldwide. For Part 1 and Part 2 , the
patients will be divided across three groups based on age : Group 1: 6 to 
<18 years ; Group 2: 1 to <6 years ; Gro up 3: 1 month to < 1 year . 
Key inclusion criteria 1.Written informed consent by parent(s)/legal guardian(s) for the 
pediatric patient must be obtained before any study -specific 
assessment is performed. A consent or assent may  also be required 
for some patients depending upon their age and local requirements
2.Male or female ,inpatient or outpatient, 1 mo nth to < 18 years of age
3.Chronic heart failure resulting from left ventricular systolic 
dysfunction, and receiving chronic HF th erapy (if not newly 
diagnosed)
4.NYHA classification II- IV (older children: 6 to <18 years old) or Ross 
CHF classification II -IV (younger children: < 6 years ol d) any time 
prior to screening
5.Systemic left ventricular ejection fraction (EF) ≤ 45% or fractional 
shortening ≤2 2.5% (assessed by most recent echocardiography, 
MRI, MUGA or left ventricular angiogram ).For Part 2, this 
assessment must be within 1 month from screening .[Note: T he study 
will target enrollment of approx imately 80% patients with a systemic 
left ventricular ejection fraction (EF) ≤ 40% or fractional shortening 
≤20% for Part 2 only].
6.Biventricular physiolo gy with systemic left ventricle
7.For Part 1 PK/PD, patients must be treated with an ACEI
(Angiotensin converting enzy me inhibitor) or ARB (Angiotensin 
receptor blockers) prior to screening. For Part 1 PK/PD, patients i n 
Group 1 and 2 must be currently treated with a daily dose equivalent 
of at least enalapril 0.2 mg/kg ( Table 3 -1) prior to the LCZ696 3.1 
mg/kg single dose assessment. For Part 1 PK/PD, patients in Group
3 must be currently treated with a daily dose equivalent of at least 
enalapril 0.1 mg/kg ( Table 3 -1) prior to the LCZ696 1.6 mg/kg single 
dose assessment
For additional information, refer to Section 4.1
Key e xclusion criteria1.Patients with single ventricle or systemic right ventricle
2.Patients listed for heart transplantation as United Network for Organ 
Sharing (UNOS) status 1A or hospitalized waiting for transplant while 
on inotropes or with ventricular assist device at time of entry into the 
study
3.Sustained or sy mptomatic dysrhythmias uncontrolled with drug or 
device therapy
4.For Part 2 only, patients that have had cardiovascular surgery or 
percutaneous in tervention to palliate or correct congenital 

Novartis Confidential Page 29
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
cardiovascular malformations within 3 months of the screening visit. 
Patients anticipated to undergo corrective heart surgery during the 12 
months after entry into Part 2.
5.Patients with unoperated obstructive or severe regurgitant valvular 
(aortic, pulmonary, or tricuspid) disease, or significant sy stemic 
ventricular outflow obstruction or aortic arch obstruction
6.Patients with restrictive or hypertrophic cardiom yopathy
7.For Part 2 only, active m yocarditis (diagnos ed with presumed or 
acute m yocarditis within 3 months of enrollment)
8.Symptomatic hypotension or blood pressures (BPs) below the 
calculated 5th percentile systolic BP (SBP) for age at screening visit 
and as described in Appendix 4
9.Renal vascular hypertension (including renal arter y stenosis)
10.Severe pulmonary hypertension (defined by pulmonary vascular 
resistance (PVR) index >6 W ood units -m2) unresponsive to 
vasodilator agents (such as oxygen, nitroprussid e or nitric oxide). 
Note measurement of PVR is not a requirement for study eligibility.
11.History or current clinical evidence of moderate -to severe obstructive 
pulm onary disease or reactive airway diseases (e.g. asthma)
12.Serum potassium >5.3 mmol/L at Visit 1 or at Visit 301
13.Patients with significant renal (eGFR calculated using the modified 
Schwartz formula < 30% mean GFR for age, Appendix 10 , Table 22 -
1); hepatic (serum aspartate aminotransferase or alanine 
aminotransferase > 3 times upper limit of normal); gastrointestinal or 
biliar y disorders (that could impair absorption, metabolism, or 
excretion of orally administered medications)
14.Concurrent terminal illness or other severe disease (e.g. acute 
lymphocy tic leukemia) or other significant laboratory values that, in 
the opinion of the Investigator, precludes study participation or 
survival
15.Patients with history of angioedema
16.Patients with allergy or hyper sensitivity to ACEI/ARB
For additional information, refer to Section 4.2
Study treatmentLCZ696
Part 1: single dose 0.8 mg/kg, 3.1 mg/kg (age Groups 1 and 2) and 0.4 
mg/kg, 1.6 mg/kg (age Group 3),(using 3.125 mg granules or liquid 
formulation )
Part 2: projected target dose 3.1 mg/kg bid for age Groups 1 and 2 (Dose 
Level 4 for Groups 1 and 2) (actual dose dependent on Part 1; us ing 3.125 
mg granules, 50 mg tablets, 100 mg tablets, 200 mg tablets or liquid
formulation ).For age Group 3, the target dose will be 2.3 mg/kg bid (Dose 
Level 4xfor Group 3 patients). In addition, Group 3 patients who turn 1 
year old during the study ,may be further up -titrated to a dose of 3.1 mg/kg 
bid (Dose Level 5xfor Age Gro up 3 patients) .See Appendix 14for details.
Enalapril
Part 1 :open -label enalapril (tablet or liquid )and 
Part 2: target dose 0.2 mg/kg bidfor Groups 1 and 2,(Dose Level 4for 
Groups 1 and 2) ; using liquid formulation, 2.5 mg tablets, 5 mg tablets, 10
mg tablets . For Group 3, the target dose will be 0.15mg/kg bid (Dose Level 

Novartis Confidential Page 30
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
4xfor Group 3 patients). In addition, Group 3 patients who turn 1 year old 
during thestudy ,may be further up-titrate d to a dose of 0.2 mg/kg bid 
(Dose Level 5xfor Group 3 patients) . See Appendix 14 for details
All study treatment in Part 2 will be biddosing.
Efficacy assessments The primary  global rank endpoint will be derived based on 5 categories 
ranking worst outcome to best outcome:
1.Category 1: Death; UNOS status 1A listing for heart transplant or 
equivalent; VAD/ECMO/mechanical ventilation /intra -aortic balloon 
pumprequirement f or life support at end of stud y
2.Category 2: W orsening HF (W HF); defined by signs and sy mptoms of 
WHF that requires a n intensification of HF therapy
3.Category 3: W orsened; worse NYHA/Ross or worse Patient Global 
Impression of Severity (PGIS); and further ranking by Ped sQL
physical functioning domain
4.Category 4: Unchanged; unchanged NYHA/Ross and unchanged 
PGIS; and further ranking by Ped sQL physical functioning domain
5.Category 5: Improved; improved NYHA/Ross or improved PGIS 
(neither can be worse); and further ranking by P edsQL physical 
functioning domain)
Key safety 
assessmentsAdverse events ( AEs)and serious adverse events ( SAEs )
Blood pressure, heart rate
Height, weight and head circumference ( ≤ 3 years)
Laboratory values (including potassium & serum creatinine)
Angioedema surveillance
Electrocardiogram (ECG )changes
Other assessmentsNYHA/Ross c lass
Patient Global Impression of Severity (PGIS)
PK of LCZ696 analytes
Plasma NTproBNP , BNP
Urine and plasma cGMP
Data analysis Part 1 PKand PD variables
The PKand PDparameters of LCZ696 will be summa rized 
desc riptively by age group (Group 1: 6 to < 18 years; Group 2: 1 
to < 6 years; Group 3: 1 month to < 1 year) ,and dose .
Part 2 efficacy variables
To characterize the effects of LCZ696 and enalapril on whether 
the patients were improved or not improved using the global rank 
endpoint. The endpoint will be assessed using a stratified 
Wilcoxon rank-sum analysis (Kawaguchi 2011 ), stratifying by 
modified age group (Group 1: 6 to < 18 years; Group 2 a: 2 to < 6 
years; Group 3a: 1 month to < 2 years) and NYHA/Ross class
group (Class I/II, Class III/IV)

Novartis Confidential Page 31
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
 
 
 
 
Key words Pediatric, heart failure, pharmacokinetics, pharmacodynamics, safety , 
efficacy , multicenter, systemic left ventricle systolic dysfunction, global 
rank endpoint

Novartis Confidential Page 32
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
1 Introduction
1.1 Background 
Pediatric heart failure (HF) is characterized by significant morbidity  and mortality , frequent 
hospitalization andmedical care , and poor qualit y of life . It is estimated that between 12,000 to 
35,000 children below age 19 are diagnosed with HF in the United States (US) each year ( Hsu 
and Pearson 2009a ). HF can develop or exacerbate in childhood, during adolescence and also 
later in adulthood as made evident by the growing number of adults with congenital heart 
disease. Congenital heart disease and cardiomy opathy  are the two most common causes of 
pediatric HF ( Sharma 2003, Andrews 2008 ). 
The largest HF burden comes from children born with congenital malformations. Congenital 
heart disease occurs in approximately  8
 per 1,000 live births of which 1-2 per 1,000 develop 
HF (Kay 2001). A wide variet y of congenital abnormalities may be present including ventricular 
or atrial septal defect, patent ductus arteriosus, aorto -pulmonary  window , hypoplastic left heart, 
aortic or pulmonary vein stenosis, anomalous origin of the left coronary artery, and coarctation 
of the aorta. Most of these children are diagnosed before ages 1 and many have early surgical 
intervention, usually  before age 2. 
The other main cause of pediatric HF is cardiomyopathy, with an estimated annual incidence 
of 1 per 100,000 children in the US, Australia, United Kingdom and Ireland (Lipshultz 2003, 
Nugent 2003, Andrews 2008). Dilated cardiomy opath y (usuall y diagnosed as idiopathic, 
familial, or myocarditis ) is the most common type. Hypertrophic cardiomy opath y due to 
familial isolated cardiomy opathy , an inborn error of metabolism, or a malformation sy ndrome 
is the next most common type. Cardiom yopathy can also be associated with 
muscular 
dystrophi es such as Duchenne’s muscular dystrophy  and myotonic dystrophy . In developing 
countries, rheumatic heart disease, nutritional deficiencies, and other tropical diseases such as 
Chagas disease can also be a substantial cause of pediatric HF. 
The clinical c ourse and outcome for pediatric HF depends on the etiology. For congenital heart 
disease, corrective surgery  will have a major impact on the clinical course. Following congenital 
heart surgery , HF can still develop for a number of reasons including myocardial systolic 
dysfunction. 
Many  pediatric patients with severe HF are usually  listed for heart transplant if available; 
however, cardiac transplantation is usually  a last resort given the limited availability  of donor 
organs, complicated clinical course management and associated morbidity  and mortality .In the 
US, one in four infants listed for heart transplant dies before a donor heart is available (Mah 
2009). Further more , nearly  40% of children in the US with symptomatic cardiomy opath y either 
undergo heart transplantation or die within 2 y ears ( Lipshultz 2003 ). 
In contrast to HF in adults, there is very limited research in pediatric HF. Consequentl y, 
treatment of HF in children is based on information and results provided by adult studies 
(Kantor 2010). Pediatric HF treatment is outlined in the recent guidelines published by the 
International Societ y of Heart and Lung Transplantatio n (ISHLT) ( Kirk 2014
). Respondents to 
the Diovan Pediatric Heart Failure Survey  confirmed that ‘efficacy  shown in adult HF trials’ 
and ‘Consensus Statements and Guidelines’ were the two most important factors they 
considered when making treatment decisions for pediatric patients with HF ( CVAL489K2304 

Novartis Confidential Page 33
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
HF Survey , 2011 ). According to this survey ofpediatric cardiologists, current clinical 
management of pediatric HF includes angiotensin converting enzyme inhibitors (ACEI), 
angiotensin receptor blockers (ARBs), β-blockers, diuretics, aldosterone -blocking agents, 
digoxin and anticoagulants.
At this point, no trial has demonstrated an outcome benefit of an y pharmacotherap y in child ren 
with HF. The largest pediatric HF trial done thus far is the randomized, double -blind, placebo -
controlled, parallel -group trial of carvedilol in patients 8 months to 14 years with HF due to 
congenital heart disease or cardiom yopath y (Shaddy  2007). The primary  endpoint for the 
pediatric carvedilol study was a composite measure of HF outcomes, assessing the response to 
treatment as worsening, improved or unchanged. While adult HF populations have shown 
benefit with β-blockade, this study  did not meet its composite primary  endpoint. This may have 
been attributable to the known issues related to pediatric HF trials in general including: varying 
causes of HF, uncertain natural history  of HF in children, and trial design challenges unique to 
the pediatr ic population. 
LCZ696 is sacubitril/valsartan and has the trade name ENTRESTO. In some countries where 
ENTRESTO is approved, it is available as 24mg/26 mg, 49 mg/51 mg, 97 mg/103 mg 
sacubitril/valsartan, but will be subsequently  referred to as L CZ696 50 mg, 100 mg, 200 mg in 
this study  protocol. LCZ696 is a first-in-class, angiotensin receptor neprily sin inhibitor 
treatment for chronic HF (CHF). Nepril ysin (NEP) inhibition with chronic oral administration 
of LCZ696 can promote the endogenous capacity  of the body  to 
compensate for HF 
exacerbations by potentiating the activit y of natriuretic peptides secreted by the heart in 
response to cardiac stress and increased intravascular volume. LCZ696, unlike any other 
therap y for HF, provides concomitant inhibition of NEP and the angiotensin type 1 (AT 1) 
receptor. The resulting increase in natriuretic peptide (NP) activit y due to NEP inhibition and 
AT 1receptor blockade through renin -angiotensin- aldosterone system (RAAS) inhibition have 
complementary effects on the cardiovascular (CV) sy stem that benefit HF patients. 
In PARADIGM -HF (CLCZ696B2314; N=8442), thepivotal Phase 3 study  in adult patients 
with HF with reduced ejection fraction (HFrEF), LCZ696 was superior to enalapril (the standard 
of care) in delay ing time to first occurrence of composite endpoint of CV death or HF 
hospitalization, with a 20% relative risk reduction (RRR) (p=0.0000002). In addition, LCZ696 
was superior to enalapril in delay ing time to CV death with a 20% RRR (p=0.00004) and in 
delay ing time to first HF hospitalization with 21% RRR (p=0.00004). PARADIGM -HF also 
showed that L CZ696 is generall y safe and well tolerated in adult patients with HF ( McMurray 
2014).
In both pediatric and adult HF due to systolic dysfunction, there is a decrease 
in systemic cardiac 
output. The pathophy siologic adaptation to decreased cardiac output for both adult and pediatric 
HF involves increased sympathetic tone and activation of the renin -angiotensin sy stem (RAS) 
(Momma 2006). In addition , also similar to adult HF, pediatric HF results in increased 
activation of the natriuretic peptide system (Favilli 2009). This pathoph ysiologic neurohu moral 
activation plays a key role in the 
progression of HF due to systolic dysfunction in adults and 
children, and this is why heart failure management in this pediatric HF subset with systemic left 
ventricular s ystolic dy sfunction is similar to adult HFrEF.

Novartis Confidential Page 34
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
This protocol focuses on study ing a subset of pediatric HF with systemic left ventricular systolic
dysfunction. The rationale for study ing this patient population is that it allows for examination 
of a more homogeneous pediatric HF population that also has pathoph ysiology  similar to adult 
HFrEF where LCZ696 has demonstrated a significant mortality  and morbidity  benefit 
(McMurray  2014) compared to current standard of care (ACEI). I n additi on, for the Carvedilol 
Pediatric HF study  using a related clinical endpoint as planned inthis study , there 
was a 
potential treatment benefit in the subgroup of patients with sy stemic left ventricle morphology 
(Shaddy 2007 ).
The efficacy  of LCZ696 over the standard of care enalapril for reducing mortality  and morbidity 
in adult HFrEF patients provides strong rationale that L CZ696 may  have clinically  meaningful 
benefits for pediatric HF patients with reduced left ventricular ejection fraction (LVEF). Despite 
differences with regards to the etiology  of pediatric and adult HF with sy stolic dy sfunction (or 
reduced LVEF), there is overlap in the pathophy siology  and clinical management between both 
populations. Thus, we are seeking to prospectively  evaluate the effects of LCZ696 in ped iatric 
patients with sy mptomatic systemic left ventricular sy stolic dy sfunction.
1.2 Purpose 
The purpose of this study  is to determine whether pediatric HF patients will derive greater 
clinical treatment benefit assessed by a global rank endpoint with LCZ696 compared to 
enalapril over 52-week treatment duration. This study  includes two parts. Part 1 will confirm
the dose for Part 2. Part 2 will be used to assess the efficacy  and 
safet y of LCZ696 compared 
to enalapril. 
2 Study  objectives and endpoints
2.1 Primary  objective s
Part 1:
The primary  objective is to determine the pharmacokinetics (PK) and pharmacody namics 
(PD) of LCZ696 in pediatric HF patients
Part 2:
The primary  objective is to determine whether LCZ696 is superior to enalapril for the 
treatment of HF as assessed using a global rank endpoint (described in Section 6.4 ) in 
pediatric HF patients
2.2 Secondary  objective s
Part 1:
To assess the safet y and tolerability of LCZ696 in pediatric patients with HF
Part 2:
To determine whether LCZ696 is superior to enalapril indelay ing time to first occurrence 
of the composite of either Category  1 or 2 event s (e.g . death ,worsening HF)

Novartis Confidential Page 35
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
To determine whether LCZ696 is superior to enalapril for impro ving NYHA/Ross 
functional class
To determine whether LCZ696 is superior to enalapril for improving the Patient Global 
Impr ession of Severit y (PGI S) score
To characterize the population PK of LCZ696 exposur e in pediatric patients with HF, 
including anassessment of stead y-state sparse PK data in a subset of Group 2 patients.
To assess the safet y and tolerability of LCZ696 compared to enalapril in pediatric patients 
with HF
 
 
 
2.4 Objectives and related endpoints
Table 2-1 Objectives and related endpoint s
OBJECTIVE Endpoint Title, Description and Reporting 
Time Frame for analysis and Unit of 
MeasureStat A nalysis Section
Primary
Part 1: The primary 
objective is to determine 
the pharmacokinetics (PK) 
and pharmacodynamics 
(PD) of LCZ696 in 
pediatric HF patientsTitle:PK and PD of LCZ696 after single dose
treatment
Unit of measure : PK: Cmax(ng/mL); Tmax(h); 
AUC last, AUCi nf(h▪ng/mL); Cl/F (L/h); T 1/2 (h); 
PD: plasma BNP, plasma NTproBNP, plasma 
cGMP, urine cGMP change from baseline 
geom etric mean ratio (GMR) after single dose 
treatment
Description : Part 1 PK assessmen t: The 
samples will be collected at the following 
intervals for the various age groups:
Patients ≥ 6 years of age: Blood 
samples  are collected at pre-dose 
(pre-dose sample for all patients), 
0.5, 1, 2, 4, 8, 10, and optional 24 
hours post dosing
Patients <6 years of age: Blood 
samples  are collected at pre-dose 
(pre-dose sample only fro m those 
patients who are on valsartan), 1, 2, Section 9.4.1 , Section 
9.5.3 and, Section 9.5.4

Novartis Confidential Page 36
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
OBJECTIVE Endpoint Title, Description and Reporting 
Time Frame for analysis and Unit of 
MeasureStat A nalysis Section
4, 10, and optional 24 hours post 
dosing
Part 1PDassessments : The blood samples 
will be collected at pre -dose, 4, 8 and optional 
24 hours post dosing. The urine sample swill 
be collected at pre-dose and once between 4 
to 8 hours post dosing.
Time Frame : Single dose PK /PDvisit
Part 2: The primary 
objective is to determine 
whether LCZ696 is 
superior to enalapril for 
the treatment of HF as 
assessed using a global 
rank endpoint in pediatric 
HF patientsTitle: Global Rank endpoint through 52 weeks 
of treatmen t
Unit of Measure : The mean global rank 
endpoint does not have a unit. Patients are 
ranked from worst to best. The ranking is 
based on clinical events such as death, listing 
for urgent heart transplant, mechanical life 
support requirement at end of study , worsening 
HF, NYHA/Ross, PGIS, PedsQL physical 
functioning domain. 
Description : The effects of LCZ696 and 
enalapril will be assessed using the Global 
Rank endpoint as outlined below through 52 
weeks of double -blind treatment. The primary 
endpoint will be derived based on 5 categories 
ranking worst to best outcome:
Category 1: Death; UNOS status 1A 
listing for heart transplant or 
equivalent; VAD/ECMO/mechanical 
ventilation /intra -aortic balloon pump
requirement f or life support at end of 
study
Category 2: W orsening HF (W HF); 
defined by signs and sy mptoms of 
WHF that requires an intensification 
of HF therapy
Category 3: W orsened; worse 
NYHA/Ross or worse Patient Global 
Impression of Severity (PGIS); and 
further ranking by PedsQL physical 
function ing domain
Category 4: Unchanged; unchanged 
NYHA/Ross and unchanged PGIS; 
and further ranking by Ped sQL 
physical fu nctioning domain 
Category 5: Improved; improved 
NYHA/Ross or improved PGIS 
(neither can be worse); and further 
ranking by PedsQL physical 
functioning domainSection 9.4.1

Novartis Confidential Page 37
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
OBJECTIVE Endpoint Title, Description and Reporting 
Time Frame for analysis and Unit of 
MeasureStat A nalysis Section
Within each category, patients are ranked from 
worst to best based on pre-defined criteria.
Time F rame : 52 W eeks 
Secondary
To determine whether 
LCZ696 is superior to 
enalapril in delay ingtime 
to first occurrence of the 
composite of either 
Category 1 or 2 events 
(e.g. death , worsening 
HF)Title: Time to first occurrence of Category 1 or 
Category 2 event through 52 weeks of 
treatment
Unit of Measure : Day s
Description :Time tofirst occurrence of 
Category 1 or Category 2 event will be 
compared for LCZ696 and enalapril through 
52 weeks of double -blind treatment
Time Frame : 52 W eeksSection 9.5.1
To determine whether 
LCZ696 is superior to 
enalapril for improving 
NYHA/Ross functional 
classTitle: NYHA/Ross functional class change 
from baseline through 52 weeks of treatment
Unit of Measure : NYHA/Ross class ification
Description :NYHA/Ross functional class will 
be compared through 52 weeks of double -
blind tr eatment
Time Frame : 52 W eeksSection 9.5.1
To determine whether 
LCZ696 is superior to 
enalapril for improving the 
Patient Global Impression 
of Severity (PGIS) scoreTitle: PGIS score change from baseline 
through 52 weeks of treatment
Unit of Measure :PGIS scale
Description :PGIS scale will be compared for 
LCZ696 and enalapril through 52 weeks of 
double -blind treatment
Time Frame : 52 weeksSection 9.5.1
To characterize the 
population PK of LCZ696 
exposure in pediatric 
patients with HF, including
anassessment of steady -
state sparse PK data in a 
subset of Group 2 
patients . Title: Population PK LCZ696
Unit of Measure : ng/mL/kg, ng*h/mL/kg, 
L/h/kg, L/kg, and 1 /h
Description : During Part 2 Efficacy , population 
PK will be assessed with chronic dosing.
Population PK allows us to estima te clearance 
and total exposure.
Time frame : week s4, 12, 52
Title:Steady -state Sparse PK data
Unit of measure: ng/mL, ng*h/mL, and L/h/kg 
Description: During Part 2 Efficacy , a sparse 
PK assessment at ste ady state will be done in 
a subset of Group 2 patients which allows for Section 9.4.1 andSection 
9.5.1

Novartis Confidential Page 38
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
OBJECTIVE Endpoint Title, Description and Reporting 
Time Frame for analysis and Unit of 
MeasureStat A nalysis Section
anestima te clearance and total exposure to 
further confirm the target dose for this age 
group. Available BioMarker data will also be 
assessed.
Time frame : week 8 or a subsequent visit
To assess the safety and 
tolerability of LCZ696 in 
pediatric patients wit h HFTitle: Safety and tolerability of LCZ696 in Part 
1
Unit of Measure: Multiple
Description: Safety and tolerability including 
AEs, laborator y, vital signs 
Time Frame: Single dose PK/PD visitSection 9.5.2
To assess the safety and 
tolerability of LCZ696 
compared to enalapril in 
pediatric patients wit h HFTitle: Safety and tolerability through 52 weeks 
of treatment
Unit of Measure: Multiple
Description: Safety and tolerability including 
AEs, laborator y, ECG, vital signs data through 
52 weeks of double -blind treatment
Time Frame: 52 weeksSection 9.5.2

Novartis Confidential Page 39
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
3 Investigational plan
3.1 Stud y design
This study  uses a seamless design which consists of two parts ( Figure 3-1): 
Part 1: This is a multi -center, open -label, study  in pediatric patients (1 month to <18 years) 
with HF (LVEF ≤ 45% or LV fractional shorteni ng ≤ 22.5%). 
A screening epoch of upto 3 weeks will be used to assess eligibility . Eligible patients who 
participate in this open -label PK/PD assessment will be plac ed into three Groups based on age 
(Group 1: 6 to < 18 years, Group 2: 1 to <6 years, and Group 3: 1 month to < 1 y
ear). To ensure 
that patients are enrolled in both high and low end of the 6 to < 18 years of age group, 
approximately 50% patients will be enrolled who are 6 to 11 y ears of age in Group 1 .
The foll owing stepwise recruitment will be utilized: 
Group 1 (6 to < 18 years): A sample size of at least 6 patients will be prospectivel y 
planned to be recruited to evaluate PK and PD of LCZ696 analy tes following the single 
dose administration of LCZ696 0.8 mg/k g (N=6 observations ) and then 
the single dose 
administration of LCZ696 3.1 mg/kg (N=6 observations ). The patients who receive the 
LCZ696 single dose of 0.8 mg/kg treatment will also have an option to subsequently  
receive the LCZ696 3.1 mg/kg dose. If a patient who received the LCZ696 0.8 mg/kg does 
not qualify  or declines to receive the LCZ696 3.1 mg/kg dose, an additional patient will be 
recruited to receive the LCZ696 3.1 mg/kg dose.
Group 2 (1 to < 6 years): A sample size o f at least 6 patients will be prospectively  planned 
to be recruited to evaluate PK and PD of LCZ696 anal ytes following the 
single dose 
administration of L CZ696 0.8 mg/kg (N=6 observations ) and then the single dose 
administration of L CZ6963.1 mg/kg (N=6 observations ). The patients who receive 
LCZ696 single dose of 0.8 mg/kg treatment will have an option to receive LCZ696 3.1 
mg/kg dose subsequently . If a patient who received the L CZ696 0.8 mg/kg dose does not 
qualify  or declines to receive the LCZ696 3.1 mg /kg dose, an additional patient will be 
recruited to receive the LCZ696 3.1 mg/kg dose.

Novartis Confidential Page 40
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Group 3 (1 month to < 1 y ear): A sample size of at least 4 patients will be prospectivel y 
planned to be recruited to evaluate PK and PD of LCZ696 analy tes following th e single 
dose administration of LCZ696 0.4 mg /kg (N= approximately  4observations) and then the 
single dose administration of L CZ696 1.6 mg/kg (N= approximately  4 observations). The 
patients who receive LCZ696 single dose of 0.4 mg/kg treatment will have an option to 
receive L CZ696 1.6 mg/kg dose subsequentl y. If a patient who received the L CZ696 0.4 
mg/kg dose does not qualify  or declines to receive the L CZ696 1.6 mg/kg dose, an 
additional patient will be recruited to receive the LCZ696 1.6 mg/kg dose . 
Available PK/PD and safety  data will be reviewed to confirm or modify  the doses tested for 
each age group (Section 3.5 and Section 9.4.1).
If deemed necessary  fordose determination for Part 2, additional age group 3 patients may  be 
enrolled in Part1.
Eligible patients will first receive the LCZ696 0.4 mg/kg single dose (Group 3) 
or 0.8 mg/kg 
single dose (Group 1 or2). Patients must be currently  treated with an ACEI or ARB (at any 
dose) at screening to be eligible for the LCZ696 0.4 mg/kg (Group 3) or 0.8 mg/kg (Group 1 
and2) single dose.
To be eligible for the subsequent LCZ696 3.1 mg/kg dose, patients in Group 1 or 2 must be 
currentl y treated with a daily  dose equivalent of at least enalapril 0.2 mg/kg (Table 3-1) prior 
to the L CZ696 3.1 mg/kg 
(Group 1 and 2) single dose assessment .
To be eligible for the subsequent LCZ696 1.6 mg/kg dose, patients in Group 3 must be currentl y 
treated with a daily dose equivalent of at least enalapril 0.1 mg/kg (Table 3-1) prior to the 
LCZ696 1.6 mg/kg single dose assessment.
If a patient who has completed the LCZ696 0.4 mg/kg or 0.8 mg/kg single dose does not 
participate in the LCZ696 1.6 mg/kg or 3.1 mg/kg dose, the next eligible replacement patient 
may be enrolled to directly  receive the L CZ696 1.6mg/kg or 3.1 mg/kg dose ,respectively . 
The LCZ696 1.6 mg/kg or 3.1 mg/kg dose can be administered after a minimum of 5 days 
following the LCZ696 0.4 mg/kg or 0.8 mg/kg dose , respectivel y(to allow for washout of the 
LCZ696 analy tes from the first dose).
Patients previously  taking an ACEI are 
required to discontinue their ACEI at least 36 hours 
before the LCZ696 dose to minimize the potential risk of angioedema due to overlapping ACEI -
NEP inhibition.  Similarly , all patients who have taken LCZ696 should discontinue their 
LCZ696 at least 36 hours before taking an ACEI. Patients takin g an ARB or renin inhibitor are 
required to discontinue the ARB or renin inhibitor the morning of the LCZ696 single dose visit.
After completion of the PK/PD assessment visit, patients can either be maintained on open -
label enalapril or their standard of care HF medical regimen until Part 2 ( Efficacy ). Patients in 
each age group can enroll in Part 2 after the target dose for that age group is determined based 
on Part 1 data for the corresponding age cohort. Patients that dis continue from Part 1 (PK/PD) 
will be allowed to screen and enroll for participation in Part 2 (Efficacy ).
Part 2 : This is a randomized, double blind, parallel -group, active controlled, 52 -week study  to 
evaluate the efficacy , safety , and tolerability  of LCZ 696 compared to enalapril in pediatric HF 
patients (1 month to < 18 years). A screening epoch of upto 3 weeks will be used to assess 

Novartis Confidential Page 41
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
eligibility . 360 eligible patients will be randomized to one of the two treatment arms (LCZ696 
vs. enalapril) and continue treatment for 52 weeks duration (see Appendix 15for USM 
exception). Both hospitalized patients and outpatients a re eligible. Chronic HF patients that are 
either previousl y treated for HF or newl y diagn osed areeligible.
Aninterim efficacy  analysis is planned to b e performed when at least 180 patients (at least 36 
patients from each age group) have completed the study (i.e., reached a terminal endpoint or 
completed the 1 y ear study  visit) , and at least 40 patients have had an event in Category  1 or 2.
Further details about interim analy ses are provided in Section 9.6.
Part 2 will stop when at least 360 patients have completed the study .
Figure 3
-1 Study  design
Part 1 (PK/PD ) -Screening epoch
Part 1 will be conducted in selected countries and centers due to the limited number of patients 
required . At least 18 patients combining the three age groups will be enrolled .All eligible 
patients will be consented (parent/legal guardian ICF and ifapplicable, patient assent) at Visit 
1. A scree ning period of approximately  upto three weeks will be used to det ermine if patients 

Novartis Confidential Page 42
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
qualify  to enter the Part 1 (PK/PD) epoch. No study medication will be administered during this 
time. Both hospitalized patients and outpatients are eligible for participation.
Qualify ing LVEF or LV fractional shortening assessment will be based on a locally  obtained 
echocardiogram (ECHO) , MRI , MUGA, or left ventricular angiogram. If a qualifying LVEF or 
fractional shortening measurement is not available, a qualify ing echocardiogram measurement 
must be obtained during screening before the patient receives study  treatment. The preferred 
LV function assessment is by ECHO. A MUGA, MRI  or ventriculogram that is done as part of 
standard of care can be used instead of ECHO .
Screening laboratory  values will be assessed by sending blood and urine samples to the local 
laboratory . Only patients with the required values per the entry  criteria will be eligible to 
continue in the study . It is recommended that at Visit 1(Part 1 PK/PD –Screening) , the site 
schedule the patient’s next visit approximately one week after Visit 1.
In order to be eligible for Part 1, patients in Groups 1 , 2 and 3 must be taking an ACE I/ARB (at 
any dose) prior to the single dose LCZ696 0.4 mg/kg (Group 3)or 0.8 mg/kg PK/PD assessment
(Group 1 and 2) and meet all the inclusion/exclusion criteria at Visit 1 .
Patients in Group 1 and2 must be currently  treated with the equivalent of at least enalapril 0.2 
mg/kg daily dose (Table 3 -1) prior to the single dose L CZ696 3.1 mg/ kg and Group 3 patients 
must be treated with the 
equivalent of at least enalapril 0.1 mg/kg daily dose (Table 3-1) prior 
to the single dose LC
Z696 1.6 mg/kg PK/PD assessment and meet all the inclusion/exclusion 
criteria at Visit 1.
Dosing will be performed with patient supine or sitting and under close observation. Enalapril 
0.1 mg/kg and 0.2 mg/kg provides similar renin angiotensin s ystem inhibition compared to the 
LCZ696 1.6 mg/ kg and 3.1 mg/kg dose being examined , respectivel y. If a patient is not taking  
one of the commonl y prescribed ACEI/ARBs shown in Table 3-1, the Investigator may use 
his/her judgment regarding the equivale nt ACEI/ARB dose based on product information, 
medical literature, medical expertise, and/or consultation with Novartis. 
Table 3
-1 P art 1: PK/PD - Minimum required pre -study  body -weight normalized 
daily  doses of commonly  prescribed A CEIs or A RBs that should be 
tolerated prior to the LCZ696 1.6 mg/kg and 3.1 mg/kg single dose 
PK/PD assessment
ACEI/ARB Body weight 
normalized daily 
doseBody weight norma lized 
daily doseAdult daily dose
Prior to the LCZ696 1.6 mg/kg (Group 3) Prior to the LCZ696 3.1 mg/kg (Group 1 and 2)
Captopril 0.3 mg/kg 0.6 mg/kg 37.5 mg
Enalapril 0.1mg/kg 0.2 mg/kg 10 mg
Enalaprilat 0.01 mg/kg 0.02 mg/kg -
Lisinopril 0.1mg/kg 0.2 mg/kg 10 mg
Valsartan 1.25 mg/kg 2.5 mg/kg 160 mg
Losartan 0.75 mg/kg 1.5 mg/kg 100 mg
Candesartan 0.25 mg/kg 0.5 mg/kg 32 mg

Novartis Confidential Page 43
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
A patient who enters screening, butis determined not to be eligible to enter Part 1 will be 
considered a screen failure. The Investigator may consider re -screening the patient for Part 1 at 
a later time if the patient’s condition has changed and they may potentiall y be eligible. A patient 
may be re -screened for Part 1 up to two times. A minimum of 2 weeks must elapse between re -
screenings. A patient not eligible for Part 1 (PK/PD) may also be re-screened for Part 2
(Efficacy )when Part 2 begins.
Part 1 (PK/PD ) -Visit s101, 201, UNS PK/PD ( if performed ) –Period 1 and 2 
epoch
Visit 101 will occur approximately  up to three weeks after Visit 1. Visit 201 may occur 
approximately  up to three weeks after Visit 1 if patient is directly  going to second dose PK 
assessment from Visit 1 . 
Part 1 PK/PD assessment is conducted using three age groups (Groups 1, 2 and 3) enrolled into 
the study  in a sequential anddescending age group order. A single dose of LCZ696 0.4 mg/kg 
(Group 3) or 0.8 mg/kg (Groups 1 and 2) followed by  a single dose of 1.6 mg/kg (Group 3) or 
3.1 mg/kg (Groups 1 and 2) will be administered for PK and PD evaluations in participating 
patients.
All patients in Part 1 will be administered the single dose of LCZ696 using the 3.125 mg 
granules . Safet y, tolerability, PK and PD data will b e evaluated by Sponsor and an independent 
Data Monitoring Committee (DMC). This data will be used to guide and/or confirm the dose 
level for the other age group s in Part 1 (Groups 1, 2 and 3) and the same age group in Part 2. 
Patients are required to discontinue their enalapril or other ACEI at least 36 hours before taking 
the single dose LCZ696 to minimize the potential risk of angioedema due to overlapping ACEI -
NEP inhibition. Patients taking an ARB or renin inhibitor are required to discontinue their ARB 
or renin inhibitor the morning of their single dose LCZ696 PK/PD visit.
Patients should, if possible, fast for 2 hours prior to the PK/PDassessment at Visit s 101, 201,
and UNS PK/PD (if performed) . Patients may eat starting attwo hours after the patient is 
administered LCZ696 . If the patient is not able to fast, this will be recorded and the PK/PD 
assessment will still be performed. The reason for collecting this information is to consider an y 
food effect on the PK/PD assessme nt
s. All eligible patients will provide a blood sample for PK 
(Section 6.6.2) and biomarkers (Section 6.5.4.5 ) prior to taking any study  medication. 
Additional bl ood and urine samples will be collected at pre- specified time points during Visit 
101, 201, andUNS PK/PD(Table 3-2). Biomarker blood samples for plasma cGMP, plasma B -
type natriuretic peptide (BNP )and plasma NTproBNP are scheduled to be collected based on
Table 3-2. Details about blood volume drawing restrictions ,blood biomarker priorit ization 
(given blood volume restrictions), blood volume laboratory requirements for PK/PD samples, 
sample collection, processing and storage instructions are provided in the laboratory  manual.
Abbreviated chemistry  laboratory  samples will be obtained atthe end of Visit 101, 201 and 
Unscheduled PK/PD (if performed) . The number of PK/PD samples collected isdependent on 
the age group and blood volume drawing restrictions (Table 18 -
1). Efforts to minimize patient 
discomfort shoul d be used when possible. To minimize discom fort and multiple needle sticks, 
pre-existing venous access may be used. Where feasible, a temporary indwelling venous 
catheter will be inserted if not already  present. Local anest hetic cream may also be considered 

Novartis Confidential Page 44
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
for useto reduce pain and discomfort from venipuncture, if possible . The collection of the 24 
hour post -dose blood sample for PK and biomarkers is optional. 
Table 3-2 Part 1 (PK/PD ) -Visit 101 ,201, and UN SPK/PD blood and urine sample 
collection
Time point Blood (PK) Plasma 
cGMPPlasma 
BNPPlasma 
NTproBNPUrine
cGMP
Group 1
≥6 yrGroups 2 
and 3
<6 yr
Pre-dose x x1x x x x3
0.5 hours post- dose x
1 hour post -dose x x
2 hours post -dose x x
4 hours post -dose x x x x x (4-8 h)3
8 hours post -dose x x2x2
10-hours post -dose x x
24 hours post -dose 
(optional)x2x2x2
1Due to blood volume restrictions (dependent on patient weight), this sample will only be collected for 
patients taking valsartan. The sample will be used to measure the plasma concentration of the pre -
dose valsartan ,if valsartan is being used by the patient prior to the single dose PK. 
2Patients with blood volume restrictions (dependent on patient weight) will no t have this sample 
collected. See Laboratory manual for details about biomarker prioritization when blood volume that can 
be drawn is limited.
3 A spot urine sample will be collected at pre -dose and at any time between 4 to 8 hours post -dose.
Additional information about LCZ696 liquid formulation preparation is available in the 
(Pharmacy  Manual ).
AEs and vital signs will be monitored throughout the PK/PD assessment visits. Other safet y 
evaluations will include abbreviated physical exam and abbreviated laboratory  tests(refer to 
Table 6-1). 
For all age groups, additional single dose PK/PD assessments may be performed if deemed 
necessary  for dose determination for Part 2. This will be a decision made by the Sponsor and 
the DMC (Section 9.6 ) . Unscheduled PK/PD visits may be used for additional PK/PD 
assessments . Additional PK/PD assessments may involve new Part 1 patients, or patients who 
have complet ed a PK/PD assessment andagree to another PK/PD assessment.

Novartis Confidential Page 45
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Part 1 (PK/PD ) -Open -label enalapril or standard of care HF medical regimen 
(Visits 102to 199 and 202 to 299) – Period 1 and 2 epoch
Visits 101 through 199 and 201 through 299 are for first PK dose and second PK dose,
respectivel y. 
A telephone call (Visit 102and/or Visit 202 ) will occur 2 weeks after Visit 101 (first PK dose 
visit) and/or Visit 201 (second PK dose visit) for safet y evaluation (refer to Table 6 -1). 
Patients who have successfully  completed Visit 101 and/or Visit 201 and will consent to 
participate in Part 2 (Efficacy ) will take open -label enalapril or be maintained on their standard 
of care HF medical regimen (which may include captopril or other ACEI/ARB). Open -label 
enalapril visits will begin after Visit 101 and/or Visit 201and continue until Part 2 (Efficacy ) 
begins. 
All patients will be seen at the site every  12 weeks (3 months) aft er Visit 101 and/or Visit 201 
until Part 2 begins with monthly  telephone visits in between the three month visits .
Patients taking the open -label enalapril adult formulation will come to the site for their 
scheduled visitsand to receive open -label enalapr ilmedication every  12 weeks (e.g. Visit 
105/20 5, 108/208, etc.). Telephone visits will occur monthly  for these patients between the 
every  3 m onth visits (e.g. 103/203, 104/204, 106/206 , etc.). Refer to Table 6-1and Table 6-2
for assessments performed by  telephone.
If needed, based on the patient’s age and/or inability to swallow tablets
,liquid enalapril may be 
used. The liquid enalapril can be prepar ed at the site’s pharmacy and can be commerciall y 
sourced such as Epaned (if available) .
Patients receiving liquid enalapril must return to the site for resuppl y at intervals dependent on 
the storage life of liquid enalapril (every  1 m onth; or every  2 m onths if Epaned (enalapril) is 
available and used ,which has a 2 month shelf life). Given the burden of traveling to the site for 
the study  visit for patients and families, the parent/caregiver can come to the site without the 
patient for dispensation of study  drug. Delivery  of study  drug to the patient can also be used 
where possible and allowed per local regulation s.If the parent/caregiver comes to the visit 
without thepatient, a telephone call to the patient (≥ 6 years old) can be used in conjunction 
with the parent/caregiver visit for the visit assessments that can be performed verball y. 
Patients that discontinue from Part 1(PK/PD) will be allowed to screen and enroll for 
participation in Part 2 (Efficacy ).
Novartis or its repres entatives will notify  Investigator s once Part 1 is complete for each age 
group . At that time, patients i n the completed age group will be scheduled for their final visit in 
Part 1 (PK/PD , for first dose Visit 199, for second dose Visit 299). For the patient who 
completed second dose PK/PD assessment , Visit 299 may occur on the same day as Visit 301
(Part 2 Pre-Randomization/S creening )if the patient will participate in Part 2. For the patient 
that only participated in first dose PK/PD assessme nt(and not second dose PK/PD assessment) , 
the Visit 199 may  occur on the same day  as Visit 301 ,if the patient willparticipate in Part 2.
Part 2 (Efficacy )
-Overview
All participating countries and centers will be eligible for Part 2 (Efficacy ).

Novartis Confidential Page 46
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Part 2 is a double -blind, randomized treatment epoch. Patients will receive either LCZ696 or 
enalapril, and matching placebo for enalapril or LCZ696, respectivel y. The target dose of 
LCZ696 for Groups 1 and 2 is dose level 4 and for Group 3 is dose level 4x , and was selected 
based on the Part 1 PK/PD results. Blinded study  drug will be titrated to the target dose as 
tolerated per the safet y monitoring criteria (Table 3-3) (e.g. if the patient does not experience 
adverse events that include symptomatic hypotension
, worsening renal function, or 
hyperkalemia) .AEs or conditions that preclude initiation or up-titration of study  drug can 
include abnormalities in laboratory  chemistry  values based on local laboratory  normal reference 
ranges and the Investigator’s judgment. Additional safety  monitoring will be required for Group 
3 
patients. Starting with the first dose of study  medication, vital signs must be checked for up 
to 4 hours after the initial dose at each dose level (i.e. dose levels 1x through 4x, as applicable). 
Note: this does not apply  for up -titrations following study drug interruptions or down- titrations 
up to the prio r achieved maximal dose level). See Appendix 13 for details.
Table 3-3 Safety  monitoring criteria for initiation/up -titration of study  drug
Parameter Description
Potassium level K ≤ 5.4 mmol/L (mEq/L)
Kidney function eGFR (calculated using the modified Schwartz 
formula) ≥ 30% mean GFR for age (Appendix 10 ,
Table 22 -1)
Kidney function eGFR reduction < 35% compared to 
randomization Visit 401 (Part 2). 
Blood pressure SBP > than the calculated 5th percentile SBP for 
ageas described in Appendix 4
AEs or conditions No conditions that preclude continuation 
according to Investigator ’s judgment, including 
hypotension.
Part 2 (Efficacy ) -Pre-randomization /screening epoch, Visit 301
All patients will be consented for Part 2 efficacy  (parent/legal guardian ICF and ifapplicable, 
patient assent) before an y study -specific procedures are performed. All patients entering Part 2 
must fulfill all inclusion criteria and none of the exclusion criteria at Visit 301 (Part 2 Efficacy -
Pre-Randomization/S creening ). Local laborator y evaluations are required to assess the patient’s 
eligibility  at Visit 301 (refer to Table 6 -1, Table 6 - 2 and Section 6.5.4 ). 
Patients may enter Part 2 (E fficacy ) via two pathway s:
Patients participating in Part 1 will be re- evaluated to assess all inclusion and exclusion 
criteria. A repeat assessment of LVEF or fractional shortening is onl y required if the last 
assessment of LVE F or fractional shortening was > 1 month prior to Visit 301 
Patients that did not participate in Part 1 (PK/PD) will be evaluated to assess all inclusion 
and exclusion criteria for participation in Part 2 (Efficacy ). 
The screening period will be upto three weeks. No study  medication will beadministered 
during this time.

Novartis Confidential Page 47
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Qualify ing LVEF or fractional shortening measurements will be based on a locally  obtained 
echocardiogram, MRI, MUGA, or left ventriculogram. If these qualify ing measurements are 
not available within 1 month of Visit 301 ( Part 2 Efficacy -Pre-Randomization/Screening ), then 
an echocardiogram should be obtained during the screening period. 
Part 2 screening laboratory  assessments should be performed locally. Only patients with the 
required values per the entry  criteria will be eligible to continue in the study . 
Both hospitalized patients and outpatients are eligible for participation in Part 2(Efficacy ). A 
hospitalized patient is defined as a patient who is being treated in the hospital at the time of 
Visit 401 (Part 2 Efficacy -Randomization ). An outpatient is a patient who is screened in stable 
health status and can initiate study  medication intake in an ambulatory  setting.
Part 2 (Efficacy ) -Random ized treatme nt epoch (Visit 401 to Visit 416 /499)
The Part 2 randomized treatment epoch begins at Visit 401. Part 2 will enroll 360 patients. 
Patients are required to discontinue their enalapril or other ACEI at least 36 hours before taking 
blinded study  drug at randomization to minimize the potential risk of angioedema due to 
overlapping ACEI -NEP inhibition. Patients taking an ARB or renin inhibitor are required to 
discontinue their ARB or renin inhibitor on the day of randomization (i.e. patient should not 
have taken ARB s,
or renin inhibitor on the day  of randomization) .
At randomization (Visit 401), patients who meet eligibility  and safety  criteria will be 
rando mized to 1 of 2 treatment arms: double -blind enalapril bid or LCZ696 bid. The initial 
study  drug dose started at randomization for Group 1 and 2 is dose level 1 or 2 (Table 3-5) ,and 
for Group 3 is dose level 1x or 2x(Table 3-6). Patients who are ACEI/ARB naïve or on low 
dose ACEI/ARB (dose levels 1 or 2; Table 3 -4 ) prior to randomization should start at dose level 
1 or 1x at randomization, depending upon the age group (Table 3-5, Table 3-6). Patients who 
are on higher doses of ACEI /ARB (dose levels 3 or 4; Table 3-4) prior to randomization may
start at dose level 2or 2x
,based on age group (Table 3-5, Table 3-6).Given the patient’s 
condition is often dy namic, patients may  start , depending upon the age group, on dose levels 1
or 1x or 2 or 2x at randomization based on I nvestigator judgement.
Patients will continue taking their background HF therapy  except for ACEI s and/or ARBs, 
which are replaced by the study  medication. The concom itant use of ACEIs, ARBs, or renin 
inhibitors with study medication is strictly  prohibited. 
Table 3-4 Part 2 (Efficacy ): Total daily  dose levels of commonly  prescribed 
ACEI/ARBs to guide selection of the study  medication starting dose
Dose levels for 
pediatric formulationEnalapril/Lisinopril 
total daily doseCaptopril total daily 
dose
Dose level 1 0.1 mg/kg 0.3 mg/kg
Dose level 2 0.2 mg/kg 0.6 mg/kg
Dose level 3 0.3 mg/kg 1.2 mg/kg
Dose level 4 0.4 mg/kg 1.5 mg/kg
Dose levels for adult 
formulationEnalapril/Lisinopril 
total daily doseCaptopril total daily 
doseCilazapril total daily 
dose
Dose level 1 5 mg 18.75 mg 0.5 mg

Novartis Confidential Page 48
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Dose level 2 10 mg 37.5 mg 1.0 mg
Dose level 3 15 mg 75 mg 2.5 mg
Dose level 4 20 mg 150 mg 5.0 mg
Dose levels for 
pediatric formulationValsartan total daily 
doseLosartan total daily 
doseCandesartan total 
daily dose
Dose level 1 0.7 mg/kg 0.4 mg/kg 0.2 mg/kg
Dose level 2 1.4 mg/kg 0.7 mg/kg 0.25 mg/kg
Dose level 3 2.0 mg/kg 1.0 mg/kg 0.32 mg/kg
Dose level 4 2.7 mg/kg 1.4 mg/kg 0.64 mg/kg
Dose levels for a dult 
formulationValsartan total daily 
doseLosartan total daily 
doseCandesartan total 
daily dose
Dose level 1 40 mg 25 mg 4 mg
Dose level 2 80 mg 50 mg 8 mg
Dose level 3 160 mg 75 mg 16 mg
Dose level 4 320 mg 100 mg 32 mg
For age groups 1 and 2, the target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) 
with a maximum dose of 10 mg bid (20 mg total daily dose). For age groups 1 and 2, the target 
dose for LCZ696 i s projected to be 3.1 mg/kg bid . Based on the PK/PD results from Part 1 for 
Group 3 patients, the target dose for LCZ696 (dose level 4x) will be 2.3 mg /kg bid . In addition, 
forGroup 3 patients who turn 1 year old dur ing the study ,consideration should be given to up -
titrate toa dose of 3.1 mg/kg bid(dose level 5x). See Appendix 14for details. The LCZ696
dose is not to exceed 200 mg bidirrespective of the body  weight (Table 3-5, Table 3-6). The 
actual target dose (dose level 4or 4x
, depending upon age group ) and lower dose levels (1, 2, 
3or 1x, 
2x, 3x, depending upon age group ) of LCZ696 for Part 2 were determined based onPK 
andPD results from Part 1 of the study . 
Study  drug is titrated to target dose level 4 for Group 1 and 2, or to target dose level 4x for 
Group 3,as tolerated based on the safet y monitoring criteria approximately  every 2  weeks 
beginning at Visit 401 (Part 2 Efficacy  –Randomization) and continuing at Visits 402 and 403
(Table 3-3) . Investigator s have the option to schedule a patient for an additional visit (Visit 404; 
6 weeks post- randomization) in order to complete the titration tothe target dose.Additional 
safet y monitoring will be required for Group 3 patients. Starting with the first dose of study  
medication, vital signs must be checked for up to 4 hours after the initial dose at each dose level 
(i.e. dose levels 1x through 4x, as applicable). Note: this does not apply  for up-titrations 
following study  drug interruptions or down -titrations up to the prior achieved maximal dose 
level) See Appendix 13for details. Unscheduled visits may be necessary  to assess the patient 
and/or adjust study  medication as needed .Group 3 patients who turn 1 year old during the study 
and for whom study  drug isto be up-titrated based on the safet y monitoring criteria , a scheduled 
or unsche duled visit may be used for these up -titration visits
. See Appendix 14 for details.
Single PK sample swill be collecte d during Part 2 (Efficacy ) at the following visits: Visit 403, 
Visit 406, and Visit 416/499 (Week 52/End of Study )(see Appendix 15for USM exc eption).
Additional samples for PK may  be considered if patient has an unscheduled visit. 
In approximately  24 Group 2 patients
, sparse PK blood samples will be collected at stead y-state 
at 3 time -points on the same day, at Visit 405 or at a subsequent scheduled or unscheduled visit

Novartis Confidential Page 49
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
(except visits 406 and 416/499), when the patient is on Dose -Level 4 or at his/her highest 
tolerate d dose for at least 1 week. Refer to Section 6.6.2 for additional PK information.
To assess the patient’s eligibility  to titrate to the next dose level, local laboratories should be 
used. 
Table 3-5 Part 2 (Efficacy ): Study drug dose levels for double -blind enalapril and 
LCZ696 for age groups 1 and 2
Dose levels for p ediatric 
formulationEnalapril dose LCZ696 dose †
Dose level 1 0.05 mg/kg bid. 0.8 mg/kg bid.
Dose level 2 0.1 mg/kg bid. 1.6 mg/kg bid.
Dose level 3 0.15 mg/kg bid. 2.3 mg/kg bid.
Dose level 4 0.2 mg/kg bid. 3.1 mg/kg bid.
Dose levels for a dult 
formulationEnalapril dose LCZ696 dose †
Dose level 1 2.5 mg bid. 50 mg bid.
Dose level 2 5 mg bid. 100 mg bid.
Dose level 3 7.5 mg bid. 150 mg bid.
Dose level 4 10 mg bid. 200 mg bid.
†Note: LCZ696 target dose (dose level 4) and other dose levels shown in table are based on targe t 
dose of LCZ696 3.1 mg/kg bid. LCZ696 target dose has been verified by Part 1 PK/PD.
Table 3-6 Part 2(Efficacy ): Study  drug dose levels for double -blind enalapril and 
LCZ696 for age group 3
Dose levels for pediatric 
formulationEnalapril dose LCZ696 dose †
Dose level 1 x 0.05 mg/kg bid. 0.8 mg/kg bid.
Dose level 2 x 0.075 mg/kg bid. 1.2 mg/kg bid.
Dose level 3 x 0.1 mg/kg bid. 1.6 mg/kg bid.
Dose level 4 x 0.15 mg/kg bid. 2.3mg/kg bid.
†Note: LCZ696 target dose 2.3 mg/kg (dose level 4 x) is based on Part 1 PK/PD Safety data .Theother 
dose levels for LCZ696 shown in table are based on target dose of LCZ696 2.3mg/kg bid and Part 1 
PK/PD Safety data . For Group 3 patients who turn 1 year old during the study, consideration should be 
given to up -titrate to a dose of 3.1 mg/kg bid (Dose L evel 5x) . See Appendix 14 for details.
Randomized, ongoing, Part 2 Age Group 3 patients (i.e. patients who are 1 month to<1 year 
old at randomization) who are safel y tolerating Dose Level 4x(i.e. LCZ696/Placebo, 2.3mg/kg 
bid / Enalapril/Placebo 0.1 5mg/kg bid) for at least 2 weeks, and who t urn 1 year old during the 
study ,may be up
-titrated to Dose Level 5x (LCZ696/Placebo, 3.1 mg/kg bid / Enalapril/Placebo 
0.2 mg/kg bid), if it is the patient’s best interest to be up-titrated based on the medical judgement 
of the investigator. SeeAppendix 14, Table 26 -1for Dose L evel 5x up-titration infor mation for
Age Group 3 patients.
Study  drug dose level adjustments should be based on overall safet y and tolerability . Patients 
should be titrated to the next dose level if there is no sy mptomatic hy potension, hy perkalemia, 
worsening renal function, or other AEs per the Investigator ’s judgment as shown in Table 3 -
3.

Novartis Confidential Page 50
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Additional safety  monitoring will be required for Group 3 patients with each initial dose level 
up-titration . See Appendix 13 for details .
Every  attempt should be made to achieve and maintain patients on the target study  drug dose 
level throughout Part 2(Efficacy ). If, in the opinion of the Investigator , the patient does not 
tolerate the assigned study  medication, the Investigator should consider whether non-disease -
modify ing medication ( e.g.calcium chan nel blockers, diuretics, α -blockers) can be reduced to 
rectify  the situation. The Investigator may adjust doses of disease -modify ing medications (e.g.
beta-blockers, aldosterone 
antagonists) if it is believed that they  are the most likely  cause of the 
adve rse effect. If adjustment/elimination of concomitant medications is not possible or does not 
alleviate the side effects of concern, the Investigator may down-titrate or interrupt the study 
drug. Refer toSection 5.5.5 for guidance on permitted study  drug dose adjustments and 
interruptions. If the reason for a dose adjustment is due to an adverse event, an adverse event 
should be reported.
At each visit after randomization (Part 2 Efficacy  -Visit 401), thepatient’s medication 
compliance, safet y, and tolerability of the study  medication are assessed. This will include, but 
not be limited to signs and symptoms of hypotension, serum potassium level, and renal function. 
Patients who experience angioedema as determined by the Investigator at any time during the 
double -blind epoch must be discontinued from the study .
Both scheduled and unscheduled visits can be utilized for up-titration/down -titration throughout 
the study  based on Investigator judgment (Section 
5.5.5) for re-evaluation of safet y criteria 
parameters and stud y drug management.
3.2 Rationale for study  design
The patient population will be d
escribed in more detail in Section 4 below.
The study  is comprised of two part s combined into a seamless design: 
Part 1: PK and PDassessment sto determine the LCZ696 dose for Part 2
Part 2: 52- week efficacy  and safet y assessment s
The purpose of this design is to improve study  efficiency  compared to a sequential approach 
involving two separate studies. 
3.3 Rationale for Global Rank primary  endpoint
There is noagreed upon, validated clinical efficacy  endpoint for this patient population. In 
additio n, the low prevalence of HF in children limits the possibility  to conduct large outcome 
trials. The Global Rank primary  endpoint is developed based on Packer’s composite score to 
assess the totality  of the interventions. Packer’s composite score has been widel yused in 
cardiovascular clinical trials (Packer 2001 )including ularitide TRUE
-AHF (Anker 2015, Chang 
2015). Packer’s compos ite score classifies patients into three categories: worse ned, unchanged, 
and improved. Similarly ,a clinical composite endpoint with three categorie s (worsen ed, neither 
worsened nor improved, and improv ed) was also used in the Carvedilol Pediatric HF study
(Shaddy  2007 )
. 
The primary  endpoint for this LCZ696 pediatric HF study  uses a Global Rank endpoint that 
builds on Packer’ s composite score with a methodology  thatfurther differentiate spatients 

Novartis Confidential Page 51
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
between treatment groups (Felker 2010 , Sun 2012 ). The Global Rank endpoint rank orders 
patients from worst to bestusing: (a) objective outcome events of death ,listing for urgent heart 
transplant or mechanical support ; (b) events of worsening HF;and(c) measures of functional 
assessment (NYHA/Ross )and patient reported outcomes: Patient Global Impression of Severity 
(PGIS)and the PedsQL (physical functioning subgroup of questions ). Thus, the global ranked 
endpoint encompasses important clinical events grouped into broadl y agreed categories of 
severit y from mortality  to disease progression (worsening HF) to measures of symptoms and 
physical functioning. This global rank endpoint for this study  has been developed with input 
and endorsement by  world leading pediatric heart failure experts .
The effects of LCZ696 and enalapril will be assessed after 52 weeks of double -blind treatment
using the Global Rank endpoint algorithm (as outlin ed inTable 6-3) (see Appendix 15for USM 
exception) . Clinical events that are potential endpoints for Categories 1 and 2 (described below) 
will be ad judicated b y a blinded, external adjudication committee.
Classification of patients in the global r
ank endpoint according to severity
Category  1: Death; UNOS status 1A listing for heart transplant or equivalent; 
VAD/ECMO/mec hanical ventilation /intra -aortic balloon pump requirement f or life 
support at end of stud y
Reducing Category  1 endpoints such as death is a major goal for treating pediatric HF. HF 
transplant is a major therapy and treatment o f last resort for pediatric HF. Listing for urgen t HF 
transplant instead of the heart transplant itself is used for the time to event analy sis given the 
assumptions that these patients would die without an imminent heart transplant and that the 
duration waiting for a heart transplant is dependent on the availability  of the donor heart . Urgent 
HF transplant is defined as UNOS status 1A or equivalent where the patient must be in the 
intensive care unit on intravenous inotropic medications and/or mechanical life support .The 
requirement for mechanical life support (VAD, ECMO, mechanical ventilation , intra-aortic 
balloon pump )at the end of the study is also Category 1. In this case, the patient would die or 
need a heart transplant if removed from this mechanical support toqualify  for Category  1.Death 
and other Category  1 events should be modifiable by treatm ents that improve HF.Within 
Category  1, the patients will be ranked b y time to first event.
Category  2: Worsening HF(WHF) ;defined b y signs and s ymptoms of WHF that requires 
an intensification of HF therap y
There is general agreement that reducing WHF isa major goal for treating pediatric HF. 
Inpatient and outpatient WHF events reflect disease -
specific endpoints related to progressive 
worsening of the HF syndrome. These WHF events should be modifiable by treatments that 
improve this condition. 
WHF is defined as new or worsening symptoms and signs of heart failure that requires 
intensification of HF therap y
(Section 6.4.1). Within Category  2, the events will be classifi ed 
into 3 sub
categories from worst to best:
Worsening HF hospitalization with intensive care unit (I CU) stay
Worsening HF hospitalization without I CU stay

Novartis Confidential Page 52
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Worsening HF without hospitalization
Within Category  2, the patients will be ranked first by  event subcategory , and then by number 
of events within each subcategory . Further ranking will be performed by time to first event in 
the worst subcategory .
Patients who do not have a clinical event that qualifies for Categories 1 or 2 will be placed into 
Categories 3, 4, and 5 (refer to Table 6 -
3).
Category  3: Worsened; worse NYHA/Ross or worse Patient Global Impression of 
Severity  (PGI S); and further ranking b y Ped sQL phy sical functioning domain
Category  4: Unchanged; unchanged NYHA/Ross and unchanged 
PGIS; and further 
ranking b y PedsQL ph ysical functioning domain
Category  5: Improved; improved NYHA/Ross or improved PGI S (neither can be wors e); 
and further ranking b y Peds QL physical functioning domain
The hypothesis is that LCZ696 will improve functional capacit y (NYHA/Ross) and HF 
symptoms (PGI S) and that these two phenot ypic characteristics are interrelated ( Figure 3 -2).
NYHA/Ross
The impact of study drugon the patient’s physical functional status will be assessed using the 
NYHA classification I-IV (older childre n: 6 to < 18 years old) or Ross HF classification I-IV 
(younger children: l month to < 6 old y ear). The NYHA and Ross functional class assessments 
are reliable instruments for rating HF patients’ functionality ( Criteria Committee NYHA 1994 , 
Ross 1992, Packer 2001, Rosenthal 2004). 

Novartis Confidential Page 53
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Figure 3 -2 Global rank endpoint categories 3, 4, 5 
Patient Global Impression of Severity (PGIS)
The impact of study  drug on the patient’s heart failure symptomatic 
status will be assessed using 
the PGISwhich is a static global impression of severity  question that will be used to capture the 
patients’ curr ent health status relative to their heart failure over a 7 day srecall period. 
Patient (7 to < 18 y ears old) : How would y ou describe the severity  of your heart failure 
symptoms over the past 7 days ? (None/ Mild / Moderate / Severe / Very Severe) [5-
point response scale ]
Parent (for < 5 years old patient s): How would you describe the severit y of your child’s 
heart failure s ymptoms over the past 7 days ? (None/ Mild / Moderate / Severe / Very  
Severe) [5-point response scale]
Patient (5 to < 7 y ears old): Point to the one face that best shows how your heart problems 
have been over the last 7 days ?(Good / Neither Good nor Bad / Bad) [3-point scale]
The PGIS uses a 5-point patient evaluation scale for patients ≥ 7years . A 5- point evaluation 
scale is used for parent/caregivers for patient s < 5 years of age.A 3-point faces scale will be 
used for patient self -report by  children 5 to < 7years. 
For the Global Rank primary  endpoint, a one class change in the PGIS is considered to represent 
a clinically  significant change. The parent/caregiver PGIS report will only be used for the 
Global Rank endpoint for patients < 5 years old.The patient PGIS report will be used for the 
Global Rank endpoint for patients ≥ 5years old. For additional information, refer to Section 
6.6.1.2 andAppendix 8 .
Categories 3, 4, 5 are ranked first on a combination of two measures of efficacy : NYHA/Ross 
functional class and the PGI S. Both measures are simple, comprehensive, and complementary . 
Worsened is defined as worsening in heart failure functional class (NYHA / Ross heart failure 
classification) at the last reported observation; orworsening of PGIS score at the last repo rted 

Novartis Confidential Page 54
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
observation. Improved is defined as a condition that is not worsening, and demonstrating
improvement in heart failure functional class at the last reported observation, and/or 
improvement in PGIS score at last reported observati on. Unchanged is define d as neither 
improving nor worsening for both NYHA/Ross and PGI S. 
PedsQL physical functioning domain
Further ranking within Categories 3, 4, 5 as needed (‘tie breaking’) will be based on a subset of 
5physical functioning domain questions of the PedsQL score (for Group 1 patients 6  to < 18 
years old).For example, patients who are equally ranked based on the NYHA/Ross and the 
PGIS will be further ordered from worst to best by the PedsQL  physical functioning assessment. 
The phy sical functioning domain o f questions from the PedsQL  focuses on proximal effects of 
health
-related qualit y of life related toheart failure (refer to Section 6.6.1.2 andAppen dix 9).
The PedsQL ph ysical functioning domain will only be used for the primary endpoint fo r Group 
1 since the same age-specific version of the patient- reported PedsQL will be collected for all 
patients in Group 1 (and this does not occur for Groups 2 and 3).
For the duration of Part 2 , the same PedsQL, NYHA and Ross instruments based on the age at 
randomization should be used.
3.4 Rationale for patient population
Pediatric heart failure differs from adult HFas it is more heterogeneous and has a different 
etiology . Pediatric HF can be due to: volume overload of the ventricle with preserved systolic 
function (e.g. left to right shunt), pressure overload, persistent arrhy thmias, dilated 
cardiom yopath y and s ystemic disorders that affect myocardial contractile function ( Chaturvedi 
2009) . This study focuses on study ing a subset of pediatric HFwith systemic left ventricular 
dysfunction. The rationale for study ing this patie nt population is that it allows for examination 
of a more homogeneous pediatric HF population that also has pathoph ysiology  similar to adult 
HFrEF where LCZ696 has demonstrated a significant mortality  and morbidity  benefit 
(McMurray  2014) compared to current standard of car e (ACEI). I n addition, for the Carvedilol 
Pediatric HF study which uses a clinical endpoint similar to this study , there was a potential 
treatment benefit in the subgroup of patients with systemic left ventricle morphology  (Shadd y 
2007). When underly ing ventricular morphology was taken into account in the Carvedilol 
Pediatric HF study , a significant interaction was seen between treatment and ventricular 
morphology  (p=0.02) indicating a possible differential effect of treatment between patients with 
a systemic left ventricle (beneficial trend) 
and those whose systemic ventricle was not a left 
ventricle (non- beneficial trend) (Shaddy  2007). 
Numerous small observational studies in children 1.5 days to <18 years old have suggested that 
ACE 
inhibition benefits patients with HF caused by systemic ventricular systolic dysfunction, 
left to right shunt, congenital heart disease, and valvular regurgitation (Leversha 1994, 
Rosenthal 
2004, Momma 2006 ). However, the use of ACEI and ARBs in infants with single -
ventricle physiology  and adults with systemic right ventricle resulted in no significant benefit 
(Hechter 2001, Dore 2005, Hsu and Pearson 2009 b, van der Bom 2013 ). 
In view of (1) a potential differential effect systemic ventricular morphology  may have on 
outcom es 
(based on the Carvedilol Pediatric HF study  ) and (2) studies in children suggesting 
benefit from ACEI in HF due to systemic left ventricular systolic dysfunction but no benefit 

Novartis Confidential Page 55
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
from ACEI or ARB treatment in HF due to single ventricle or systemic right ventricle 
anatomy /physiology  (Bengur 1991, Lewis 1993, Hechter 2001, Rosenthal 2004, Lipshultz 2003, 
Dore 2005, Duboc 2005 and 2007, Hsu and Pearson 2009 b, van der Bom 2013 ) ,this study  will 
examine a more homogeneous population with biventricular hearts and HF due to sy stemic left 
ventricle with decreased EF. Such an approach will result in a patient population that resembles 
more closel y the adult HF population in which LCZ696 has been shown to be more effective 
than enalapril in reducing mortality , HF hospitalization and improving symptoms in patients 
with HF.
Given the concern that use of a RAS blocker may affect kidney  development based on 
preclinical rat toxicity  studies, children < 1 month old (full term infan t) (or < 44 weeks post 
conception for pre-term infant) are excluded from the study . Thus, the study  population is 1 
month (or ≥ 44 weeks post conception for pre- term infants) to < 18 y ears old.
3.5 Rationale for dose/regimen, route of administration and durati on 
of treatment
Rationale for dose selection
The approach for dose selection examines safet y, PK, and PD responses following 
administration of two doses equivalent to adult LCZ696 50 mg (lowest) and 200 mg (highest) 
doses, respectivel y. The objective is toselect a dose that provides similar exposures of LC Z696 
analytes to that observed in adult heart failure patients and that maximizes neprily sin inhibition.
The PD effect of nepril ysin inhibition in children will be assessed through the measurement of 
urine and plasma biomarkers.
For the estimation of precision for pharmacokinetic parameters, data obtained from both dose 
levels will be pooled as pharmacokinetics of LCZ696 analytes is dose-independent (dose 
linearity  has been established). Dose -exposure response for pharmacod ynamics parameters will 
be compared with available adult data.
Rationale for dose/regimen
Part 1 (PK/PD )
Part 1 (PK/PD) was designed with safet y of the trial subjects in mind, sequentially  exposing 
older and then younger age groups to L CZ696: 
The d ose of LCZ696 0.8 mg/kg corresponds to the L CZ696 50 mg dose foradult subjects
with a body  weight of 65 kg .Further more , the LCZ696 50 mg dose is the recommended 
starting dose for adult HF patients who are ACEI/ARB naïve ,
on a low dose of 
ACEI /ARB treatment , have severe renal impairment, or have moderate hepatic 
impairment. TheLCZ696 0.8 mg/kg dose delivers valsartan exposure bioequivalent of 0.6 
mg/kg valsartan which is below the starting dose for valsartan in pediatric hy pertension 
(1.3 mg/kg). LCZ696 0.8 mg/kg is also expected to have similar tolerability  as enalapril 
0.05 mg/kg which is below the recommended daily  starting dose of enalapril for pediatric 
heart failure . Note that enalapr il doses ranging from 0.1 to 0.5 mg/kg/day  are used in the 
treatment of pediatric HF. 

Novartis Confidential Page 56
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
To further ensure patient safet y, patients must be treated with an ACEI or ARB prior to 
screening. Patients in Group 1 and 2 must be currently treated with a daily  dose equivalent 
of at least enalapril 0.2 mg/kg ( Table 3 -1) prior to the L CZ696 3.1 mg/kg single dose 
assessment , and patients in Group 3 
must be currently  treated with a dail y dose equi valent 
of at least enalapr il 0.1 mg/kg ( Table 3 -1) prior to the L CZ696 1.6 mg/kg single dose 
assessment . For those patients who participated, the L CZ696 0.4 mg/kg or 0.8 mg/kg
single dose assessment must have been tolerated in ord er to participate in the L CZ696 1.6 
mg/kg or 3.1 mg/kg single dose assessment. 
TheLCZ696 3.1 mg/kg dose corresponds to the LCZ696 200 mg dose in adult subjects of 
65 kg bod y weight. In adult HF patients, no significant impact of bod y weight on the PK 
of LCZ696 anal ytes was observed over a range of 41.5 kg to 157.3 kg. Therefore, for 
patients in this weight range, LCZ696 3.1 mg/kg isexpected to have similar exposure to 
that 
observed in adult heart failure patients
Furthermore, simulations using ph ysiolog ically  based PK(PBPK) models and allomet ric 
scaling techniques indicate exposure similarity  between pediatric patients (6 to < 18 years
old) and adult HF patients.
The proposed maximum LCZ696 dose of 3.1 mg/kg delivers valsartan exposure similar to
that observed with 160 mg valsartan marketed tablets which is the target dose 
administered twice daily in adult HF patients . Valsartan at a 2.0 mg/kg dose 
administered 
orally  was studied in children 1 to 16 yearsold with hy pertension ( Blumer 2009 ). In this 
study , with patients (1 –16 years old ) valsartan exposure (C maxand AUC) did not vary  
significantl y with age . The body  weight -adjusted CL /F values were also comparable 
across the 1- 16 year old children and were similar to th ose observed in adult subjects .
It should be noted that the LCZ696 3.1 mg/kg single dose for Part 1 ( PK/PD )is half the 
LCZ696 200 mg bid (or pediatric equivalent 3.1 mg/kg bid target dose) maximal daily  
dose in Part 2 (Efficacy )
.
The dose for Group 2 (1 to < 6 y ears) may  be adjusted depending on safety , PK, and PD 
information from Group 1. In Group 2 (1 to < 6 years), the projection is to similarly  
evaluate the LCZ696 0.8 mg/kg and 3.1 mg/kg doses. 
The dose for Group 3 (1 month to <1 y ear) may  be adjusted depending on safet y, PK, and 
PD information from Groups 1 and 2. Since the phy siologicall y based pharmacokinetic 
modeling (PBPK) simulations predicts higher exposure in Group 3 (1 month to < 1 y ear)
compared to older ages, the projection is to evaluate the L CZ696 0.4 mg /kgand 1.6 mg/kg
dose in Group 3.
Safety  will be closel y monitored during Part 1 of the study . Dosing will be performed in an 
experienced pediatric clinical unit setting with close observation, and patient supine/sitting. 
Part 2 (Efficacy )
For Part 2 randomization, patients are assigned in a blinded manner to enalapril or LCZ696. 
The target dose and dose regimens are outlined in Table 3-5andTable 3-6. B ased on Part 1 
data,
the target dose for Group 3 has been increased from the originall y planned 1.6 mg/kg to 
2.3 mg/kg as observed exposures in Part 1 Group 3 patients were lower than initially  expected. 
The study  drug is uptitrated to the target dose  at 2 week intervals
, astolerated .Safety  criteria 

Novartis Confidential Page 57
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
for dose escalation are provided in Table 3-3. The patient should achieve the target dose (dose 
level 4or 4x, depending upon the age group ) by Visit 403 or optional Visit 404 if tolerated. 
Additional safet y monitoring for hy potension isrequired for Group 3 patients with each initial 
dose level up -titration . See Appendix 13for details. Both scheduled and unscheduled visits can 
be utilized for up
-titration/down -titration throughout the study  based on Investigator judgment.
Therationale for theprojected target dose of LCZ696 3.1 mg/kg bid for Groups 1 and 2 in Part 
2 of the study  are:
LCZ696 3.1 mg/kg bid is expected to be consistent with the adult dose target of 200 mg 
bid 
Simulations using phy siologicall y based PKmodels and allometric scaling techniques 
indicate dthatadose o f 3.1 mg/kg in pediatric patients of age > 2 y ears provides similar 
exposure to that observed in adult heart failure patients, therefore justify ing administration 
of3.1 mg/kg in 6 to < 18
years age group
The LCZ696 dosesused in Part 2 (Efficacy ) will be confirmed based on the observed PK, PD
and safet y data obtained from Part 1 of the stud y .
Rationale for duration of treatment
The rationale for the 52-week treatment duration is based on the positive LCZ696 treatment 
effect for relevant clinical endpoints that were evident as early as 4 to 6 months treatment 
durat
ionin the LCZ696 adult PARADI GM-HF study . The 52-week treatment duration will also 
increase the number of clinical events in Categories 1 and 2.
There was a sustained separation of Kaplan
-Meier survival curves as early  as 6 months for 
the primary  composite endpoint consisting of cardiovascular death and time to first HF 
hospitalization.
At four months compared to baseline, there was less worsening of HF s ymptoms and 
physical limitations compared t o enalapril as measured by  the KCCQ (p=0.0423).
At four months, there were more improved patients with the Global Assessment, and 
fewer worsened patients for both NYHA and the Global Assessment for the L CZ696 
group compared to the enalapril group (NYHA, p=0.0028; Global Assessment, p=0.0039).
Safety  areas of interest such as hypotension, h yperkalemia, renal impairment, angioedema, and 
liver toxicity  can be assessed in the 52 week period based on experience from the adult LCZ696 
HF studies.
The study duratio n will provide 1 y ear(52 weeks) growth and safet y data in growing children.
3.6 Rationale for choice of comparator
Enalapril has been chosen as the comparator as it is the most commonly  used renin angiotensin 
system (RAS) blocker in children with HF (The Report on the Expert Group Meeting of 
Pediatric Heart Failure, London, 29 November 2010 ( EMA/112144/2011 )). Additionally , 
enalapril is considered the standard of care in the treatment of chronic heart failure in most 
geographic areas. Enalapril doses ranging from 0.1 to 0.5 mg/kg/day  are use d in the treatment 
of pediatric HF.

Novartis Confidential Page 58
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
The dose of 0.4 mg/kg/day  was thetarget dose in the “Enalapril in infants with singl e ventricle” 
study  published (Hsu 2010 ) , and isthe target dose in the ongoing “The labeling of enalapril 
from neonates up to adolescents”, or LENA Stud y (http://www.lena -med.eu ).
In addition, enalapril has a twice daily  dosing regimen similar to LCZ696. Two other commonly  
used ACEIs in pediatric HF are captopril and lisinopril. However captopril is typicall y dosed 
three times dail y and lisinopril is ty picall y dosed once dail y. 
3.7 Purpose and ti ming of interim analy ses/design adaptations
In Part 1,a review of PK/PD and safet y data will be performed for Group 1 and 2after both 
doses (LCZ6960.8 mg/kg and 3.1 mg/kg) are administered. For Group 3, this analy siswill be 
conducted after both doses (L CZ696 0.4 mg/kg and 1.6 mg/kg) are administer ed.
The dosing of each corresponding age group can begin in Part 2 after the dose has been
confirmed from Part 1 for that age group. Based on Part 1, these dose regimens may also be 
adjusted. To determine the LCZ696 dose for Part 2 : (1) the exposure normalized to dose/body 
weight of pharmacologically  active LCZ696 analy tes (LBQ657, valsartan) will be compared 
between pediatric patients and adult HFpatients; and (2) the exposure -response will be 
examined for nepril ysin pharmacod ynamic effect.
Interim efficacy  analy sis of the global rank endpoint
In Part 2 (Efficacy ), a
ninterim efficacy  analysis and futility  analysis is planned when at least 
180 patients (at least 36 patients from each age group) have completed the study  (i.e., reached 
a terminal endpoint or completed the 1 year study  visit), and at least 40 patients have had an 
event in Category  1 or 2.This interim analy sis will be done to allow for early  stopping of the 
study  in the event that efficacy  is observed at thetime of the interim analysisor in the event 
that the study  is unlikely  to demonstrate a benefit for patients. 
In addition ,an anal ysis of sparse PK data collected in a subset of patients in Part 2 Age Group 
2, is planned (see Section 9.6 for details).
 
 
 
 
 
 
3.8 Risks and benefits 
The study  will assess theefficacy  of LCZ696 in pediatric HF patients. To date no trial has 
demonstrated an outcome benefit of any  pharmacotherapy  in children with HF. L ittle progress 
has been made in improving the significant mortality  and morbidity  associated with 
symptomatic heart failure. In the 1980s, 1 -year mortality  rates in pediatric HF rates were 20% 

Novartis Confidential Page 59
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
to 30%, reaching 40% by 5 years. The advent of pediatric heart transplantation has decreased 
mortality  in the first year after presentation but only where available ( Hsu and Pearson 2009b ). 
The mortality  and morbidity  benefit of LCZ696 compared to the standard of care enalapril for 
the treatment of adult HF with reduced systolic function (HFrEF) is evident from the 
PARADIGM -HF study . Clinical trial data in adults demonstrate that LCZ696 has an overall 
safety profile generally  comparable to other RAS inhibiting agents. Hypotension, hyperkalemia, 
renal impairment and angioedema have been identified as possible safety  risks in LCZ696 
studies. While the incidence rate of hypotension in study  CLCZ696B2314 was higher for 
LCZ696 compared with enalapril, hypotension assessed as severe or serious was not higher in 
the LC Z696 group compared to the enalapril group. Also, no major difference was observed for 
hypotension leading to study  drug discontinuation .In contrast , the incidence of hy perkalemia, 
renal impairment and cough was numerically  lower in the LCZ696 group compared to the 
enalapril group in study  CLCZ696B2314. 
In the PANORAMA -HF study , two patients in the high dose group (1.6 mg/kg) of Part 1 Age 
Group 3 ex perienced AEs of h ypotension. While the risk for h ypotension may be lower for this 
age group in Part 2 of the study  where study  drug will be up-titrated in a step -wise manner 
compared to the single, high-dose setting in Part 1, additional safet y measures have been 
implemented in an effort to decrease the risk of, and to monitor for , hypotension in Part 2 Age 
Group 3 patients: (1) lower target dose compared to Age Group s 1 and 2 despite similar 
observed exposures adjusted for dose in Part 1; (2) smaller up-titration steps compared to Age 
Group s1 and 2; (3) a 4 hour observation period following the initial dose at each dose level to 
monitor 
vital signs; and (4) an additional phone call at 3 day s (+/-1 day ) after each initial dose 
level up -titration step in order to check for s ymptoms of hy potension.
Results of juvenile studies with valsartan in rats have identified kidney  and bone aspotential 
targets for adverse effects associated with LCZ696 administration. Renal changes observed in 
rats treated with valsartan are consistent with those observed for other compounds which 
interact with RAAS, and occurred as a result of valsartan administration during a critical period 
of renal development (i.e. completed by post-natal weeks 4-6 weeks) (Zoetis 2003). 
Corresponding renal development is complete in the human by ~35
-36 weeks of gestation, 
occasionall y extending to 44 weeks. 
Results of juvenile rat studies with sacubitril demonstrated minimal bone changes that are 
considered possibly  due to associated body  weight reductions. These changes were not 
associated with any changes in bone strength, matrix or growth plate. These findings also did 
not adversel y affect the health of the animal. The non-clinical finding s described do not 
demonstrate safet y findings that preclude study ing LCZ696 in the proposed pediatric HF 
population.
In addition, neprily sin is one of multiple pathways involved in the clearance of amyloid β
peptide from the brain and CSF. In a study in young cynomolgus monkeys, administration of 
LCZ696 for 2 weeks resulted in increased total cerebrospinal fluid levels of amyloid β 1-42, 1 -
40 and 1 -38. In this study, there were no changes in amyloid βlevels in brain tissue . There was 
also no evidence for brain amyloid βdeposition and plaque formation in a 39-week study  in 
cynomolgus monkey s with a dose of LCZ696 that was 6-fold higher than the dose used in the 
2-week stud y.

Novartis Confidential Page 60
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
In contrast to the non -clinical study , administration of LCZ696 400 mg once daily  for 14 day s 
in healthy  subjects did not result in changes in cerebrospinal fluid concentrations of amyloid β
1-40 and 1 - 42, although there was an increase in amy loid β 1 -38. The clinical relevance of the 
small increase in CSF Aβ1
-38 observed with LCZ696 is unknown. These observations suggest 
that enzy mes and disposition pathway s other than nepril ysin appear to be more important in 
clearance of CSF Aβ in humans. There was also no increased incidence of cognition -or 
dementia -related AEs in the LCZ696 clinica l program with up to 5 year LCZ696 exposure in 
the PARADIGM -HF study .The clinical implication of pharmacological changes in CSF 
amyloid βmetabolism is unknown (Ryman 2014). Increased CSF amyloid βlevels found in
Down’s syndrome patients (Schupf 2002) and associated with specific familial Alzheimer’s 
disease mutations are not associated with dementia symptoms unt
il late in life (> 40 –50 years 
old) ( Wang 2006 ).
Given the significant morbidity  and mortality  of pediatric HF patients and the context of the 
current data and knowledge of this issue, the benefit risk assessment is considered to be positive. 
To mitigate potential risks inpediatric study  participants, safety  parameters will be monitored 
closely , and these parameters will include vital signs, physical exam (including height and 
weight), biomarkers, hematology , blood chemistry , urinal ysis tests and ECG.
4 Population
The study  population consists of pediatric HF patients 1 month to <18 years, inpatient or 
outpatient, with systemic left ventricle systolic dysfunction (LVEF ≤45% or a fractional 
shortening ≤
22.5%). For inclusion criteria details regarding LVEF and fractional shortening, 
refer to Section 4.1 . The study  will enroll at least 18 
patients in Part 1 and 360 patients in Part 
2 (Efficacy ) at centers worldwide. With an expected screen failure rate of 35% for both Part 1 
(PK/PD) and Part 2 (Efficacy), it is estimated that approximately  46 patients will have to be 
screened for Part 1 and 554 patients will have to be screened for Part 2.
For Part 1, at least 18 subjects will be divided across thr ee groups based on age: Group 1: 6 to
<18 years(6 observations for theLCZ696 0.8 mg/kg dose and 6 observations for the LCZ696 
3.1mg/kg dose); Group 2: 1 to < 6 years(6 observations for the LCZ696 0.8 mg/kg dose and 
6 observations for the LCZ696 3.1 mg /kg dose) ; Group 3: 1 month to < 1 year (approximatel y 
4 observations for LCZ696 -
0.4mg/kg dose and approximately  4 observations for the LCZ696 
1.6 mg/kg dose). Eligible patients will participate in the LCZ696 0.8 mg/kg and 3.1 mg/kg doses 
in Groups 1 and 2 and in the LCZ696 0.4 mg/kg and 1.6 mg/kg doses in Group 3 .  Patients who 
do not participate in the LCZ696 3.1 mg/kg (Group 1 or 2) or 1.6 mg/kg (Group 3) dose will be 
replaced. To ensure that p atients are enrolled in both high and low end of the 6 t o < 18 years of 
age group, approximately  50% patients will be enrolled who are 6 to 11 years of age in Group 
1.
For Part 2, 
patients will be stratified by age(Age Groups 1, 2 and 3)and NYHA/Ross class
group (Class I/II, Class III/IV)at randomization to ensure a balanced distribution of treatment 
allocation within each age group. Patients who discontinue from Part 2 will not be replaced.

Novartis Confidential Page 61
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
4.1 Inclusion criteria
Patients eligible for inclusion in this study  (Part 1 and Part 2) must fulfill all of the following 
criteria:
1.Written informed consent by  parent(s)/legal guardian(s) for the pediatric patient must be 
obtained before an y study -specific assessment is performed.* A consent or assent may  
also be required for some patients depending upon their age and local requirement.
2.Male or female ,inpatient or outpatient , 1 month ( ≥44 weeks post -conception for pre -term 
infants) to < 18 years of age .
3.Chronic heart failure resulting from left ventricular s ystolic dy sfunction, and receiving 
chronic HF therap y (if not newly diagnosed)..
4.NYHA classification II -IV (older children: 6 to less than 18 year old) or Ross HF 
classification II- IV (younger children: less than 6 y ear old) any time prior to screening. 
[Note: Age Group 1 patients may be NYHA class I at time of screening if there is a prior 
history  of NYHA 
class II-IV. Age Group 2 patien ts must be Ross class II or higher at time 
of randomization].
5.Systemic left ventricular ejection fraction (EF) ≤ 45% or fractional shortening ≤22.5% 
(assessed b y echocardiogram, MRI , MUGA or left ventricular angiogram within 1 month 
before patient begins Part 2
).[Note: The study  will target enrollment of approximately  
80% patie nts with a sy stemic left ventricular ejection fraction (EF) ≤ 40% or fractional 
shortening ≤20% for Part 2 only ].
6.Biventricular ph ysiology  with sy stemic left ventricle.
7.For Part 1 PK/PD, patients must be treated with an ACEI  or ARB prior to screening. For 
Part 1 PK/PD, patients in Group 1 and 2 must be currentl y treated with a daily  dose 
equivalent of at least enalapril 0.2 mg/kg ( Table 3 -
1) prior to the L CZ696 3.1 mg/kg 
single dose assessment. For Par t 1 PK/PD, patients in Group 3 must be currently  treated 
with a daily  dose equivalent of at least enalapril 0.1 mg/kg ( Table 3 - 1) prior to the 
LCZ696 1.6 mg/kg single dose assessment 
8.HF etiologies includ e: Congenital Cardiac Malformation with sy stemic ventricular s ystolic 
dysfunction; I diopathic Cardiomy opathy ; Familial/Inherited and/or Genetic 
Cardiomy opath y; History  of My ocarditis; Neuromuscular Disorder; Inborn Error of 
Metabolism; Mitochondrial Disorder; Acquired (Chemotherap y, Iatrogenic, Infection, 
Rheumatic, Nutritional) ; Ischemic ( e.g. Kawasaki Disease, post -
operative) ; Left 
ventricular noncompaction
*Assessments of HF (e.g. ECHO) in patients that are done according to current local 
institutional/h ospital standard protocol or that are part of routine clinical care can be used to 
support patient screening and may have takenplace before signing informed consent. An 
informed consent must be obtained from a patient once they become 18 years old during the 
study .
4.2 Exclusion criteria
Patients fulfilling an y of t he following criteria are not eligible for inclusion in this study (Part 1 
and Part 2) . No additional exclusions may  be applied by the Investigator , in order to ensure that 
the study  population will be representative of all eligible patients.

Novartis Confidential Page 62
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
1.Patients with single ventricle or s ystemic right ven tricle
2. Patients listed for heart transplantation asUnited Network for Organ Sharing (UNOS) 
Status 1A or hospitalized waiting for transplant while on inotropes or with ventricular 
assist device at time of entry  into the study
3.Sustained or sy mptomatic dy srhythmias uncontrolled with drug or device therapy
4.For Part 2 onl y, patients that have had cardiovascular surgery  or percutaneous intervention 
to palliate or cor rect congenital cardiovascular malformations within 3 months of the 
screening visit .Patients anticipated to undergo corrective heart surgery  during the 12 
months after entry  into Part 2.
5.Patients with un
operated obstructive or severe regurgitant valvular (aortic , pulmonary ,or 
tricuspid) disease, or significant sy stemic ventricular outflow obstruction or aortic arch 
obstruction
6.Patients with restrictive or hypertrophic cardiom yopathy
7.For Part 2 onl y, active myocarditis (diagnosed with presumed or acute m yocarditis within 
3 months of enrollment)
8.Symptomatic hy potension or blood pressures (BPs) below the calculated 5th percentile 
systolic BP (SBP) for age at screening visit and as described in Appendix 4
9. R enal vascular h ypertension (including renal artery stenosis )
10.Severe pulmonary  hypertension ( defined b ypulmonary  vascular resistance (PVR) 
index >6 Wood units-m2) unresponsive to vasodilator agents ( such as oxy gen, 
nitroprusside or nitric oxide). Note measurement of PVR is not a requirement for study
eligibility
11.History  or current clinical evidence of moderate- to severe obstructive pulmonary  disease 
or reactive airway  diseas es (e.g. asthma)
12.Serum potassium >5.3 mmol/L at Visit 1 or at Visit 301
13. Patients with significant renal (eGFR calculated using the modified Schwartz formula < 
30% mean GFR for age, Appendix 10, Table 22-1); hepatic (serum aspartate 
aminotransferase or alanine aminotransferase > 3 times upper limit of normal); 
gastrointestinal or biliary disorders (that could impair absorption, metabolism, or excretion 
of orall y administered medications)
14.Concurrent terminal illness or other severe disease (e.g. acute ly mphocy tic leukemia) or 
other significant laboratory  values that, in the opinion of the Investigator , precludes study  
participation or survival
15. Patient s with a histor y of angioedema
16.Patients with allergy  or hy persensitivity  to ACEI or ARB
17.Patients who have parents or legal guardians who do not give consent or allow the child to 
give assent, or inability  of the patient or the parents/legal guardians to follow instructions 
or comply  with follow -up procedures
18.Pregnan t or nursing (lactating) women
19.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they are using highly  effective methods of contraception 
during dosing of investigational drug and for 7 day s after study drug discontinuation. 
Highl y effective contraception methods include:

Novartis Confidential Page 63
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subjectandif acceptable by  the local regulation ). Periodic abstinence (e.g. calendar, 
ovulati on, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks befo re taking 
investigational drug. In case of oophorectom y alone, only when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 m onths prior to screening). For female subjects on the 
study, the vasectomized male partner should be the sole partner for that subject
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine sy stem 
(IUS), or other forms of hormonal contraception that have compara ble efficacy  
(failure rate <1%); for example hormone vaginal ring or transdermal hormone 
contraception 
In case of use of oral contraception women should have been stable on the same pill 
for a minimum of 3 months before taking investigational drug
20.
Use of other investigational drugs within 5 half- lives or within 30 day s ofenrollment, 
whichever is shorter
21.History  of hypersensitivity  to any  of the study  drugs or its excipients or to dr ugs of similar 
chemic al classes
22.Any major solid organ transplant recipient
23.History  of malignancy  of any  organ s ystem, treated or untreated, within the past y ear with 
a life expectancy  less than 1 y ear
24.Any advanced severe or unstable disease that may interfere with the primary  or secondary  
study  outcome evaluations or put the patient at special risk
25.Any other medical conditions that may  put the patient at risk or influence study  results in 
the Investigator ’s opinion, or that the Investigator deems unsuitable for the study
26. Patient breastfed b y a mother taking ACEI
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
The sponsor will provide the following stud y drugs:
Part 1 -PK/PD treatment epoch
All eligible patients that enter Part 1 will receive LCZ696.
The LCZ696 study medication is available as granules or liquid formulation based on age, 
weight, dosing, and patient’s ability  to take stud y medication (Pharmacy  Manual).
The following stud y drug will be provided:

Novartis Confidential Page 64
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
LCZ696 3.125 mg granules (packaged in capsules containing 4 or 10 granules) 
Sites will be provided with study drug to administer for single dose Part 1 PK/PD to all eligible 
patients atthat site. LCZ696 granules can be ingested after removing from the capsule. The 
liquid formulation can be compounded at the site /pharmacy [Pharmacy  Manual] .
Patients will be instructed to not use an ACEI  for 36 hours after taking the single dose of 
LCZ696 to minimize the potential risk of angioedema due to overlapping ACEI -NEP inhibition. 
Patients should not use an ARB or renin inhibitor on the day  ofthe sing le dose PK assessment
visit.
At the completion of the single dose PK assessment visit (Visit 101and/or 201), patients will 
be provided with open -label enalapril or will be instructed to resume their usual care as deemed 
necessary  by the Investigator . The open -label enalapril will be obtained from a local commercial 
source by the site and provided to the patient . If needed, based on the patient’s age and/or 
inability  to swallow tablets ,liquid enalapril may be used. The liquid enalapril is prepared at the 
site’s pharmacy as per local regulations, andcan be commercially  source d such as Epaned (if 
available) . Patients receiving enalapril liquid formulation must return to the site for resupply  at 
intervals dependent on the storage life of enalapril liquid for mulation (every 1 month; or ever y 
2 months if Epaned (enalapril) which has 2 month shelf life, is available and used ). 
Part 2 (Efficacy ) -Randomized treatment epoch
The LCZ696 study  medication is available in three formulations: tablets, granules (mini -tablets) 
or liquid formulation (if patient cannot swallow granules) (refer to Table 5 -1). 
The enalapril study  medication is available in two formulations: tablets or liquid formulation
(refer to 
Table 5 -2).
Patients will be randomized to initiate study  medication at dose levels 1 or 2 for Group s 1 and
2,and 1x or 2x for Group 3, depending on whether they  are ACEI /ARB naïve or depending on 
their ACEI /ARB dose 
prior to randomization (refer toTable 3-4, Table 3-5, Table 3-6). The 
study  medication will be titrated at subsequent visits to the target dose. In addition to study  
medication, patients will continue to take optimal background HF therapy  as considered 
appropriate by the Investigator and in accordance with standard HFtreatment guidelines. The 
exception is that ACEI  or ARB will be repla ced by study drug. The use ofopen -label ACEI, 
ARB, or renin inhibitor in addition to randomized study  drug is strictly  prohibited.
The following stud y drug s will be provided for Part 2 (Efficacy):
LCZ696 12.5mg (bottle will contain capsules, each capsule contains 4 granules of 
LCZ696 3.125mg)
Placebo to match LCZ696 12.5mg (bottle will contain capsules, each capsule contains 4 
granules of LCZ696 3.125mg matching placebo)
LCZ696 31.25mg ( bottle will contain capsules, each capsule contains 10 granules of 
LCZ696 3.125mg)
Placebo to match LCZ696 31.25mg (bottle will contain capsules, each capsule contains 10 
granules of LCZ696 3.125mg matching placebo)
LCZ696 50mg tablets 

Novartis Confidential Page 65
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Placebo to match LC Z696 50mg tablets 
LCZ696 100mg tablets 
Placebo to match LCZ696 100mg tablets 
LCZ696 200mg tablets 
Placebo to match LCZ696 200mg tablets 
Enalapril 2.5mg tablets 
Placebo to match enalapril 2.5mg tablets 
Enalapril 5mg tablets 
Placebo to match enalapri l 5mg tablets 
Enalapril 10mg tablets 
Placebo to match e nalapril 10 mg tablets
All study  medications will be supplied in bottles or blister cards. Capsules of LCZ696/matching 
placebo containing 4 granules or 10 granules per capsule will be provided for oral use. The 
granules can be swallowed (after the removal of the outer capsule )by the patient.
LCZ696/matching placebo liquid formulation will be compounded by the site /pharmacy 
[Pharmacy  Manual] . Patients taking < 8granules (< 25 mg) for a dose will use the liquid 
formulation . The appropriate aliquot of liquid medication corresponding to the patient’s dose 
will be given to the patient. Appropriate oral sy ringes will be provided to facilitate study  drug 
administration as a liquid.
Suffi cient medication will be provided for the treatment according to the study protocol (Table 
5-1and Table 5-2). Medication labels will be in the local language and comply  with the legal 
requirements of the country . The labels will include storage conditions for the drug and the 
medication number, and will
not include information about the patient.
Patients taking theliquid f
ormulation of LC Z696/matching placebo or enalapril /matching 
placebo must return to the site every  4 weeks for resupply . The enalapril or enalapril placebo -
liquid formulation will be prepared at the site / pharmacy based on the patient’s age and abilit y 
to swallow adult tablets. The site personnel or the pharmacy  at the sites isresponsible for 
preparing enalapril liquid formulation (Pharmacy  Manual) . Given the burden of traveling to the 
site for study  visit sfor patients and families, the parent/caregiver can come to the site without 
the patient for dispensation of study  drug. Delivery of study drug to the patient can also be used 
where possible and allowed per local regulation s.
Instructions for preparation of the liquid study  drugs are provided in the Pharmacy  Manual.
Table 5-1 LCZ696 drug supply  for Part 1 (PK/PD )and Part 2 (Efficacy )
Study d rug –Part 1 PK/PD 
open-labelStrength Formulation
LCZ696 3.125 mg Granules packaged in capsul es 
of 4 or 10 granules in bottle
Study d rug –Part 2 Efficacy 
double blindStrength Formulation
LCZ696 or matching placebo 3.125 mg Granules packaged in capsules 
of 4 or 10 granules in bottle

Novartis Confidential Page 66
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
Study d rug –Part 1 PK/PD 
open-labelStrength Formulation
LCZ696 or matching placebo 50mg Tablets in bottle
LCZ696 ormatching placebo 100mg Tablets in bottle
LCZ696 or matching placebo 200mg Tablets in bottle
Table 5-2 Enalapril drug supply  for Part 2 (Efficacy )
Study d rug –Part 2 Efficacy
double blindStrength Formulation
Enalapril or matching placebo 2.5 mg Tablets in bottle /blister
Enalapril or matching placebo 5 mg Tablets in blister
Enalapril or matching placebo 10 mg Tablets in blister
Part 1:
The LCZ696 study  medication is available as granules or liquid formulation based on age, 
dosing, and patient’s ability  to take stud y medication (Pharmacy  Manual) .
Part 2:
The LCZ696 study  medication is available in three formulations: tablets, granules (mini-tablets) 
or liquid formulation (refer to Pharmacy Manual) (if patient cannot swallow granules) (refer to
Table 5-1). 
The enalapril study  medication is available in two formulations: tablets or liquid formulation.
All pediatric formulations of study  medication (LCZ696 granules or liquid, enalapril liquid) 
will be made available to all age groups. The adult tablet formulations of LCZ696 and enalapril 
will be available to patients based on the patient’s dosing and ability  to swallow adult tablets 
(refer to Pharmacy  manual).
Dispensing of medication to the subjects will be controlled by an Interactive Response 
Technology  (IRT) s ystem. 
5.1.2 Additional treatment
No additional treatment beyond investigational drug (LCZ696) and active comparator drug 
(enalapril) are included in this trial.
5.2 Treatment arms
Part 1(PK/PD) :All patients will receive open -label LCZ696. Patients completing Part 1 and 
who arewilling to participate in Part 2 will be provided open -label enalapril (or their standard 
of care HF regimen) by the study  site.
Part 2 (Efficacy ): Patients are assigned to one of the following two double blind treatment arms 
in a ratio of 1:1 at the randomization Visit 401:
LCZ696 
Enalapril

Novartis Confidential Page 67
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
5.3 Treatment assignm ent and randomization 
At V isit 401, all eligible patients will be randomized via Interactive Response Technology  (IRT) 
to one of the treatment arms. Patients will be stratified by agegroup (Age Groups 1, 2 and 3)
and NYHA/Ross class group (Class I/II, Class III/IV) at randomization to ensure a balanced 
distribution of treatment allocation within each age strata .The Investigator or his/her delegate 
will contact the I RT after confirming that the patient fulfills all the inclusion/exclu sion criteria. 
The IRT will assign a randomization number to the patient, which will be used to link the patient 
to a treatment arm and will specify  a unique medication number for the first package of study 
drug to be dispensed to the patient. The randomiz ation number will not be communicated to the 
caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients/subjects and Investigator staff. 
A patient randomizat ion list will be produced by  the IRT provider using a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced b y or under the responsibilit y 
of Novartis Drug Supply  Management using a validated system that automates the random 
assignment of medication numbers to packs containing the investigational drug( s). 
The randomization scheme for patients will be reviewed and approved by a member of the 
Randomization Group.
5.4 Treatment blinding
Part 1 ( PK/PD )involves open -label LCZ696.
Part 2 (Efficacy )is a randomized, double -blind, active controlled study . Patien ts, Investigator
andstaff, persons performing the assessments, and data analy sts will remain blind to the identit y 
of the treatment from the time of randomization until database lock using the following methods:
Randomization data are kept strictly  confid ential until the time of unblinding, and will 
not be accessible b y anyone involved in the study  with the following exceptions:
1. The independent and unblinded statistician, programmer and data personnel who are 
involved in preparing safety  and efficacy  inter im analy sis reports for the DMC. These 
personnel will not be involved in any  other trial conduct related activities
2.The DMC members
3.An unblinded team ,which is not involved in the conduct of the study ,will evaluate the 
steady -state sparse  PK blood samples collected from approximately  24 patie nts 
(approximately half of whom are expected to be randomized to L CZ696) in Part 2
Group 2
(Section 9.5.1).
4.  
A double
-dummy  design is used becaus e the identity  of the investigational treatment 
cannot be disguised, as the drug products are visibly  different

Novartis Confidential Page 68
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
The identity  of the treatments will be concealed by the use of investigational treatment 
that are all identical in packaging, labeling, schedule of administration, appearance, taste 
and odor
Unblinding will only occur in the case of patient emergencies (Section 5.5.9 ) ,at the time of 
interim analy ses (Section 9.6 ),and at the conclusion of the study . 
The randomization codes associated with patients/subjects from whom Part 2 PK samples are 
taken will be disclosed to PK analy sts who will keep Part 2 PK result s confidential until data 
base lock.
An assessment will be done by the appropriate site personnel and the Medical Lead (or designee) 
for any patient whose treatment code has been broken inadvertently  or for any nonemergency 
reason to assess whether or not study  treatment/investigational treatment 
should be discontinued 
and, if applicable, whether the patient can continue in the trial .
5.5 Treating the patient
Sponsor qualified medical personnel will be readily available to advise on trial related medical 
questi ons or problems.
5.5.1 Patient numbering
Each patient is uniquely identified by a Subject Number which is composed by the site number 
assigned b y Novartis and a sequential number assigned b y the Investigator. Once assigned to a 
patient, the Subject Number will n ot be reused. 
Upon signing the informed consent form, the patient is assigned the next sequential number by 
the Investigator. The Investigator or his/her staff will contact the IRT and provide the requested 
identify ing information for the patient to register them into the IRT. The site must select the 
CRF book with a matching Subject Number from the EDC sy stem to enter data. 
If the patient fails to be treated for any reason, the IRT must be notified within 2 day s that the 
patient was not treated. The reason for not bein g treated will be entered on the Screening epoch 
Study  Disposition case report form (CRF ).
5.5.2 Dispensing the study drug
Each stud y site will be supplied with study  drug in packaging of identical appearance.
The study  drug packaging has a 2-part label. A unique randomization number is printed on each 
part of this label which corresponds to one of the two treatment arms and dose level. 
Investigator 
staff will identify  the study  drug package(s) to dispense to the patient by contacting the IRT and 
obtaining the medication number(s). Immediatel y before dispensing the package to the patient, 
Investigator staff will detach the outer part of the label from the packaging and affix it to the 
source document (Drug Label Form) for that patient’s unique subject number. 

Novartis Confidential Page 69
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
5.5.3 Handling of study  and additional treatment
5.5.3.1 Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only  the Investigator and designees 
have access. Upon receipt, all study  treatment must be stored according to the instructions 
specified on the labels. Clinical supplies are to be dispensed only in accordance with the 
protocol. Technica l complaints are to be reported to the respective Novartis CPO Qualit y 
Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no in formation about 
the patient except for the medication number .
The Investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
monitors during site visits or remotely  and at the completion of the trial. Patients/subjects will 
be asked to return all unused study  treatment and packaging at the end of the study  or at the 
time of discontinuation of study  treatment. 
At the conclusion of the study, and as appropriate during the course of the study , the Investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of the completed drug 
accountability  log to the Novartis monitor or to the Novartis address provided in the Investigator
folder at each site.
Where applicable and as per local regulations, the study  medication can be shipped from the 
study  site or site pharmacy  to the patients home. Pharmacy  to home operating procedures will 
be provided to the site b y the sponsor.
5.5.3.2 Handling of additional treatment
The Investigator should instruct the patient to notify  the study  site about any  new medications 
he/she takes after the patient was enrolled into the study . All medications, procedures and 
significant non-drug therapies (including physical therap y and blood transfusions) administered 
after the patient was enrolled into the study  must be recorded.
The patient should be receiving optimal standard of care medical and surgical treatment for 
their HF and comorbidities. In Part 2 of the study, study  drug (LCZ696 vs. enalapril) will be 
used instead of ACEI or ARB .
5.5.4 Instructions for prescribing and taking study treatment
Novartis will supply  the Investigators with all study  medications required for the course of the 
study . Patients will be provided with bottles and blisters containing study  drug corresponding 
to their assigned treatment arm and dose level, sufficient to last until the next scheduled visit. 
Part 1:
LCZ696 granules : 3.125 mg (packaged in capsule contain ingeither 4 or 10 granules)
supplied in a bottle 

Novartis Confidential Page 70
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
LCZ696 liquid formulation (compounded b y site /pharmacy )(refer to Pharmacy  Manual)
Part 2:
Patients will be taking the following as provided in blinded packaging:
LCZ696 tablets: 50 mg or matching placebo, 100mg or matching pla cebo, 200 mg or 
matching placebo
LCZ696: 3.125 mg granules or matching placebo, supplied in a bottle containing capsules 
with granules. Each capsule will contain either 4 or 10 granules
LCZ696 liquid formulation (compounded b y site /pharmacy )(refer to Pharmacy  Manual)
Enalapril liquid formulation (compounded b y site /pharmacy )(refer to Pharmacy  Manual) 
or matching placebo, 2.5 mg tablets or matching placebo, 5 mg tablets or matching 
placebo, 1
0mg tablets or matching placebo
The above Part 2 supplies are provided in blinded packaging.
Details regarding preparation of liquid formulation for LCZ696 and enalapril are provided in 
the [Pharmacy  Manual ].
For Part 1 (PK/PD ), the site will provide the single dose open -label LCZ6 96 to the patient for 
administration. For Part 2 (Efficacy ), patients will be instructed to take their morning study  drug 
doses between 6:00 and 09:00 (6 - 9AM) and their evening stud y drug dos e between 18:00 and 
21:00 (6 - 9PM). The study  drugs (tablets) should be taken with a glass of water with or without 
food. The L CZ696 granules can be administered as solid or mixed with soft food .LCZ696 can 
also be administered as a liquid form [Pharmacy  Manual] . If the patient misses taking any study 
drug dose, s/he should take it as soon as possible, unless it is almost time for the following 
scheduled dose. In this case, the patient should skip the missed dose and return back to his/her 
regular stud y drug administration schedule.
All dosages prescribed and dispensed to the patient and all dose changes during the study must 
be recorded on the Dosage Administration Record (DAR ) CRF. All kits of study  treatment 
assigned b y the IRT will be recorded in the IRT.
The Investigator must promote compliance by instructing the patient to take the study  treatment 
exactly  as prescribed and by stating that compliance is necessary  for the patient’s safet y and the 
validity  of the study . The patient must also be instructed to contact the Investigator if he/she is 
unable for any  reason to take the study  treatment as prescribed .
5.5.5 Permitted dose adjustments and interruptions of study  treatment 
The stud y drug is up- titrated every  2 weeks as tolerated to target dose (level 4 for Group 1 and 
2,and 4x for Group 3 ) as outlined in (Table 3 -5andTable 3 -6) based on the safet y monitoring 
criteria (Table 3-3). Additional safety  monitoring will be required for Age Group 3 patients 
with each initial dose level up-titration . See Appendix 13for details. Following up-titration, the 
maximum tolerated or target dose will then be maintained for the duration of the study . Both 
scheduled and unscheduled visits can be utilized for up -titration/down -titration throughout the 
study  based on 
Investigator judgment .

Novartis Confidential Page 71
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
For patients who are unable to tolerate the protocol -specified dosing scheme, dose level 
adjustments and interruptions of study  treatment are permitted in order to keep the patient on 
study  drug. The following guidelines should be followed: 
The Investigator should adjust doses of concomitant medicati ons if it is believed that they  
are the most lik ely cause of an adverse effect
If adjustment/elimination of concomitant medications is not possible or does not alleviate 
the side effects of concern, the I nvestigator may  down titrate to the next lower study drug 
dose level down (Table 3 -5andTable 3 -6)to temporary  or permanent discontinuation of 
study  drug 
The patient should be re challenged with the higher dose when the Investigator feels it is 
appropriate to do so per the directions provided below in this section
If the stud y drug is temporaril y or permanentl y discontinued, then the patient should 
continue to attend the study  visits and be followed until the completion of th e study
Patients may  be seen at any time for unscheduled visits during the ra ndomized treatment epoch 
for re evaluation of safet y criteria parameters. Study drug dose level adjustments should mainl y 
be based on overall safety and tolerability  with focus on a) hyperkalemia; b) symptomatic 
hypotension; and c) renal dysfunction. Local laboratory  assessments of 
serum sodium, 
potassium, creatinine, and eGFR (calculated based on the modified Schwartz formula (Schwartz 
2009) will be utilized . Refer to Appendices 15, 16,and 17for treatment guidelines for renal 
dysfunction, management of hy potension and h yperkalemia , respectively .
Adjustment of study drug dose level
During 
the double -blind treatment epoch, down titration of the study  drug at any time is allowed 
based on thesafety  and tolerability  criteria defined in (Table 3-3). If down titration is necessary , 
the patient should be down titrated to a lower study  drug dose level ( Table 3 - 5andTable 3 -6).
The Investigator may down titrate to the next lower study  drug dose level. If the tolerabilit y 
issues are not alleviated despite down titration by multiple dose levels, the Investigator may 
temporaril y discontinue study  drug. Once the patient’s condition is stable, s/he can be up-
titrated to the next higher dose level every  1 to 4 weeks in an attempt to bring back the patient 
graduall y to the target study  drug dose level (dose level 4 for Group 1 and 2 ,and 4x for Group 
3). The Investigator may choose the next dose level for down -or up-titration according to his 
or her judgment ( Table 3 -
5andTable 3 -6). 
All changes should be recorded on the DAR CRF . In addition, IRT should be contacted to 
register any changes in the patient’s study  drug dose level, in cases of temporary  and permanent 
discontinuation of the study  drug, and to obtain the medication numbers of the study  drug 
supplies required for the new st udy drug dose level. 
Study drug restart after temporary  treatment interruption
Patients who have temporaril ydiscontinued study  drug should be restarted as soon as possible 
as deemed appropriate by the Investiga tor. The Investigator should restart the patient on the 
study  drug at the most appropriate dose level (Table 3-5andTable 3-6) as per the Investigator’s 
clinical judgment. Patients must discontin ue their ACEI  medication(s) 36 hours prior to re-
starting study  drug to allow for an ACEI -free washout period. If the patient does not tolerate 

Novartis Confidential Page 72
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
the newl y restarted study drug dose level, s/he may be down titrated again (if appropriate) or 
the study  medicat ion may  be temporaril y discontinued again.
Patients restarted on the study  drug will retain their original randomization and study  
identification numbers. 
Investigators may  discontinue the study  drug due to serious or intolerable AEs suspected to be 
causall y related to study  drug. If study  drug is discontinued for any reason, the exact time and 
date of study  drug discontinuation must be recorded on the DAR CRFs. In addition, patients 
who discontinue study  drug should continue to be followed at all study  visits as defined in the 
protocol ( Table 6 -1andTable 6-2). 
The use of an open -label ACEI , ARB or a renin inhibitor during a period in which the patient 
may be off study  drug is discouraged. However, if a patient off study  drug has started open -
label treatment with an ACEI , the ACEI must be discontinued ≥36 hours prior to restarting 
study  drug. Patients who have temporarily  discontinued study  drug and are presentl y taking an 
ARB or a renin inhibitor must discontinue their current ARB or renin inhibitor on the day study 
drug is started . These changes must be recorded on the DAR and Concomitant Medication CRF s .
If the patient is discovered to be pregnant during the course of the study , the patient should 
discontinue study  drug immediately . Meanwhile, the patient should continue to attend 
scheduled stud y visit s.
Refer to(Section 6.5.7 and Section 7.7) for further details on pregnancies and reporting 
guidelines.
5.5.6 Rescue medication
If in the opinion of the Investigator, the patient does not tolerate the assigned study medication, 
the Investigator should consider whether non disease -modify ing medication (e.g. CCBs, 
diuretics, α -blockers) can be reduced to rectify  the situation.
Guidance on handling renal dysfunction, hypotension, and hyperkalemia are provided to 
Investigator s in ( Appendix 3 , Appendix 4, and Appendix 5 ) respectivel y. 
The Investigator may  prescribe any  medications and/or supportive care during the study  based 
on clinical needs. Use of rescue medication and/or supportive care must be recorded on the 
Concomitant med
ications CRF .
5.5.7 Concomitant medication
The Investigator must instruct the patient to notify  the study  site about any new medications 
he/she takes after the patient was enrolled into the study . All medications, procedures and 
significant non-drug therapies (including physical therap y and blood transfusions) administered 
after the patient was enrolled into the study  must be recorded in the concomitant medications / 
procedures ( significant non-drug therapies )CRF .
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt
,the Investigator should contact the Novartis medical monitor before 
randomizing a patient or allowing a new medication to be started.

Novartis Confidential Page 73
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
5.5.8 Prohibited medication
Use of the treatments display ed in Table 5-3is NOT allowed while taking study  drug after 
randomization due to safety  reasons. If the medications display ed in Table 5-3must be used, 
study  drug must be discontinued and the actions specified below must be taken.
Table 5
-3 Prohibited treatment by  medication clas s
Medication Action taken
Any ACEI Discontinue study drug. ACEI must be stopped 
for 36 hours prior to re -initiation of study drug 
Any ARB Discontinue study drug. ARB must be stopped for 
prior to re -initiation of study drug
Renin inhibitor (a liskiren) Discontinue study drug. Renin in hibitor must be 
stopped prior to re -initiation of study drug
ACEIs,ARBs, and renin inhibitors
The concomitant use of open -label ACEI, ARB, or renin inh ibitor is strictly  prohibited while 
the patient is receiving study  drug. If the Investigator believes the addition of an ACEI, ARB 
or renin inhibitor is required; the study  drug must be temporaril y discontinued. Study  drug 
should be stopped 36 hours prior to starting open -label ACEI. Study drug should be stopped 
prior to starting open -label ARB or renin inhibitor . 
Similarly , if study  drug is to be restarted, the open -label ACEI  should be stopped >36 hours 
pri
or to resuming study  drug. Open -label ARB or renin inhibitor should be stopped prior to 
resuming stud y drug.
5.5.9 Emergency  breaking of assigned treatment code
Emergency  code breaks must only be undertaken when it is required to in order to treat the 
patient safel y. Most often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  treatment code breaks are performed using the IRT. When the 
Investigator contacts the system to break a treatment code for a patient, he/she must provide the 
requested patient identifying information an d confirm the necessit y to break the treatment code 
for the patient. The Investigator will then receive details of the investigational drug treatment 
for the specified patient and a fax or email confirming this information. The system will 
automatically  inform the Novartis monitor for the site and the Study  Team that the code has 
been broken.
It is the Investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emer gency . The Investigator
will provide:
protocol number
study  drug name (if available)
patient number

Novartis Confidential Page 74
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
In addition, oral and written information to the subject must be pr ovided on how to contact the 
investigator’s backup in cases of emergency , or when the inv estigator is unavailable, to ensure 
that un- blinding can be performed at an y time. 
5.6 Stud y completion and d iscontinuation 
5.6.1 Study completion and post
-study treatment
A patient will be considered to have completed the study  when the patient has completed the 
last visit planned in the protocol.
Continuing care should be provided by  Investigator and/or other caring phy sician . The patient 
should be placed on an A CEI or ARB for HF treatment as determined b y the caring physician.
5.6.2 Discontinuation of study t reatment 
Patients may  voluntaril y discontinue study  treatment for an y reason at an y time. 
The emergence of the following circumstances will require permanent study  drug 
discontinuation:
Withdrawal of informed consent
Investigator believes that continuation would be detrimental to the patient’s well -being
Suspected occurrence of angioedema; a patient with any signs or s ymptoms of clinically  
significant angioedema should be thoroughl y evaluated b y the Investigator
The emergence of the following circumstances will require temporary  or permanent 
discontinuation (study  drug may  be restarted once these circumstances no longer exist):
Use of an open- label ACEI , ARB or renin inhibitor
Pregnancy  and post -pregnancy  during lactation period ( Section 7.7)
Study  drug may  be discontinued at the Investigator ’s discretion if an y of the following occurs:
Any severe or suspected drug
-related AE
Any other protocol deviation that results in a significant risk to the patient’s safet y
The appropriate personnel from the site and Novartis will assess whether study  drug should be 
discontinued for any patient whose treatment code has been broken inadvertently  for any reason.
If permanent discontinuation of study  treatment occurs and the patient/parents/guardians have 
not withdrawn consent , the patient should NOT be considered withdrawn from the study . The 
patient should return to the clinic as soon as possible, after discontinuation of study  drug, for a 
study  treatment discontinuation visit. Treatment discontinuation visit assessments detailed in 
the “unscheduled treatment discontinuation visit” (UNS) in Table 6 -1andTable 6 -2should be 
completed and recorded in the CRF . The Investigator must determine the primary  reason for 
the patient’s premature discontinuation of study  treatment and record this information on the 
Dosage Administration CRF . 
After study  treatment discontinuation, thefollowing minimum data should to be collected at 
clinic visits or via telephone visits: 
new / concomitant treatments

Novartis Confidential Page 75
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
adverse events/serious adverse e vents
If the patient cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact with the patient, caregiver/parent, or with a person pre-designated by the 
patient. This telephone contact should preferably be done according to the study  visit schedule. 
The Investigator must also contact the IRT to register the patien t’s discontinuation from study 
treatment.
If study  drug discontinuation occurs because treatment code has been broken, please refer to 
Section 5.5.9.
5.6.3 Withdrawal of informed consent
Parents/guardians may voluntarily  withdraw consent for their child to participate in the study 
for an y reason at an y time. Withdrawal of consent occurs onl ywhen a parent/guardian:
Does not want the child to participate in the stud y any
more , and
Does not allow further collection of personal data
In this situation, the Investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary reason for the parent/guardian's decision to withdraw his/her consent for 
their child and record this information in the CRF . 
Study  treatment must be discontinued and no further assessments conducted , and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact the patient are not allowed unless safety  findings require 
communicating or follow -up. 
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient’s study  withdrawal should be made as detailed in Table 6 -
1andTable 6-2.
Novartis will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawa l) according to applicable 
law.
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form. 
For E uropean Union and Rest of World : All biological samples not y et analy zed at the time of 
withdrawal will no longer be used, unless permitted by applicable law. They  will be stored 
according to applicable legal requirements. Any child's request to be withdrawn from the stud y 
should be respected and discussed in detail with parents/guardians and the local Investigator
before acting upon the request.
5.6.4 Loss to follow -up 
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the Investigator should show "due diligence" by 

Novartis Confidential Page 76
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
documenting in the source documents steps taken to contact the patien t, e.g. dates of telephone 
calls, registered letters, etc. A patient cannot be considered as lost to follow -up until the time 
point of his/her scheduled end of study  visit has passed. 
An assessment of the child's well- being must be made if the family  is non-compliant with study 
visits. Appropriate referral to local social services should be considered based on safety 
concerns for the child.
5.6.5 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit risk assessment of participating in the study , practical reasons (including 
slow enrollment) , or for regulatory  or medical reasons . Should this be necessary , the patient 
must be seen as soon as possible and treated as a prematurely  discontinued patient. The 
Investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient’s interests. The Sponsor will be 
responsible for informing theInvestigator, the national competent authority  andInstitutional 
Review Board/Independent Ethics Committee (I RBs/IECs) of the earl y termination of the trial
as per local regulations
.In some countries and based on local regulations, the sponsor may 
delegate to the Investigator the duty  to inform the ECs about the earl y termination.
6 Visit schedule and assessments
Table 6-1and Table 6-2lists all ofthe assessments and indicates with an “x” when the visits 
are performed.
After identify
ing a potential patient, an informed consent form (I CF) and assent (if applicable) 
must be signed by the parent(s)/legal guardian(s) and by the patient (as applicable) before 
performing any study -related procedures that are not considered standard of care for pediatric 
HF patients at that site. Procedures that are part of a site’s standard of care for a pediatric patient 
may pre-date the signed ICF. The AE and SAE reporting period will begin at the time the ICF 
is signed. 
Part 1 of the study  consists of Visits 1 to 299. After screening (Visit 1 ), there are two L CZ696 
single dose PK/PD assessments (V isit 101 and Visit 201). There aretelephone visit s(Visit 102
and 202) followed by a  sequence of telephone visits monthly  in between the in person visits 
every  3 months (Visits 103 to 120, Visits 203 to 220).
Patients taking open -label liquid enalapril should obtain study  drug from the site monthly  until 
Part 2 begins (due to the 1 month storage life of liquid enalapril). If the patient is taking Epaned 
liquid enalapril that has a 2 month storage life, patients must obtain open -label enalapril every 
2 months until Part 2 begins. If the parent/caregiver comes to the site without the patient to pick 
up the open label liquid enalapril, a telephone call to the patient ( ≥6 years old) can be used in 
conjunction with the parent/caregiver visit. At the telephone visits for Part 1, the following 
assessments will not beperformed: vital signs, abbreviated ph ysical exam, weight, abbreviated 
laboratories and urine pregnancy .
Visit 199 and 299 are end of LCZ696 PK/PD first dose visit and second dose visit,respectively. 
For the patient that only  participate sin the LCZ696 PK/PD first dose, the Visit 199 may  occur 

Novartis Confidential Page 77
Amended Cl inical Trial Protocol Version 07 (Clean ) Protocol No CLCZ696B2319
on the same day as Visit 301, if patient is going to participate in Part 2.For the patient that 
participates in the LCZ696 PK/PD first and second PK dose s
, Visit 199 may occur on the same 
day as Visit 201. For the patient that only participates in the LC Z696 PK/PD second dose, Visit 
299 may occur on the same day as Visit 301, if patient is going to participate in Part 2. Visit 
301 is a pre-randomization screening visit for Part 2.Part 2 of the study  consists of Visits 301 
to 499. Visit 401 (randomization) will be considered the reference visit for all study  visits during 
Part 2(Efficacy ). Regardless of the occurrence of any unscheduled visits, scheduled visits 
should be performed within the specified timeframe in relation to Visit 4 01. 
Patients must be seen for all visits on the designated day, or as close to it as possible. Missed or 
rescheduled visits should not lead to automatic discontinuation. Patients/subjects who 
prematurel y discontinue the study  for any reason should be scheduled for a visit as soon as 
possible, at which time all of the assessments listed for the final visit will be performed. At this 
final visit, all dispensed investigational product should be reconciled and the adverse event and 
concomitant medications reco nciled on the CRF.
After Visit 406 (12 weeks), patients using the adult formulation will be seen at 12 
week intervals. 
The liquid formulation of study  drug (LCZ696/matching placebo or enalapril/ matching placebo) 
andLCZ696 granules have a limited shelf life. Therefore, Visits 407, 408, 410, 411, 413, 414
are visits intend ed primarily  to 
permit dispensation of study  drug for patients who are using 
blinded liquid enalapril/matching placebo and/orLCZ696/matching placebo granules . Given 
the burden of traveling to study  visits for patients and families, the parent/caregiver can come 
to the site fo r dispensation of study  drug. If the parent/caregiver comes to the visit without the 
patient, atelephone call to the patient (≥ 6 years old) can be used in conjunction with the 
parent/caregiver visit for the visit assessments (all can be performed verbally ).Delivery  of study 
drug to the patient can also be used where possible and allowed per local regulations . At these 
visits (407, 408, 410, 411, 413, and 414), the following assessments are performed: concomitant 
medic
ations, AE/SAEs, dosage administration record , study  medication compliance, endpoint 
collection (for additional details refer to Table 6-2). Urine pregn ancy  testing will be done for 
females of childbearing potential (for additional details see Table 6
-2). IRT will be contacted if 
study  medications are dispensed.
Visits 407, 408, 410, 411, 413, 414 are telephone visits for patients using the adult formulation
of study  drug. The assessments listed for these visits (Table 6-2)can be performed by telephone. 
Patients who prematurel y discontinue the inves tigational treatment will remain in the study  and 
should undergo all the assessments illustrated in Table 6-2. If a patient/parent(s)/legal 
guardian(s) withdraws from participation in the study , refuses to return for study  assessments 
or is unable to do so, every  effort should be made to contact them or a knowledgeable informant 
by telephone and/or other measures to determine the patient’s survival status 52 weeks from 
randomization (Visit 499). 
Patients will be contacted for safet y evaluations during the 30 days following the last 
administration of study  treatment. 

Novartis Confidential Page 78
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
Table 6-1 Part 1 Assessment Schedule
EpochScree
ningPeriod 1
First Dose PKPeriod 2
Second Dose PKPre-
Randomizat
ion
Visit1 101 102
(telephone 
visit)103 to 
120*UNS
PK/PD199** 201 202
(telephone 
visit)203 to 
220*UNS
PK/PD299** 301**
(Part 2
Screening)
Week ♦ ♦ ♦ ♦ ♦ up to -3
Obtain Informed Consent (parent (s) -legal 
guardian (s)/consent -assent (patient, as 
applicable)13x, S x, S
Demography x x1
Inclusion/Exclusion Criteria x x
Medical History x x1
Pediatric Heart Failure History x x1
Concomitant Medications x x x x x x x x x x x x
Alcohol & Smoking History x x1
Vital Signs (BP and pulse) x x2x9x2x x2x9x2x x
Height x x x x
Weight3x x x9x x x x9x x x
Head Circumference ( ≤ 3 years old) x x x x
Physical Examination (complete) S S
Physical Exam (abbreviated) S S9S S S S9S S
ECG x x x x
ECHO, LVEF or fractional shortening 
measurement4 x x
Urinalysis x x x x
Serum/Urine Pregnancy Test5x x x9x x x x9x x x
Complete Laboratories6x x x x
Abbreviated Laboratories7x x9x x x9x
PK Blood Samples x x x x
Plasma Biomarkers/PD8x x x x

Novartis Confidential Page 79
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
EpochScree
ningPeriod 1
First Dose PKPeriod 2
Second Dose PKPre-
Randomizat
ion
Visit1 101 102
(telephone 
visit)103 to 
120*UNS
PK/PD199** 201 202
(telephone 
visit)203 to 
220*UNS
PK/PD299** 301**
(Part 2
Screening)
Week ♦ ♦ ♦ ♦ ♦ up to -3
Urine cGMP8x x x x
NYHA/ Ross Classification x X x x
AEs/SAEs x x x x x x x x x x
Dosage Administration Record x x
Study Medication Compliance10S11S S S11S S
Contact IRT x x x x x x x x
Dose Open -Label LCZ (single dose) x x x x
Dispense Open -Label Enalapril12x x x x x x
Screening Disposition (Parts 1 and 2) x x
Part 1 Disposition x x
UNS PK/PD = Unscheduled PK/PD visit. Only one unscheduled visit either in Period 1 or Period 2 should be conducted. 
S = assessment to be recorded on source documentation only
♦Visit 101 will occur approximately up to three weeks after Visit 1. Visit 201 may occur approximately up to three weeks after Visit 1 if patient is directly going to second dose PK 
assessment from Visit 1. The Visit 102/202 aretelephone visit sthat occur 2 weeks after completion of Visit 101/201 respectively.
* Visits 10 3 to 120 / 203 to 220 are combination of in person and telephone visits . Telephone visits will occur monthly between the every 3 month in person visits. At these telephone 
visits the following assessments will not be performed: vital signs, abbreviated phy sical exam, weight, abbreviated laboratories and urine pregnancy
** For the patient that participates in the second PK /PDdose, Visit 299 may occur on the same day as Visit 301, if the patient is going to participate in Part 2. F or the patient that only 
participate sin the first dose PK /PDassessment , the Visit 199 may occur on the same day as Visit 301, if the patient is going to participate in Part 2 . If the patient participates in both first 
and second PK/PD doses Visit 199 may occur on the same day as V isit 201.   
1 Demography, medical history, pediatric HF history alcohol & smoking history are only obtained at Visit 301 for patients who d idnot p articipate in Part 1.
2 Patients who have PK done at Visit 101/201 /unscheduled PK/PD will have vital signs (blood pressure and heart rate/pulse) collected at 0, 30 min, 1 hr, 2 hrs, 3 hrs, 4 h rs, 5 hrs, 6 hrs, 
7 hrs, 8 hrs, 9 hrs, 10 hrs, 11 hrs,12 hrs, 18 hrs and24 hours post -dose. Vi tal signs at 11 hrs, 12 hrs and 18hrs are optional unless the patient physically stays on -site. The 24 -hr post 
dose vital signs will be measured if the patient either stays on -site or returns to the site the next day.
3 Weights are measured for safety andfordose administration at V101 a nd/or V 201 or UNS PK/PD (if this visit occurs) . 
4For Part 1, patients are to meet inclusion criteria regarding ECHO, LVEF or fractional shortening measurement (i.e. Systemic left ventric ular ejection fraction (EF) ≤ 45% or fractional 
shortening ≤22.5%),by history at any time prior to screening (V1). If there is no history of LVEF or fractional shortening measurements an ECHO can be performed at screening ( Visit 1 ).
(see Section 4.1, Inclusion criteria).

Novartis Confidential Page 80
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
EpochScree
ningPeriod 1
First Dose PKPeriod 2
Second Dose PKPre-
Randomizat
ion
Visit1 101 102
(telephone 
visit)103 to 
120*UNS
PK/PD199** 201 202
(telephone 
visit)203 to 
220*UNS
PK/PD299** 301**
(Part 2
Screening)
Week ♦ ♦ ♦ ♦ ♦ up to -3
5 For child bearing potential females (CHBP) only. Urine pregnancy test is analyzed locally and done at all visits on all female patients ≥11 years of age and all female patients who are 
<11 years of age if they are menstruating. In addition, a serum pregnan cy test is performed and analyzed locally at Visit 1 and Visit 301. 
6Complete laboratory evaluations will be performed by local lab for Part 1. 
7Abbreviated laboratories will be collected and sent to the local lab at specified visits for all patients. Abbreviated laboratories consist of sodium, potassium, creatinine, eGFR (modified 
Schwartz formula). Abbreviated laboratories may be performed at any visit based on the Investigator’s clinical judgement. At Visit 101, 201 or/and UNS PK/PD (if occurs) the 
abbreviated labs will be collected at the end of the visit.
8At Visit 101, 201, or/and UNS PK/PD (if this visit occurs), samples will be collected for plasma NTproBNP, plasma and urine c GMP, and plasma BNP. Central laboratory will be used 
for these biomark ers.
9For Visits 103 -120 / 203 –220 vital signs, abbreviated physical exam, weight, abbreviated laboratories and urine pregnancy test are performed every 3 m onths when the patient 
comes to the site for a visit.
10For Part 1, only applicable for patient s taking open -label enalapril. For Parts 1 and 2, dosage administration record and compliance will be performed when the study drug is dispensed 
and when the last dispensed study drug is presented to the site for tablet/granule count or liquid assessment.
11Patients will be asked via telephone if they completed a 36 -hour washout period after the single dose LCZ696 PK and prior to starting enalapril (or ACEI). This information will be 
captured in the source document.
12Patients who are taking open- label en alapril will be provided enalapril medication at the completion of visit 101 or/and 201. Patient will be instructed to take it after 36 hour washout 
period. Compliance will be evaluated at Visit 102 or/and 202 via telephone call.
13Patient Assent document iscaptured as a source document and not stored in the clinical database .

Novartis Confidential Page 81
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
Table 6-2 Part 2 A ssessment Schedule
EpochPre-
Randomiza
-tionDouble- blind
Visit301**
(Part 2 
Screening)401401JPNJ402403404 Optional405406407†408†409410†411†412413†414†415UNS/
TDUNS416/ 
499(PSD)
Week up to -3 0 1 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52
Obtain Informed Consent (parent (s) -legal 
guardian (s)/consent -assent (patient, as 
applicable)2x, S
Demography x1
Inclusion/Exclusion Criteria x
Medical History x1
Pediatric Heart Failure History x1
Concomitant Medications x x x x x x x x x x x x x x x x x x x x
Alcohol & Smoking History x1
Vital Signs (BP and pulse)17x x x x x x x x x x x x x x
Height x x
Weight3x x x x x x x x x x x x x x
Head Circumference ( ≤ 3 years old) x x
Physical Examination (complete) S S
Physical Exam (abbreviated) S S S S S S S S S S S S
ECG x x
ECHO, LVEF or fractional shortening 
measurement4 x
Urinalysis x x x x
Serum/Urine Pregnancy Test5x x x x x x x x x x x x x x x x x x x
Complete Laboratories6, 13x x x x

Novartis Confidential Page 82
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
EpochPre-
Randomiza
-tionDouble- blind
Visit301**
(Part 2 
Screening)401401JPNJ402403404 Optional405406407†408†409410†411†412413†414†415UNS/
TDUNS416/ 
499(PSD)
Week up to -3 0 1 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52
Abbreviated Laboratories7(x) x (x) x x x x(x)
18(x)
18
Population PK Blood Samples13, 15x X15 (x)
18X15, 
19
Sparse PK blood Sam ples (Group 2 Subset 
of patients )13, 14 x14(x)
14
Plasma Biomarkers/PD8, 13x x x(x)
18 X
Plasma Biomarker/PD ( Sparse PK Group 2 
Subset of patients) 13, 16 x16 (x)
16
NYHA/ Ross Classification x x x x x x(x)
18x
PGIS ( Global I mpression of Severity): 
Patient9 x x x x x(x)
18x
PGIS : Parent/Care -giver9x x x x x(x)
18x
PedsQL: Patient10x x x x(x)
18x

Novartis Confidential Page 83
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
EpochPre-
Randomiza
-tionDouble- blind
Visit301**
(Part 2 
Screening)401401JPNJ402403404 Optional405406407†408†409410†411†412413†414†415UNS/
TDUNS416/ 
499(PSD)
Week up to -3 0 1 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52
AEs/SAEs x x x x x x x x x x x x x x x x x x x
Dosage Administration Record11x x x x x x x x x x x x x x x (x)(x) x
Study Medication Compliance11S S S S S S S S S S S S S S S S (S) (S) S
Contact IRT x x x x x x x x x x x x x x x x x x x
Dispense Double- Blind Study Medications x x x x x x x x x x x x x x x (x)
Screening Disposition (Parts 1 and 2) x
Endpoints x x x x x x x x x x x x x x x x x x
Efficacy Study Treatment Disposition (Part 
2)x
End of Study Treatment Discontinuation 
(Part 2)x
UNS = Unscheduled visit
S = assessment to be recorded on source documentation only
TD = Study treatment discontinuation and patient continues study visits;
PSD = Premature subject/patient discontinuation
(x)/ (S) = optional assessment
Visit 404 Optional = Investigators have the option to schedule a patient for an additional visit (Visit 404) for up titration.
** A patient may be screened and randomized the same day for Part 2. Visits 299 and 301 (for patient in second dose PK) and Visits 199 and 301 (for patient only going to take first 
dose PK) may occur on the same day if patient is participating in Part 2. Any assessments should not be repeated if visits occur on the same day. 

Novartis Confidential Page 84
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
EpochPre-
Randomiza
-tionDouble- blind
Visit301**
(Part 2 
Screening)401401JPNJ402403404 Optional405406407†408†409410†411†412413†414†415UNS/
TDUNS416/ 
499(PSD)
Week up to -3 0 1 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52
† Visits 407, 408, 410, 411, 413, 414 are telephone visits. Patients who are dispensed LCZ696 liquid formulation/matching placebo , liquid enalapril/matching placebo and 
LCZ696/matching placebo granules will come to the site for dispensation of study drug. If the parent/caregiver come s to the site without the patient, a telephone call to the patient 
(≥6 years old) can be used in conjunction with the parent/caregiver visit for the visit assessments. IRT will be contacted only if study drug is dispensed.
JVisit 401J PN(week 1 )is applicable only to patients enrolled at sites in Japan.
1 Demography, medical history, pediatric HF history alcohol & smoking history are only obtained at Visi t 301 for patients who did not p articipate in Part 1.
2 Patient Assent document is captured as a source document and not stored in the clinical database.
3 Weights are measured for safety. For patients 1 month to < 1 year old, last available study weight measurement will be used t o ascertain dose. For patients 1 to < 6 years old, 
weight measurements e very 3 months will be used for dose determination. For patients who are ≥ 6 years old, weight measurement every 6 months will be used for dose 
determination.
4This must be performed within 1 month of Visit 301 (Part 2). Patients who have participated in Part 1 (PK) and remain in study for Part 2 (efficacy) need a repeat assessment of 
LVEF or fractional shortening to determine eligibility for Part 2 if the assessment is greater than 1 month prior to Visit 301(see Section 4.1, Inclusion criteria) .
5 For child bearing potential females (CHBP) only. Urine pregnancy test is analyzed locally and done at all visits on all female patients ≥11 years of age and all female patients who 
are <11 years of age if they are menstruating. In addition, a serum pregnancy test is performed and analyzed locally at Visit 301 and centrally at Visit 416/499 respectively. Urine 
pregnancy tests will not be done at visit 401JPN (i.e. week 1 visit, which is applicable only to patients e nrolled at sites in Japan). Note: In addition to the testing done in the clinic, all 
female subjects ≥11 years of age and all female subjects who are <11 years of age if they are menstruating, will be given a u rine pregnancy test kit for each month between in-
person study visits and will be instructed to do a urine pregnancy test at home, for each visit designated to be a telephone visit (i.e. Visits 40 7, 408, 410, 411, 413 and 414). 
Patients will be instructed to save the pregnancy test kits in a container (e.g. plastic) and bring them to the next in -person clinic visit . Study site personnel are to review the 
pregnancy test kits the patients bring to the clinic and record the results in the source documentation and on the appropriat e CRF. If, according to l ocal requirements, pregnancy 
tests cannot be done at home, the patient can have the test done at the study site or an alternative venue ( additional details are included in the Central Lab Manual ).Patients will 
be instructed to come to the clinic for a ser um pregnancy test if the urine pregnancy test is positive.
6Local lab oratories should be used for all laboratory tests at Visit 301. Central lab should only be used for Visit 301, if local lab is unavailable using unscheduled visit. Central 
laboratory should be used at Visits 401, 409, and 416/499 for all patients , where possible .
7Abbreviated laboratories will be collected and sent to the local lab at specified visits for all patients. Abbreviated labora tories consist of sodium, potassium, creatinine, eGFR 
(modified Schwartz formula). Abbreviated laboratories may be performed at any visit based on the Investigator’s clinical judge ment. Central lab should only be used for abbreviated 
lab testing only if local lab is unavailable, using unscheduled visit. Note: The Abbreviated laboratories scheduled at Visit 402 (week 2) and Visit 40 4(week 6) are optional if it is 
considered safe and where the patient is not being up-titrated (applicable to Visit 402 and 404) .For Age Group 3 patients who turn 1 year old during the study and who are up -
titrated to Group 3 Dose L evel 5x(if applicable) at a scheduled visit or at an unscheduled visit, abbreviated labs are to be done at theadditional up titration visit.

Novartis Confidential Page 85
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B2319
EpochPre-
Randomiza
-tionDouble- blind
Visit301**
(Part 2 
Screening)401401JPNJ402403404 Optional405406407†408†409410†411†412413†414†415UNS/
TDUNS416/ 
499(PSD)
Week up to -3 0 1 2 4 6 8 12 16 20 24 28 32 36 40 44 48 52
 
9Patient or parent/caregiver will complete the PGIS , depending on the age of patient.
11 For Part 1, only applicable for patients taking open -label enalapril. For Parts 1 and 2, dosage administration record and compliance will be performed when the study drug is 
dispensed and when the last dispensed study drug is presented to the site for tabl et/granule count or liquid assessment.
 
13 For countries where blood samples cannot be shipped out of the country due to local regulations, the PK blood samples and Plasma Biomarkers /PD are not required. In these 
countries, complete laboratories at visit 401, 409 and 416/499 will be collected and sent to the local lab. 
14In approximately 24 patients in Age Group 2, sparse PK blood samples will be collected at steady -state, at 3 time -points on the same day, at Visit 405 or at a subsequent 
scheduled or unscheduled visit (with the exception of Visit 406 and 416/499), Please refer to Section 6.6.2 and Table 6 -5for instructions regarding sample collection .  
15For the subset of patients who participate in the sparse PK sampling visit , blood samples for Population PK will NOT be required to be collected at Visits 406 and 416/499.
16  For the subset of patients who participate in the s parse PK sampling visit, (e.g.visit 405 or a 
scheduled or unscheduled visit with the exception of visits 406 and 416/499) .
17 For Part 2 Group 3 patients, starting with the first dose of study medication, vital signs need to be checked for up to 4 hou rs after the initial dose at each dose level . Patients are 
to remain in the study site clinic for this 4 -hour post -dose Vital Si gn monitoring period. Vital signs (i.e. blood pressure and heart rate) are to be measured pre -dose (time 0), and 
post- dose at 0.5, 1, 2, 3 and 4 hours for the initial study medication dose at each dose level. See Appendix 13 for details.
18For patients impacted by the urgent safety measure (USM), additional evaluations are to be done at the visit that is used to discontinue study medication (see Appendix 15 for 
details ). PK  must be collected ,and NYHA/Ross Classification and all PROs (PedsQL, PGIS, ) mustbe completed ,at this visit .
19 Forpatients impacted by the USM and who transitioned to SOC before the EoS visit, a sample for Population PK should NOT be collecte d.

Novartis                                                          Confidential                                                          Page 86
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
6.1 Information to be collected on screening failures
All patients who have signed informed consent for Part 1 (PK /PD) and/or Part 2 (Efficacy ),but 
have not entered into the next epoch will have the study  completion page for the screening 
epoch, demographics, inclusion/exclusion, and SAE data collected. Adverse events that are not 
SAEs will be followed by the Investigator and collected onl y in the source data.
A patient who has failed screening may have abnormal test findings that occurred prior to the 
informed consent. Investigato rs have the discretion to record these abnormal test findings on 
the CRF .
Re-screening
A patient who enters screening but is determined not to be eligible for the study  will be 
considered a screen failure. The Investigator may consider rescreening the patient at a later time 
if he/she believes that the patient’s condition has changed and they  may  potentially  be eligible. 
In this case, a new patient number will be allocated to the subject and he/she will need to 
perform all screening Visit 1 (Part 1-PK/PD) or Visit 301 (Part 2 Efficacy -Pre-
randomization/Screening )procedures again. A patient may be rescreened up to two times. A 
minimum of 2 weeks must elapse between rescreening . The parent(s)/legal guardian(s) for the 
pediatric patient must provide new written informed 
consent before each time the patient is 
rescreened. Patients required to provide assent must also provide new assent before being 
rescreened.
6.2 Patient demographics/other baseline characteristics
Patient demographic and baseline characteristic data to be collected on all patients include: year 
of birth, age, sex, race, ethnicity , concomitant medications, alcohol/smoking history , 
NYHA/Ross class, pediatric heart failure history , vital signs, weight and height. Relevant 
medical history /current medical condition data includes data until the start of study  drug.
Rationale for collecting race and ethnicity  data: Race and ethnicit y dataare colle cted forpatients 
in this study , as available. The rationale for this is noted in a 2016 FDA Guidance document 
“Collection of Race and Ethnicity  Data in Clinical Trials,” which states “…evidence must be 
reviewed to establish whether or not there are potentially  clinically important sex-and 
racial/ethnic -based differences in the anticipated effects of the intervent ion.” ICH E5is also 
cited in this Guidance document and states that the “Question and Answer Addendum to E5 
introduces the multi- regional clinical trial study  design as one means to evaluate treatment 
response heterogeneity  and extrapolation. Multi -regional clinical trials may present special 
situations for the collection and self -reporting of race and ethnicity .” (FDA 2016)
6.3 Treatment exposure and compliance
This information should be captured in the source document at each visit and specific CRFs. 
All study  treatment dispensed and returned must be recorded in the Drug Accountability  Log. 
Compliance will be assessed by the Investigator and/or study  personnel using pill counts , liquid 
study  medication assessment and information provided by the caregiver. This information 

Novartis                                                          Confidential                                                          Page 87
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
should be captured in the source document and specific CRFs. All study  treatment dispensed 
and returned must be recorded in the Drug Accountability  Log. The Investigator and/or study 
personnel should counsel the patient and his/her parent(s)/legal guardian-caretaker (s), as 
appropriate, if compliance is below 80% at any time during the study . Study  drug accountability 
will be determined by the site monitor while performing routine site visits and at the completion 
of the study .
The duration of randomized treatment exposure will be calculated based upon the start and stop 
dates recorded in the CRF .
6.4 Efficacy
6.4.1 Efficacy  assessment
The efficacy  of LCZ696 compared to enalapril after 52-week of double -blind treatment is 
asses sed using a global rank endpoint as outlined below (Table 6-3) (see Appendix 15for USM 
exception) . Clinical events (Categories 1 and 2)are adjudicated by an external independent 
adjudication committee. The NYHA/Ross classification (Criteria Committee NYHA 1994,
Ross 1992, Rosenthal 2004 ), PGIS, and PedsQL are conducted at randomization and end of 
study  (and during the study  as shown in Table 6 -2assessment schedule ).
Table 6-3 Primary  endpoint algorithm using ranked analysis
Category Sub-category Description Ranking algorithm
1 Death; UNOS status 1A listing for heart transplant or equivalent; 
VAD/ECMO/mechanical ventilation /intra -aortic balloon pumprequirement for 
life support at end of study.
A Category 1: Death; 
UNOS status 1A listing 
for heart transplant or 
equivalent; 
VAD/ECMO/mechanica
l ventilation /intra -aortic 
balloon pump
requirement for life 
support at end of study.Rank within this 
categor y by time to first 
event. All Category 1 
events are considered 
equa l.
2 Worsening HF (W HF); defined by signs and s ymptoms of WHF that requires 
an intensification of HF therapy.

Novartis                                                          Confidential                                                          Page 88
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Category Sub-category Description Ranking algorithm
B Worsening heart failure 
hospitaliza tion with 
intensive care unit stay 
(HFH -ICU).Within Categor y 2, the 
patients will be ranked 
first by event 
subcategory, and then 
by number of events 
within each 
subcategory. Further 
ranking by time to first 
event in the worst 
subcategory.
C Worsening h eart failure 
hospital ization without 
intensive care unit stay 
(HFH -No ICU) .Within Categor y 2, the 
patients will be ranked 
first by event 
subcategory, and then 
by number of events 
within each 
subcategory. Further 
ranking by time to first 
event in the worst 
subcategory.
D Worsening heart failure 
without hospitalization
(WHF-No Hosp) . Within Categor y 2, the 
patients will be ranked 
first by event 
subcategory, and then 
by number of events 
within each 
subcategory. Further 
ranking by time to first 
event in the worst 
subcategory.
3 Worsened; worse NYHA/Ross or worse Patient Global Impression of 
Severity (PGIS); and further ranking by PedsQL physical functioning 
domain.
E NYHA/Ross or Patient
Global Impression of 
Severity (PGIS) 
worsened based on 
last available 
assessment compared
to baseline .Rank by combination of 
NYHA/Ross and PGIS
degree of change . 
Within a group of the 
same degree of 
NYHA/Ross and PGIS 
change , further rank by 
PedsQL (ph ysical 
functioning domain)
change from baseline .
4 Unchanged; unchanged NYHA/Ross and unchanged PGIS; and further 
ranking by PedsQL physical functioning domain.

Novartis                                                          Confidential                                                          Page 89
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Category Sub-category Description Ranking algorithm
F NYHA/Ross andPGIS 
unchanged based on 
last available 
assessment compared 
to baseline .Worst baseline 
combination of 
NYHA/Ross functional 
class and PGIS without 
change is ranked 
worse tha na better 
baseline NYHA/Ross 
functional class and 
PGIS . Within a group of 
the same baseline 
NYHA/Ross and PGIS , 
further rank by PedsQL 
(physical functioning 
domain) change from 
baseline. 
5 Improved; improved NYHA/Ross or improved PGIS (neither can be worse); 
and further ranking by PedsQL physical functioning domain).
G NYHA/Ross or PGIS 
improved based on last 
available assessment 
compared to baselineRank by combination of 
NYHA/Ross and PGIS 
degree of change . 
Within a group of the 
same degree of 
NYHA/Ross and PGIS 
change, further rank by 
PedsQL (physical 
functioning domain) 
change from baseline.
Changes in heart transplant status should be documented by completing a new ‘Heart Transplant 
Listing Endpoint ’ CRF.
Worseni ng HF is defined as new or worsening symptoms and signs of HF that require an 
intensification of HF therapy .The symptoms of WHF include but are not limited to: dyspnea 
on exertion; dyspnea at rest; orthopnea; parox ysmal nocturnal dyspnea; decreased exerci se 
tolerance due to fatigue ; abdominal bloating/discomfort; tachy pnea with feeding; diaphoresis 
with feeding; fatigue with feeding ; feeding intolerance/emesis/weight loss and fluid retention . 
The signs of WHF include but are not limited to: pulmonary edema or rales; tachypnea or rapid 
respiration rate; increased jugular venous pressure; peripheral hypoperfusion; radiographi c 
evidence of pulmonary edema, radiographic evidence of pulmonary  vascular congestion, 
radiographic evidence of pleural effusion; hypoxe mia; growth failure or failure to thrive ; 
peripheral edema; hepatomegaly  and any  other sign consistent with heart failure . 
Treatments for worsening heart failure include intravenous diuretics, intravenous vasodilators, 
intravenous vasopressors, intravenou s inotropes, mechanical fluid removal (e.g., ultrafiltration 
or dialy sis), ventricular assist device, extracorporeal membrane oxygenation (ECMO), intra-
aortic balloon pump, mechanical ventilation, non-invasive ventilation, surgical or catheter -
based interv
entions. Treatment for worsening heart failure with oral medication includes the 
initiation or intensification of standing oral diuretics. Intensification of oral diuretics must be a 
50% increase or more of the daily  maintenance dose for at least 2 weeks duration. For worsening 
heart failure characterized by growth failure or failure to thrive, treatments can include feeding 

Novartis                                                          Confidential                                                          Page 90
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
tube placement or parenteral nutrition (Section 3.3) .Further details are documented in the 
Clinical Endpoint Committee (CEC) charter.
Primary  endpoint Categories 3, 4and 5areranked by NYHA/Ross class and PGIS score. The 
combined change from the end of study  compared to baseline for both the NYHA/Ross class 
and the PGIS score will be used to rank patients from worst to best within categories 3, 4 and 
5.Within a group of patients with the same degree of combined NYHA/Ross and PGIS change, 
thePedsQL (physical functioning domain) change from baseline will be used to further rank 
these patients from worst to best. Further ranking within Categories 3, 4, 5 as needed (‘tie 
breaking’) will be based on a subset of 5 physical functioning domain questions of the PedsQL 
score (for patients 6 to < 18 years old). The PedsQL will not be used for the youngest two age 
strata (1 month to < 1 yearand 1 to < 6 years), as the patient reported PedsQL  data will not be 
collected for allpatients in these 
strata.(Note : Patient < 5 years old only have a parent report 
for the PedsQL).
6.4.2 Secondary  efficacy  endpoints
The secondary  efficacy  endpoints include:
To determine whether LCZ696 is superior to enalapril in delay ingtime to first occurrence 
of the composite of either Category  1 or 2 even ts(e.g. death ,worsening HF)
To determ ine whether LCZ696 is superior to enalapril for improving NYHA/R oss 
functional class
To determine whether LCZ696 is superior to enalapril for improving the Patient Global 
Impr ession of Severit y (PGI S) score
To characterize the population PK of L CZ696 exposur e in pediatric patients with HF . Also 
t
o further confirm the LC Z696 target dose for Age Group 2 using a population PK approach 
with stead y-state sparse PK blood samples (i.e. 3 samples per patient drawn on the same 
day) collected from approximately  24 patients, approximately  half of whom are expected to 
be randomized to LCZ696. Therefore, blood samples from approximately  12 patients 
randomized to L CZ696 will be used in the PK analy sis.
 
 
 
 
6.5 Safet y 
Novartis may request additional information on specific AEs or laboratory  events of interest 
and may make requests to perform additional diagnostic tests to further assess the safet y profile 
of the study  drugs. Such information may include diagnostic procedure reports, discharge 

Novartis                                                          Confidential                                                          Page 91
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
summaries, autopsy  reports, and other relevant information that may help in assessing the 
reported AE. All additional information is de-identified prior to collection by Novartis or its 
agents. In addition to AE/SAEs, the following safety  related data will be collected:
Physical examinations
Vital signs
Height, weight, and head circumference (head circumference is only  collected in patients 
≤3 years of age at enrollment)
Laboratory  evaluations
Electrocardiogram s(ECG)
Pregnancy
Angi oedema
6.5.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
and extremities, vascular and neurological. If indicated based on medical history  and/or 
symptoms, rectal, external genitalia, breast, and pelvic exams will be performed. 
A complete physical examination will be performed atthe screening visits for Part 1 (Visit 1) 
and Part 2 (Visit 301), and also the end of study  Visit 416/499. An abbreviated physical 
exam ination will be performed at other in person visits as shown in Table 6-1andTable 6-2. 
A
n abbreviated physical exam will include the examination of general appearance and vital 
signs (BP and pulse) as well as other examinations based on Investigator discretion .
Information for all phy sical examinations must be included in the source documenta tion at the 
study  site. Significant findings that are present prior to signing informed consent must be 
included in the Medical History  part of the patient’s CRF . Significant findings made after 
signing the informed consent which meet the definition of an AE must be recorded on the AE 
section of the CRF . 
6.5.2 Vital signs 
Vital signs include BP and pulse measurements and are assessed when a complete or 
abbreviated physical examination is performed . BP will be measured in the sitting position after 
5 minutes of rest using an automated validated device (e.g. OMRON) or a standard 
sphy gmomanometer with an appropriate size cuff on the non -dominant arm. Supine BP instead 
of sitting BP will be measured in patients who are infants or who canno t sit comfortably . 
Guidelines for the management of hypotension are provided in Appendix 4 .
Vital signs (blood pressure and heart rate/pulse) will be collected atVisit 101, 201 during PK 
assessment (and unscheduled PK/PD visit if it occurs) at: 0, 30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs, 5 
hrs, 6 hrs, 7 hrs, 8 hrs, 9 hrs, 10 hrs, 11hrs,
12 hrs, 18 hrs, and 24 hours post-dose LCZ696.
Vital signs at 11 hrs, 12 hrs and 18 hrs are optional unless the patient physically  stays on-site. 
The 24-hr post dose vital sign swill be measured if the patient either stays on-site or returns to 
the site the next day.The vital signs will be collected in Part 1 and Part 2 of the study  as depicted 
in the assessment schedule ( Table 6
-1and Table 6 -2).

Novartis                                                          Confidential                                                          Page 92
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
For Part 2 Age Group 3 patients, starting with the first dose of study  medication, vital signs 
need to be checked for up to 4 hours after the initial study  medication dose at each dose level. 
Patients are to remain in the study  site clinic for this 4-hour post-dose Vital Sign monitoring 
period. Vital signs are to be measured pre-dose (time 0), and post-dose at 0.5, 1, 
2, 3 and 4hours 
for the initial study  medication dose at each dose level.
Clinically  notable vital signs for this patient population are defined in Appendix 1 .
6.5.3 Height /length, head circumference and weight 
Height/length in centimeters (cm) will be measured using a standard device at Visit 1 (Part1 
PK/PD-Screening ), Visit 199 and/or Visit 299, Visit 301 (Part 2 
Efficacy -Pre-
randomization/Screening ), and Visit 416/499 (Week 52/Final Visit) . Use of a stadiometer for 
standing height measurements is recommended.
For patient s ≤ 3 years, head circumference in centimeters (cm) is measured at Visit 1
(Part 1 
PK/PD -Screening ), Visit 199 and/or Visit 299, Visit 301 (Part 2 Efficacy -Pre-
randomization/S creening), and Visit 416/499 ( Week 52/Final Visit ).
Body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) is measured 
at every  in-person visit. Body  weight during hospitalization is to be recorded only if available 
as per standard of care. For patients 1 month to < 1 year old, last available study  weight 
measurements will be used to ascertain dose. For patients who are 1 to < 6 years old, weight 
measurements every  3 months will be used for dose determination. For patients who are ≥6 
years old, weight measurement every  6 months will be used for dose determination.
6.5.4 Laboratory  evaluations
Complete laboratory  evaluations (hematology, blood chemistry, and urine) as outline d in Table 
6-4are performed in Part 1 atVisit 1 (Screening) ,Visit 199and/or 299, and in Part 2 atVisit 
301 (Screening) , Visit 401 (
Randomization ),Visit 409and Visit 416/499 (Week 52/Final Visit ). 
Local laboratory  should be used for Visit 1, 199, 299 and 301 for complete laboratory 
evaluations. Central laboratory should only be used for Visit 301, if local lab is unav ailable 
using unscheduled visit. Central laboratory  must be used for Visit 401, 409and 416/499 for 
complete laboratory  evaluations for all pati
ents. Details on the collections, shipment of samples 
and reporting of results by the central laboratory will be provided to the Investigator s in the 
laboratory  manual. Patient can be randomized based on safet y laboratory  results from Visit 
199/299/301 unless the Investigator feels the need to wait for laboratory results from Visit 401.
Abbreviated safet y laboratory  evaluation consists of serum sodium, potassium, creatinine , and 
eGFR. Abbreviated safety  laboratories should be performed locally . If the local laboratory  is 
unavailable (either for abbreviated or complete labs), thecentral laboratory should be used as 
an unscheduled visit. Abbreviated laboratory  evaluations are to be per formed at Part 1 PK/PD 
Visits 101, 201, 103 to 120 (when patient comes to the site for a visit about every  three months ), 
203to 220 ( when patient comes to the site for a visit about every  three months ), UNS PK/PD; 
and Part 2 (Efficacy ) Visits 402(Abbreviated labs are optional if considered safe and where 
pati
ent is not being up-titrated ) , 403, 404 (optional visit; Abbreviated labs are optional if 
considered safe and where patient is not being up-titrated ), 405, 406, 412, 415 and as an optional
assessment at UNS TD, and UNS . For those patients who have Visits 299 and 301 on the same 

Novartis                                                          Confidential                                                          Page 93
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
day(for second PK dose patient) or Visits 199 and 301 on the same day (for the first PK dose 
only patient) , laboratories will be performed only once. Local laboratory results will allow 
Investigat ors to proceed with study  visit procedures without the need to wait for central 
laboratory  results. The local laboratory  results must be recorded in the appropriate CRF . Given 
limitations of 
blood volume, the local laboratory  assessments will be a priority for urgent 
medical decision making (including for study drug dose titration). 
Local and central laboratory  results need not agree in order for the Investigator to qualify  a 
patient for the trial or make a dose titration decision. A patient enrolled in the study  based on 
local laboratory results and subseque ntly determined to be above an exclusion criteria based on 
central laboratory  results may  be continued or discontinued from the study at the discretion of 
the Investigator. The Investigator should usehis/her clinical judgment on how best to manage 
the study  drug dose level in the event adose titration decision based on
alocal laboratory  results 
is subsequently  found to be discrepant with central laboratory  result s.If the central laboratory 
is used, i t may  take up to 72 hours or more to obtain the results .
For child bearing potential females only , serum pregnancy  testing will be performed at Visit 1 
(Part 1 PK/PD -Screening ), Visit 301 (Part 2 Efficacy -Pre-Randomization/Screening )and Visit 
416/499 (Part 2 Week 52/End of Study ). Child -bearing potential females (CHBP) are defined 
as all female patients ≥ 11 y ears of age and all female patients who are <11 years of age if they 
are menstruating. Patients with a positive urine/serum pr egnancy  at any  time in the study  must 
be excluded. Urine pregnancy test is anal yzed locally  and done at all visits on all CHBP female 
patients (for additional details regarding urine pregnancy  testing requirements for visits 407, 
408, 410, 411, 413, and 414, please see Table 6 -2). Serum pregnancy  test will be analyzed 
centrall y (for Visit 416/499) or locally  (for Visits 1 and 301). A positive urine pregnancy  test 
should be confirmed with a serum pregnancy test.
Table 6
-4 L aboratory  examinations
Hematology Biochemistry Urine measurements **
Hematocrit Alanine aminotransferase (ALT) Specific gravity
Hemoglobin Albumin (Alb) pH
Platelet count Alkaline phosphatase (ALP) Glucose
Red blood cell count (RBC) Aspartate aminotransferase 
(AST)Protein (Total)
White blood cell count (W BC) Blood urea nitrogen (BUN) Ketones
WBC differential Calcium Bilirubin
Magnesium Urobilinogen
Phosphate Hemoglobin (blood)
Red blood cell distribution width 
(RDW)Chloride Leukocyte esterase
Mean corpuscular volume 
(MCV)Creatinine * Nitrite
Mean corpuscular hemoglobin 
concentration (MCHC)Glucose WBC
Potassium* RBC sediments
Sodium* Hyaline casts

Novartis                                                          Confidential                                                          Page 94
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Hematology Biochemistry Urine measurements **
Bicarbonate Granular casts
Total bilirubin (TBL) Waxy casts
Fractionated bilirubin (if total 
bilirubin >2x ULN)WBC casts
Total protein RBC casts
Uric acid
eGFR*
*Abbreviated laboratory evaluations must include these parameters
**Urinalysis with dipstick includes specific gravity, pH, glucose, total protein, bilirubin, ketones, 
urobilinogen, nitrite, leukocytes esterase and hemoglobin (blood). Other urine measurements listed are 
not required. If a urine dipstick is positive, other urine measurements such as a qualitative microscopic 
determination of WBC, RBC sediments (and casts) will also be measured .
Study  procedures may  be performed without restriction while the central laboratory  results are 
pending. In these cases, the Investigator or his/her designee should review the central laboratory 
results as soon as they  become available to decide on whether any  adjustments in the patient’s 
study  drug or non -study  drug regimen are needed.
Abnormal laboratory  values (as defined in Appendix 1) may require additional laboratory 
evaluations be performed, as judged 
appropriate by the Investigator . If the laboratory 
abnormality  induces clinical signs or symptoms, or requires therapeutic intervention, then the 
diagnosis or medical condition must be entered on the AE page of the patient's CRF . If the 
laboratory  abnormalit y is the primary  reason for an unforeseen hospitalization or otherwise 
fulfills the seriousness category  of an AE, then the procedure for rapid notification of SAEs 
must be followed. Likewise, if the laboratory  abnormality  leads to discontinuation from the 
study  drug (temporarily  or permanentl y), the patient must be followed until the abnormality  
resolves or until it is judged to be permanent. This investigation may include continued 
monitoring b y repeat laboratory testing or b y performing additional laboratory  tests as deemed 
necessary  by the Investigator or the Novartis medical monitor.
A table which provides the maximum, a llowable blood -draw volumes by  weight can be found 
in Appendix 6 . 
There are countries 
where plasma potassium is used instead of serum potassium for routine 
clinical care. Plasma potassium can be used instead of serum potassium in this study .Serum 
potassium thresholds in the study  protocol, including those values cited in Appendix 1and 
Appendix 5,can be converted to plasma potassium thresholds for the study by subtracting 0.4 
mmol/L  from the serum pot assium threshold (Hartland 1999).
6.5.4.1 Hematology
Hemoglobin, hematocrit, red blood cell count, MCV, MCH C,RDW, white blood cell count 
with differential counts, and platelet count are to be measured as part of the complete laboratory 
assessments (Table 6-4)at scheduled study  visits (Table 6-1and Table 6-2) .Results from the 
local laboratory  are to be recorded in the CRF.

Novartis                                                          Confidential                                                          Page 95
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
6.5.4.2 Clinical chemistry
Blood urea nitrogen (BUN), serum creatinine, total bilirubin, fractionated bilirubin (if total 
bilirubin >2x ULN (upper limit of normal )), AST, ALT, alkaline phosphatase, sodium, 
potassium, chloride, calcium, phosphate , magnesium, bicarbonate, total protein, albumin, uric
acid, glucose are measured as part of complete laboratory assessments ( Table 6-4) at scheduled 
study  visits (Table 6-1and Table 6-2). Results from local laboratory  are to be recorded in the 
CRF .
6.5.4.3 Estimated GFR
Estimated glomerular filtration rate (eGFR) as per Schwartz formula (Schwartz 2009) will be 
calculated and reported by  the central laboratory  whenever a serum creatinine is performed by 
the central laboratory .eGFR must be calculated by the laboratory  or the 
Investigator for local 
labs.
The calculation is based on the following formula:
eGFR (ml/min/1.73m2) = 0.413 x height (cm) / serum creatinine (mg/dl)
Height will be provided by  the site to the local and/or central lab.
For eGFR, baseline value for the decrease from baseline criterion for the analy sis will be 
calculated from screening for local labs and from randomization for central labs.
6.5.4.4 Urinaly sis
Urinaly sis with dipstick includes specific gravit y, pH, glucose, total p
rotein, bilirubin, ketones,
urobilinogen, leukocy te esterase, nitrite and hemoglobin (blood). If a urine dipstick is positive, 
other urine measurements such as a qualitative microscopic determination of WBC and RBC 
sediments (and casts) will also be measur ed. 
Urinaly sis will be performed for all patients at Visit 1 (Part 1 PK/PD -Screening) , Visit 199
and/or 299 and Part 2 (Efficacy ) Visit 301, Visit 401, Visit 409, and Visit 416/499 (Week 
52/End of Study )
.For those patients who have visits 299 and 301(for second dose PK), or Visit 
199 and Visit 301(for the first dose PK) on the same day, urinaly sis will be performed only 
once .
6.5.4.5 Biomarkers
 
 
 
 
 
In Part 1 (PK/PD) (in the absence of the above -mentioned collection / sample handling issues): 
plasma BNP, plasma and urine cGMP and plasma NTproBNP samples are collected at Visits 
101, 201 and UNS PK/PD (if performed). Plasma BNP and plasma cGMP are collected at pre -
dose, 4 hour and 8 hour time points post
-dose. Plasma NTp roBNP is collected at pre -dose and 
24 hours post -dose (optional). Urine cGMP is collected at pre -dose and between 4 -8 hours. 

Novartis                                                          Confidential                                                          Page 96
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
At Visit 101, 201or UNS PK/PD (if performed) ,infants who weigh < 15.5 kg will only have
plasma cGMP and BNP collected; infants w
ho weigh ≥ 15.5kg, will have three biomarker 
(plasma BNP, cGMP and plasm aNTproBNP) sample scollected as long as blood volume 
restriction allow s.
Urine cGMP should be collected in Part 1 (PK/PD) at Visit 101, 201 and UNS PK/PD (if 
performed) at pre-dose and once at any time between 4 to 8 hours after LCZ696 single dose 
administration. 
Details 
about biomarker prioritization when blood volumes are restrictive; blood volume 
requirements for each of the biomarkers; sample collection, processing and storage are provided 
in the laboratory  manual.
Details about blood sample collection for biomarkers in Part 1 arealso provided in Table 3-2. 
 
6.5.5 Electrocardiogram (ECG) 
ECGs are conducted at Visit 1 (Part 1 PK /PD -Screening ), Visit 199and/or 299, and Visit 301 
(Part 2 Efficacy -Pre-Randomization/Screening ) and Visit 416/499 (Week 52/End of Study ). 
ECGs are interpreted locally  for study  entry and for purpose of safet y assessment. For those 
patients who have Visit 299 and Visit 301 (for second dose PK) orVisit 199 and Visit 301 (for 
the first dose PK) on the same day , ECG will be performed onl y once.
ECGs must be recorded in the supine position, after at least 10 minutes restif possible to ensure 
a stable baseline. The preferred 
sequence of cardiovascular data collection during study  visits 
is ECG collection first, followed by vital signs, and blood sampling The Fridericia QT 
correction formula (QTcF = (QT/ [RR]0.33)) should be use d for clinical decisions.
Single 12 lead ECGs are collected. The original ECGs, appropriatel y signedby the ECG reader , 
must be collected and archived at the study  site.
Each ECG tracing must be labeled with study  number, subject initials, subject number, date and 
time, and filed in the study  site source documents. For any  ECGs with subject safet y concerns, 
two additional ECGs must be performed to confirm the safet y finding . Clinically  significant 
ECG findings at baseline must be discussed with the sponsor before administration of study  
treatment.
Clinically  significant ECG abnormalities must be recorded on the relevant section of the 
medical history  or adverse event CRFs as appropriate.
6.5.6 Left ventricular ejection fraction (LVEF )or fractional shortening 
assessments
All patients e ntering Part 1 (PK/PD ) will require a qualify ing LVEF or fractional shortening 
assessment by echocardiogram, MRI , MUGA or left ventricular angiogram. If a qualify ing 
LVEF or fractional shortening assessme nt is not available, the patient may enter the study  based 
on a qualify ing echocardiogram performed during the screening epoch between Visit 1 and 

Novartis                                                          Confidential                                                          Page 97
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
before patient receives the first dose of open label LCZ696 (Visit 101or V 201). Patients who
have participat ed in Part 1 (PK /PD) and continue toPart 2 (E fficacy ) need a repeat assessment 
of LVEF or fractional shortening in order to determine eligibility  for Part 2 (Efficacy ) unless 
the most recent assessment iswithin 1 month prior to Visit 301 (Part 2 Pre-
Randomization/Screening ). 
Patients entering directl y into Part 2 (Efficacy ) will require a LVEF or fractional shortening 
assessment obtained within 1 month prior to Visit 301 (Part 2Pre-Randomization/Screening ). 
If a qualify ing LVEF or fractional shortening assessment (echocardiogram, MRI, MUGA, or 
left ventricular angiogram) within 1 month of Visit 301 is not available, the patient may enter 
the study  based on a qualify ing echocardiogram performed during screening before the patient 
receives study  treatment .
6.5.7 Pregnancy  and assessments of fertility  
Pregnancy  test (uri ne) is anal yzed local ly and done at all visits on all female patients ≥11 y ears 
of age and all female patients who are <11 years of age if they are menstruating (for additional 
details regarding urine pregnancy  testing requirements for visits 407, 408, 410, 411, 413, and 
414, see Table 6-2). In addition, serum pregnancy  test is only conducted at Visit 1 (Part 1 PK/PD 
-Screening) ,Visit 301(Part 2 Efficacy -Pre-Randomization/Screening )and Visit 416/499 (Part 
2 at Week 52/End of Study ); and serum pregnancy  test will be analy zed centrally (for Visit 
416/499) or locall y(for Visits 1 and 301) . A positive urine pregnancy test should be confirme d 
with a serum pregnancy  test.
All menarchal girls and their parents/caregivers should be informed about the potential risks of 
pregnancy  and the need to prevent pregnancy  during the study. It is important to be sensitive in 
introducing this issue, as unde rstanding and comprehension of puberty , sexual activity, 
pregnancy  and contraception is influenced by  age; as well as, factors such as precocit y, socio-
educational economic and familial background. These discussions with the patient and her 
parents/caregiv ers are therefore best performed by Investigator s familiar with the pediatric 
patient and her family and should be guided b y requirements of the local regulator y authorities. 
These discussions should take into account the socio- economic, cultural factors and religious 
beliefs of the adolescent participant and her family . The Investigator should also discuss the 
management of the pregnancy  test results with the patient and her parents/caregivers. The 
privacy  of the patient should be considered in accordance with the local law and ethics.
Any patient with a positive pregnancy  test must discontinue study  drug immediately  and the 
patient should remain in study  and continue to attend scheduled stud y visits .
6.5.8 Angioedema
Angioedema is a ty pe of abrupt swelling that occurs under the skin and/or mucous membranes 
and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, 
including the genitalia and intestines. Severe cases may be associated with airway  compromise. 
It is important that theInvestigator pays special attention to any swelling or edema that may 
resemble angioedema or angioedema -like events that may be reported by patients. If such an 
event occurs, the Investigator will complete angioedema case report forms to summarize the 
event, its treatment, and its ultimate outcome. This report along with the requisite medical 

Novartis                                                          Confidential                                                          Page 98
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
documentation must be submitted to Novartis as soon as possible. Follow -up reports must be 
communicated to Novartis as soon as new information regarding the event bec omes available. 
All hospital records related to the event must be communicated to Novartis. 
The Investigator may also be contacted by Novartis and complete specific forms regarding AEs 
that may resemble an angioedema -like event. The Investigator or his/he r delegated staff must 
complete the required forms and provide the required medical records for all such events, 
regardless of whether the Investigator views the event in question as angioedema or not.
All angioedema reports will be forwarded to an externa l independent Angioedema Adjudication 
Committee by  Novartis for assessment. 
Information regarding this committee is outlined inSection 8.4. Details on the procedures for 
reporting angioedema events wil l be provided to Investigator s in a manual.
6.5.9 Appropriateness of safety  measurements 
The safet y assessments selected for this trial are standard assessments for demonstrating safet y 
in this pediatric patient population, based on safet y data from adult LCZ696 studies 
(Investigator Brochure )
, and in accordance with guidelines ( ICH E11Clinical Investigation of 
Medicinal Products in the Pediatric Population ). 
6.6 Other assessments
6.6.1 Clinical outcome a ssessments (COA s)
6.6.1.1 Clinician reported o utcomes (ClinRO)
The impact of study drugon the patient’s physical functional status will be assessed using the 
NYHA classification I
-IV(older children: 6 to < 18 yearsold) or Ross HF classification I-IV 
(younger children: l month to <6 year s old). The NYHA and Ross functional class assessments 
are reliable instruments for rating HF patients’ functionality ( Criteria Committee NYHA 1994 , 
Ross 1992, Packer 2001, Rosenthal 2004). 
The NYHA functional class system is commonly  used and is a clinically  important sy
stem for 
staging the severit y of HF ( Spertus 2005 ). Similar to NYHA, the Ross classification system is 
a common system for grading the severit y of HF in infants (Ross 1992 ). 
The most recent 
pediatric HF Guidelines from the I nternational Society  of Heart and L ung Transplant (I SHL T)
mentio n both NYHA and Ross as Heart Failure Severity  Classifications (Kirk 2014). A one 
class change in the NYHA or Ross functional class scale is considered to represent a clinicall y 
significant change (Ross 1992, Madsen 1994) based on the fact that the four stages in each 
classification differ considerabl y in severity.
Assessment of NYHA/Ross class will be conducted at screening visits for Part 1 (Visit 1) and 
Part 2 (Visit 301); randomization for Part 2 (Visit 401); end of study for Part 2 (Visit 416/499), 
and other visits as per Table 6 -
1and Table 6 -2.
For the duration of Part 2, the same PedsQL, NYHA and Ross instruments based on the age at 
randomization should be used
.

Novartis                                                          Confidential                                                          Page 99
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
6.6.1.2 Patient reported o utcomes (PRO)
The impact of HF on the patient’s status will be assessed b y the following measures:
Patient global impression of s everit y (PGIS)
Pediatric quality  of life inventory (PedsQL) 4.0 g eneric scales
All questionnaires will be completed in the language most familiar to the respondent, and at the 
scheduled study  visit prior to the patient seeing the Investigator for any clinical assessment or 
evaluation. The patient should be given sufficient instructio n, space, time and privacy  to 
complete the questionnaire. The study  coordinator should check the responses to the 
questionnaire for completeness and encourage the patient to complete an y missing responses.
A detailed training manual relating to the administrative procedures of the questionnaires will 
be provided to the sites. The Investigator enters the data from the questionnaire into the CRFs. 
The original questionnaire will be kept with the patient’s file as the source document. 
In Part 2 the patient orparent/caregiver will complete the patient reported outcome (PGIS ,
and PedsQL) evaluations based on age at randomization.
Patient global i mpression of severity  (PGIS)
The patient global impression of severity  (PGIS )is a static global impression of severit y 
question 
that will be used to capture the patients’ current health status relative to their heart 
failure over 7 day srecall period.
Patient (7 to < 18 years old) : How would y ou describe the severity  of your heart failure 
symptoms over the past 7days ? (None/ Mild / Moderate / Severe / Very Severe)
Parent (for < 5 years old patients) : How would you describe the severit y of your child’s 
heart failure s ymptoms over the past 7 days? ( None / Mild / Moderate / Severe / Very  
Severe)
A 3-point faces scale (corresponding/coded to Good / Neither Good nor Bad/ Bad ) will be 
used for patient self -report by  children 5 to < 7years(Appendix 8 ). 
For the global rank primary endpoint, a one class change in the PGI S is considered to represent 
a clinically  significant change . The patient PGIS report will be used for the Global Rank 
endpoint for patients ≥ 5years old.
Given the nature of heart failure sy mptoms, the PGI S will be performed when the patient is at 
rest and at the same location during the study  visit. Additionally , instructions will be provided 
to the child and/or parent/caregiver that describe several symptoms of heart failure for 
consideration while responding to the PGIS. When the pediatric patient is completing the PGIS, 
the parent/caregiver will be instructed to not interfere with the child’s response. There will be 
standardized instructions for patient and parent/caregiver to complete the PGIS. If a child is 
unable to complete the PGIS, this will be noted. If a patient 5 years and older is unable to 
complete the assessment, the assessment will be considered not done. The parent/caregiver 
PGIS report will only  be used for the Global Rank endpoint for patients < 5 years oldbecause 
patients < 5 years old are not considered mature enough to complete the patient PGIS self-report.

Novartis                                                          Confidential                                                          Page 100
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Parents and caregivers should be instructed to minimize any interaction, assistance and 
influence on the patient while the patient is completing the P GIS.
Patient or parent/caregiver will complete the PGIS atrandomization for Part 2 (Visit 401); end 
of study  for Part 2 (Visit 416/499), and other Part 2 visits as per Table 6-1 and Table 6-2.
Pediatric quality  of life inventor y (PedsQL )
The PedsQL is a patient- reported outcome instrument that evaluates health related quality  of 
lifein healthy  children and adolescents and in pediatric patients with acute and chronic health 
conditions (Varni 2003, 2011). The PedsQL has published data in over 25,000 children and 
adolescents in multiple disease areas including pediatric cardi
ology ( Varni 2003; Uzark 2008). 
The PedsQL  has been validated in multiple pediatric disease populations and has demonstrated 
responsiveness to meaningful clinical change (Uzark 2008, Uzark 2013, Desai 2014). The 
PedsQL  is the most widely  used pediatric patient reported outcome assessment, and it is 
currentl y being used in the PEDIMACS (pediatric mechanical circulatory  support devise) 
registry  (INTERMAC S protocol 2014) and in an observational study  of pediatric solid organ 
transplant recipients (ClinicalTrials.gov 20
08).
 
The physical functioning domain of questions that focuses on 
proximal effects of health -related qualit y of life related to heart failure will be used for the 
Global Rank primary  endpoint. The responsiveness of the PedsQL physical functioning domain 
in pediatric patients with cardiovascular disease has been demonstrated in several studies. In a 
prospective study  of 475 families including 347 children with cardiovascular disease, the 
PedsQL  score for physical functioning by patient self-report was significantly  lower than the 
norms for healthy  children (Uzark 2008). In this study , PedsQL physical functioning scores 
were also significantl y lower for patients with more severe cardiovascular disease compared to 
milder 
cardiovascular disease. In a study  of 126 families from Sweden with congenital heart 
disease, the PedsQL physical functioning scores were significantl y lower for patients with more 
severe compared to mild/moderate congenital heart disease; and PedsQL physical functioning 
scores were also significantly  lower comparing non-operated to operated congenital heart 
disease ( Sand 2013). PedsQL  physical functioning scores were significantly lower for children 
who received a heart transplant compared to healthy  peers and children who r eceived curative 
heart surgery (Uzark 2012). Another study  demonstrated that children with the more severe 
condition of hypoplastic left ventricle had significantly  lower Peds QL physical functioning 
scores compared to the less clinically  severe tetralogy  of Fallot pediatric patients (Eagleson 
2013).
The PedsQL is administered to both the patient via child self-report and the patient’s 
parent/legal guardian
-caretaker via parent proxy-report. The PedsQL requires on average 5 
minutes for co mpleting. A 5- point response scale is used for 8 -18 years old patients; while a 3 -
point scale is used for 5-7 years old patients.  
 
 
The patients’ self-report will be used for the primary  endpoint for patients 
≥ 6 years.  

Novartis                                                          Confidential                                                          Page 101
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Parents and caregi vers should be instructed to minimize any interact ion, assist ance and 
influence onthe patient while the patient is completing the PedsQL. The patient’s age at 
randomization (Part 2 Efficacy  -Visit 401) will be utilized to determine the correspondin g 
PedsQL  questionnaire to be administered at that visit and all subsequent visits.
The PedsQL  will be completed at randomization for Part 2 (Visit 401); end of study  for Part 2 
(Visit 416/499), and other Part 2 visits as per Table 6 -2.
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6.2
Pharmacokinetics
Part 1 (PK/PD)
At Visit 101, 201and UNS PK/PD the PK samples will be collected at the following intervals 
for the various age groups:
Patients >6 years of age: Blood samples  are collected at pre- dose (pre -dose sample for all 
patients) 0.5, 1, 2, 4, 8, 10, and optional 24 hours post dos ing
Patients <6 y ears of age: Blood samples  are collected at pre- dose (pre -dose sample only  
from those patients who are on valsartan ) 1, 2, 4, 10, and at an optional 24 hours post 
dosing
The exact time of the treatment administration, dose of LCZ696, samp le number, and time of 
sample collection are recorded for each sample collected in the CRF . Sampling problems are to 

Novartis                                                          Confidential                                                          Page 102
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
be documented in the CRF and may include but are not limited to hemoly zed samples, 
insufficient sample volumes, and/or a lack of sample collections.
The plasma 
levels of LCZ696 analytes are determined using a validated LCMS/MS method 
with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, 
and 10 ng/mL  for valsartan. The detailed method description of analysis will be included in 
bioanaly tical report .
The following PKparameters will be determined for LCZ696 analytes (sacubitril, LBQ657, and 
valsartan) using Phoenix version 6.2 or higher using non-compartmental methods: Cmax, Tmax, 
AUC last, AUC inf, T1/2, Cl/F, and other relevant PKparameters (data permitting) . In case of data 
limitations for estimating PKparameters using non-compartmental methods, apopulation PK
approach will also be used 
to estimate exposure of L CZ696 analy tes.
The information about pharmacod ynamic parameters (biomarkers) is provided in Table 3-2and
Section 6.5.4.5.
Part 2 (Efficacy )
Population PK data collection:
Pre-dose PK blood sample swill be collected at Visit 403, Visit 406, and Visit 416/499 for 
population PKanalysis(see Appendix 15 for USM exception) . Every  effort should be made to 
collect PK samples at all three visits. If a PK sample is not obtained at Visit 40 3or 406 , the PK 
sample can be colle cted at a subsequent scheduled or unscheduled visit. A population PK blood 
sample should only  be obtained if permissible b y blood volume limits ( Appendix 6 ). 
Steady -state sparse PK data collection ( Group 2 patients only ): 
In approximately  24 patients (approximately  half of whom are expected to be randomized to 
LCZ696) in Group 2 (1-<6 years old), sparse PK blood samples will be collected at stead y-state, 
at approximately  3 time-points on the same day, at Visit 405 or at a subsequent scheduled or 
unscheduled visit (with the exception of Visit 406 and 416/499), when the patient is on Dose-
Level 4 or at his/her highest tolerated dose for at least 1 week. The study  site personnel are to 
confirm that blood volume restrictions for each patient are not an issue for the patient before 
blood sampling for steady -state sparse PK Visit is started. Patients will be instructed to hold 
their morning dose the day of the stead y-state, sparse PK Visit to enable the collection of a pre -
dose blood sample. The time of the last dose taken the day before the sparse PK visit will be 
recorded in the CRF. Patients will take their morning dose at the study  site after the pre-dose
blood sample is collected. Two additional blood samples will be collected at 2 hours post dose 
and 6 hours post dose. In this sub -set Age Group 2 
patients, collection of additional PK blood 
samples for Population PK at Visits 406 and 416/499 will not be required.
Table 6-5 Spar sePK A ssessment Schedule Part 2 Group 2 Subset
Timepoint Visit 405 (week 8)# Visit 409,412,415, UNS
Pre-dose X X#
2 hours post-dose X X#
6 hours post dose X X#

Novartis                                                          Confidential                                                          Page 103
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
# If sparse PK blood samples cannot be collected at V405 than one of the following visits can be used 
for collection of the s parse PK samples: Visit 409, Visit 412, Visit 415 or an UNS visit.
Steady  state concentrations of valsartan, sacubitril, and LBQ657 will be analy zed by  graphical 
methods to determine an appropriate structural PK model to fit the data. Data obtained from 
Part 1 will also be included in this PK modeling . Following this, a p opulation PK model will be 
developed using the data obtained from this study  and/or in combination with PK data obtained 
from other studies to quantify  PKof valsartan, sacubitril, and LBQ657. Significant covariates 
that influence PK properties of these an alytes will also be examined.
Patients/caregivers should be instructed not to take their morning dose of study  treatment during 
the PK blood sample collection visits. 
For the Population PK blood samples that are to be collec ted at Visits 403, 406, and 416/499, 
if a patient takes his or her morning study  drug dose prior to obtaining the PK blood sample, 
the PK blood sample must still be collected and the actual time of study  drug dosing and sample 
collection time must be recorded. 
For the sparse PK samples that are to be collected at the sparse PK Visit for 
Age Group 2 
patients, if a patient takes his or her study  drug dose the morning of this sparse PK Visit, the 
patient will be asked to return at a later date to complete the sparse PK blood sam ple collection 
Visit.
All samples are given a unique sample number and a collection number (laboratory  manual) . 
The exact time of the treatment administration, study  drug dose, sample number, and time of 
sample collection are recorded for each sample colle cted on the CRF . Whether the patient fasted 
prior to the single dose PK assessment should also be collected in the CRF . Sampling problems 
may include but are not limited to hemoly zed samples, insufficient sample volumes, and/or a 
lack of sample collections are to be documented in the CRF . PK samples are to be collected 
when the patient is expected to be at stead y state, i.e., patient has been receiving the stud y drug 
regularl y on the same dose levels as prescribed for at least 1 week.
PK blood sample handli ng
The PK section of the (Laboratory Manual )for this study  will provide details regarding sample 
handling including collection, labeling ,processing, storage and shipping. The Laboratory  
Manual will also provide details regarding which samples to exclude if blood volume is an issue.
7 Safety  monitoring
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investi gation subject after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are 
also considered an 
adverse event irrespective if a clinical event has occurred.

Novartis                                                          Confidential                                                          Page 104
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
The occurrence of adverse events must be sought by non -directive questioning of the patient at 
each visit during th e study . Adverse events also may  be detected when they are volunteered b y 
the patient during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically significant 
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typical in patient with 
underly ing disease. Investigators have the responsibility  for managing the safet y of individual 
patient and identify ing adverse events. Alert ranges for laboratory  and other test abnormalities 
are included in Appendix 1 .
Adverse events must be recorded in the AECRF under the signs, symptoms or diagnosis 
associated with them, accompanied by  the following information:
the severit y grade 
mild: usually  transient in nature and g enerally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
All adverse events must be treated appropriatel y. Treatment may include one or more of the 
followin
g: 
no action taken (e.g. further observation only ) 
investigational treatment dosage adjusted/temporarily  interrupted 
investigational treatment permanentl y discontinued due to this adverse event 
concomitant medication given 
non-drug therap y given 
patient hospitalized/patient’s hospitalization prolonged (refer to Section 7.2 for definition 
of SAE)
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved wit h sequelae; fatal; or unknown)
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent, and assessment must be made at each visit (or more frequently , if necessary ) of 
any changes in severity, the s
uspected relationship to the study drug, the interventions required 
to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the patient 
informed consent and should be discussed with the patient during the study  as needed. Any new 
information regarding the safet y profile of the medicinal product that is identified between IB 

Novartis                                                          Confidential                                                          Page 105
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
updates will be communicated as appropriate, for example, via an Investigator Notification or 
an Aggregate Safet y Finding. New information might require an update to the informed consent 
and has then to be discussed with the patient.
The Investigator must also instruct each patient to report any newadverse event (beyond the 
protocol observation period) that the patient, or the patient’s personal physician, believes might 
reasonabl y be related to study  treatment. This information must be recorded in the Investigator ’s 
source documents; however, if the AE meets the criteria of an SAE, it must be reported to 
Novartis.
7.2 Serious adverse events
7.2.1 Definition of SA E
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing )]
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that i s unrelated to the 
indication under study  and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission 
social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  require 
medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (refer to Annex IV, ICH -E11D Guideline ).
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the patient or might 
require intervention to prevent one of the other outcomes listed above. Examples of such events 
are intensive treatment in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization or deve lopment of dependency or 
abuse (refer to Annex IV, I CH-E11D Guideline ).

Novartis                                                          Confidential                                                          Page 106
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious advers e reaction.
7.2.2 SAE reporting
To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has 
provided informed consent and until 30 days after the last study  visit must be reported to 
Novartis safet y immediately , without undue delay, but under no circumstances later than within 
24 hours of obtaining knowledge of the events (Note: If more stringent, local regulat ions
regarding reporting timelines prevail.) . Any SAEs experienced after the 30 day per iod after the 
last study  visitshould only be reported to Novartis if the Investigator suspects a causal 
relationship to study  treatment. 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported asfollow -up to the original episode
immediately , without undue delay , but under no circumstances later than within 24 hours of the 
Investigator receiving the follow -up information (Note: If more stringent, local regulat ions
regarding reporting timelines prevail.) . An SAE occurring at a different time interval or 
otherwise considered completely  unrelated to a previously  reported one must be reported 
separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatm ent), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the submission process and requirements for signatures are to be found 
in the investigator folder provided to each site.
Follow -up information is submitted in the same way as the original SAE Report. Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation
Follow -up information provided must describe whether the event has resolved or continues, if 
and how it was treated, whether the treatment code was broken or not and whether the patient 
continued or withdrew from study  participation. Each re-occurrence, complication, or
progression of the original event must be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a Drug Safety  and Epidemiology 
Department associate may urgently require further informa tion from the Investigator for health 
authority  reporting. Novartis may need to issue an Investigator Notification (IN) to inform all 
Investigator s involved in any study with the same study  treatment that this SAE has been 
reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collect ed and 
reported to the competent authorities and relevant ethics committees in accordance with EU 
Guidance 2011/C 172/01 or as per national regulatory  requirements in participating countries.

Novartis                                                          Confidential                                                          Page 107
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
7.3 Protocol specific unblinding rules
7.3.1 Adverse events that are commo nly seen in the study population 
Investigators will report AEs or SAEs that are common ly seen in the study population, but they 
will not be unblinded and will not be reported as SUSARs to regulatory  agencies, ethics 
committees (ECs), or Investigator s duri ng the study (Table 7 -1). 
These SAEs will be reviewed by an external independent DMC (Section 8.3) appointed to 
monitor the safety  of study  participants. If the DMC observes a clinically important imbala nce 
in the AEs or SAEs, it will inform Novartis. Novartis will then inform all health authorities, 
ECs, and Investigator s in an expedited manner and implement any  additional actions required.
These events will be presented in the clinical study  report (CSR) at the end of the study .
Table 7
-1 Adverse events (AEs) commonly  seen in study population
Cardiovascular events Non-cardiovascular events
Worsening HF Bronchitis Influenza
Edem a Vomiting Nasopharyngitis
Hypotension Cough Nausea
Renal impairment Diarrhea Pneumonia
Failure to thriveUpper respirator y 
infection
Fatigue Weight change
Study -specific unblinding rules for SUSA Rs that are disease related and 
present efficacy  endpoints
The integrity  of this study  may be compromised, if the blind is systematically  broken for 
SUSARs that could also be efficacy  endpoints [for relevant EU guidance please refer tothe 
European Commission ENTR/CT 12 Guideline (2006) , FDA Guidance 2012 ]. Therefore, the 
rules for unblinding will apply  as follows.
A
SUSAR will not be unblinded, if it could represent one of the following pre -specified 
disease related endpoints:
Death (All cause, Cardiovascular, Non -cardiovascular), Ventricular Assist 
Device/ECMO/Mechanical Ventilation/ Intra-aortic Balloon Pump requirement, 
Worsening HF (with and without hospitalization)
In addition, no report to competent authorities and relevant EC and no issuance of an 
Investigator Notification (IN) will occur. An external independent DMC ( Section 8.3) has been 
previously  appointed and will review efficacy  and safety  data of the ongoing trial on a regular 
basis. DMC opinion and recommendations will be notified by Novartis as soon as possible to 
the competent authorities and the ECs where they  qualify  for expedited reporting.
If specificall y requested by a local Health Authority (HA), pre -specif ied endpoints (see above) 
that also meet the criteria for SUSARs will be expedited to this HA as blinded reports. INs will 
not be issued for these events.

Novartis                                                          Confidential                                                          Page 108
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Any other SUSAR that will not meet the pre-specified disease related endpoints as mentioned 
above will be unblinded and a report to competent authorities and relevant ethics committees 
and issuance of an IN will occur .
7.4 Liver safety  monitoring
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
The following tw o categories of abnormalities/ AEs have to be considered during the course of 
the study :
Liver laboratory  triggers, which will r equire repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 14-1 inAppendix 2for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event as defined in Table 14-1 of Appendix 2should be 
followed up by the Investigator or designated personal at the trial site as summarized below. 
Follow up information is outlined in 
Table 14-2 in Appendix 2 .
For the liver laboratory  trigger:
Repeating the LFT within the next week to confirm elevation
These LFT repea ts should be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
patient. Repeats laboratory  should then be performed at the central laboratory  assoon as 
possible. If a liver event is subsequentl y reported, any local LFTs previously  conducted that are 
associated with this event should be reported on the L iver CRF pages.
If the elevation is confirmed, close observation of the patient will be initiat ed, including 
consideration of treatment int erruption if deemed appropriate
For the liver events:
repeating the LFT to confirm elevation as appropriate
discontinuation of the investigational drug if appropriate
hospitalization of the patient if appropriate
a causalit y assessment of the liver event via exclus ion of alternative causes (e.g. disease, 
co-medications)
an investigation of the liver event which needs to be followed until resolution
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultation. These investigations can be performed based on Investigator ’s 
discretion. All follow -up information, and the procedures performed should be recorded on 
appropriate CRF pages, including the liver event CRF pages.

Novartis                                                          Confidential                                                          Page 109
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
7.5 Renal safety  monitoring 
To ensure patient safety  and enhance reliability  in determining the nephrotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
renal events has to be followed. 
Thefollowing two categories of renal AEs have to be considered during the course of the study :
1.Serum event:
Confirmed (after ≥ 24h) decrease in estimated glomerular filtration rate (eGFR) of ≥ 
25% compared to baseline during normal h ydration status as estimated by  Schwartz 
equation AND eGFR <90 mL/min/1.73m2
2.Urine event:
New onset ( ≥ 1+) proteinuria, hematuria or glucosuria
New onset of proteinuria should be confirmed b y urinary  protein creatinine ratio 
Every  renal laboratory  trigger or renal event as defined in Table 15 -1in Appendix 3 should be 
followed up b y the Investigator or designated personnel. 
7.6 Reporting of study  treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).
Misuse refers to situations wher e the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychologi cal effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR CRF irrespective of whether or not associated with an AE/SAE and reported to Safet y 
only if associated with an SAE (Table 7-2). Misuse or abuse will be collected and reported in 
the safet y database irrespective of it being associated with an AE/SAE.
Table 7
-2 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error 
typeDocument in Dose 
Administration 
(DAR) CRF (Yes/No)Document in A E 
CRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AE .Only if associated with an 
SAE.
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE.
7.7 Pregnancy  reporting
To ensure patient safet y, each pregnancy  occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 

Novartis                                                          Confidential                                                          Page 110
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newbo rn complications (with up to 12 months follow up after the birth of the baby, where 
consent is provided ).
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and reported by the 
Investigator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnanc y 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study  treatment. 
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
8 Data revie w and database management
Site monitoring
Before study  initiation, at a site initiation visit,or at an Investigator ’s meeting, a Novartis 
representative will review the protocol and CRFs wit h the Investigator s and their staff. During 
the study , Novartis employ s several methods of ensuring protocol and Good Clinical Practice 
(GCP )compliance and the quality /integrity  of the sites’ data. The field monitor will visit the 
site to check the comple teness of patient records, the accuracy  of entries on the CRF s, the 
adherence to the protoc ol and to GCP , the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits. Continuous remote 
monitoring of each site’s data may  be performed by a centralized Novartis CRA organization. 
Additionally , a central analy tics organization may analyze data & ident ify risks & trends for 
site operational parameters, and provide reports to Novartis Clinical Teams to assist with trial 
oversight.
The Investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The Investigator must also keep the original informed consent form signed b y the 
patient (a signed cop y is given to the patient).
The Investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the CRF entries. Novartis 
monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and of data that will be used for all primary  variables. Additional checks of the 
consisten cy of the source data with the CRFs are performed according to the study -specific 
monitoring plan. No information in source documents about the identity  of the patients/subjects 
will be disclosed.

Novartis                                                          Confidential                                                          Page 111
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
8.1 Data collection
Designated Investigator staff will enter the data required by the protocol into the clinical 
database system. Designated Investigator site staff will not be given access to the sy stem until 
they have been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by generating appropriate error messages, allow the data to be confirmed 
or corrected online by the designated Investigator site staff. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the Investigator will receive copies of the patient data for archiving at the 
investigational site. 
8.2 Database management and quality  control
Novartis staff review the data entered into the CRFs by investigational staff for completeness 
and accuracy  and instruct the site personnel to make any required corrections or additions. 
Queries are sent to the investigational site using an electronic data query . Designated 
Investigator site staff is req uired to respond to the query  and confirm or correct the data. If the 
electronic query  system is not used, a paper Data Query  Form will be faxed to the site. Site 
personnel will complete and sign the faxed copy and fax it back to Novartis staff that will m ake 
the correction to the database. The signed copy  of the Data Query  Form is kept at the 
Investigator site.
Concomitant medications entered into the database will be coded using the World Health 
Organization (WHO) Drug Reference List, which employ s the Anatomical Therapeutic 
Chemical classification system. Concomitant procedures, non-drug therapies and adverse 
events will be coded using the Medical dictionary  for regulatory  activities (MedDRA) 
terminology .
Laboratory  samples processed centrally  will have results sent electronically to Novartis.
Randomization codes and data about all study  drug(s) dispensed to the patient and all dosage 
changes will be tracked using an Interactive Response Technology  (IRT). The system will be 
supplied by a vendor, who will also manage the database. The database will be sent 
electronically  to Novartis (or a designated Clinical Research Organization (CRO)).
Each occurrence of a code break via I RT will be reported to the clinical team and monitor. The 
code break functionality  will remain 
available until study  shut down or upon request of Novartis. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time can only be made after written agreement by Novartis 
Development management.
8.3 Data monitoring c ommittee (DMC)
An external and independent DMC will evaluate the unblinded data during the course of stud y, 
which will be provided by an independent and external Statistical Data Analy sis Center. Data 

Novartis                                                          Confidential                                                          Page 112
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
may also be provided to Health Authorities, if required for an ong oing marketing authorization 
application regulatory  review and Novartis will inform the DMC should this occur.
In addition, the DMC will review efficacy  data from one prespecified interim efficacy  and 
futility  analysis when at least 180 patients and at lea st 36 patients from each age group have 
completed the study (i.e. reached a terminal endpoint or c ompleted the 1 year study  visit ), and 
at least 40 patients have had an event in Category 1 or 2. Further details about interim analyses 
are provided in Section 9.6. 
As necessary , the DMC may also review the data associated with the analy sis of s
parse PK 
steady  state data from a subset of patients in Part 2 Group 2 (Section 9.5.1).
Both the DMC andNovartis (Section 
8.5) will be responsible for the review of Part 1 PK/PD
data and dose determination for Part 2 (Efficacy ) . Any major recommendation from the DMC 
will be communicated to the study  Executive Committee and must be reviewed and ratified by 
the study  Executive Committee in consultation with Novartis prior to its enactment. Further 
information 
is provided in the DMC Charter.
8.4 Adjudication c ommittee 
Clinical endpoint committee
All clinical events, which could potentially  fulfill the Category 1 or 2 endpoints will be assessed 
during the stud y and reported to the Clinical Endpoint Committee for adjudication.
The CEC willreview and adjudicate events including but not limited todeaths (CV and non-
CV death) , circulatory  and/or respiratory  mechanical assistance for life support, listing for heart 
transplantation , and clinical worsening of heart failure (with or without hosp
italization) for 
endpoint determination. The detailed definitions of the endpoints, required documentation, and 
the adjudication process will be included in a separate CEC Manual . 
Sites are instructed to take a conservative approach when reporting endpoints. If the Investigator
suspects an endpoint may  have occurred, it is best to report the event in the endpoint CRF . 
Angioedema adjudication committee
If an angioedema or angioedema -like event occurs, the Investigator will complete case report 
forms for angioedema adjudication. Details on the process of reporting angioedema and 
angioedema -like events are outlined in a manual provided to Investigator s.
Submission of an angioedema report is not a substitution for the submission of an SAE report. 
If an angioed ema-like event satisfies the definition of an SAE, the Investigator must submit an
SAE report in addition to the adjudication report for an angioedema -like e vent.
The membership and responsibilities of the Angioedema Adjudication 
Committee are defined 
in aseparate document that will be provided to the sites.
8.5 Part 1 PK/PD data review
As described in Section 3.1, the age group s will be enrolled sequentiall y from Group 1to Group 
3. For the oldest agegroup (Group 1: 6 to < 18 years) , the PK, PD,and safet y data obtained  
from all 12 observations will be reviewed by the DMC prior to starting Group 2 in Part 1 and 

Novartis                                                          Confidential                                                          Page 113
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
to support the dose recommendation before patients will be enrolled into Part 2 of the same age 
group . Simil arly, for Group 2 (1to < 6 years), the PK, PD ,and safet y data obtained from all 12 
observations will be reviewed by the DMC prior to starting Group 3 in Part 1 and to support the 
dose recommendation for Part 2 of the same age group. For Group 3 (1 month to < 1years)the 
PK, PD,and safet y data obtained from approximately 8 observations will be reviewed by the 
DMC to support the dose recommendation for Part 2 in the same age group . All suspect 
abnormalities will be discussed before enrollment into the next dose group/age group is allowed. 
The decision on the dosing for Part 2 (Efficacy ) for each age group will be made jointly  by 
Novartis and the DMC.
Data review is anticipated to include the following, when available: 
AEs and SAEs and their causal relati onship to the study  drug
Evidence of pharmacod ynamic interactions between L CZ696 and co -medications
Vital signs 
Blood chemistry  and hematology
PK and PK/PD response
9 Data analy sis 
The analysis will be conducted on all subject data at the time the trial ends. Any data analysis 
carried out independently by the Investigator should be submitted to Novartis before publication 
or presentation.
9.1 Analysis sets
For Part 1: All subjects with at least one dose of study  drug will be included in safety  analysis 
set. All subjects with evaluable PK /PDdata will be included in the PK/PDdata anal ysis.
For Part 2 (Efficacy ), the following populations will be used for the statistical anal yses 
The full anal ysis set (FAS) will consist of all randomized patients with the exception for those 
patients who have not been qualified for randomization and have not received study  drug, but 
have been inadvertently randomized into the study . Following the intent -to-treat principle, 
patients will be analy zed according to the treatment to which they were assigned at 
randomization. Efficacy  variables will be analyzed based on the FAS as the primary  population.
The Safet y Population (SAF) will consist of all patients who received at least one dose of stud y 
drug and have at least one post -baseline safet y assessment. Of note, the statement that a patient 
had no AEs also constitutes a safet y assessment. Patients will be analyzed according to the 
treatment actually  received. The safet y population will be used for the analyses of safet y 
variables. 
The Per -Protocol (PP) population will be a subset of the FAS which will consist of the patients 
who do not have major deviations from the protocol procedures in the double -blind study  stage. 
Major protocol deviations will be pre-specified prior to unblinding treatment codes for analyses. 
This supplemental efficacy  population will be used to support the primary anal ysis results.

Novartis                                                          Confidential                                                          Page 114
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
9.2 Patient demographics and other baseline characteristics
Summary  statistics for Part 1 (PK/PD) and Part 2 (Efficacy ) will be provided by treatment group 
for demographics and baseline characteristics, including age, age group (Group 1: 6 to < 18 
years; Group 2: 1 to < 6 y ears; Group 3: 1 month to < 1 y ear), modified age group (Group 1: 6 
to < 18 years; Group 2a: 2 to < 6 years; Group 3a: 1 month to < 2 years ),sex, race, ethnicity , 
weight, height, body  mass index (BMI), category of prior HF medication, HF etiology , prior 
HF hospitali zation, NYHA/Ross class,  and vital signs. BMI will be calculated as 
weight (kg) / height2(m2) from the collected height and weight attheScreening visit. 
Continuous variables will be summarized using n, mean, standard deviation, median, minimum, 
and maximum. Categorical variables will be summarized using frequency  and percentage. 
Additionally , summary  statistics will be provided by treatment and age group ,and by treatment 
and modified age group ,for demographics and baseline characteristics forboth Part 1 and Part 
2.
For Part 2 (Efficacy ), baseline value is defined as the last non-missing assessment prior to the 
first dose of randomized study  medication unless specified otherwise. 
For Part 1(PK/PD) , 
all subjects with at least one dose of study  drug will be included in the 
above analyses. For Part 2(Efficacy ), the FAS set will be the patient population for the above 
analyses.
9.3 Treatments
Part 1 (PK/PD )
The study  drug administration (single dose of LCZ696 in mg/kg) will be summarized for 
subjects who received study  drug during Part 1(PK/PD) . The summary  will beconducted by 
age group and overall; and the summary  will use mean, standard deviation, median, minimum, 
and maximum. The number and percentage ofpatients will be summarized by age group and 
dose levels (mg/kg).
Concomitant medications will be summarized by therapeutic class, preferred term (PT) and 
dose level for each age group and overall for all subjects who received study  drug in Part 1 
(PK/PD). 
Part 2 (Efficacy )
The overall duration ofthe double -blind study  drug will be summarized for the SAF population 
by treatment group using mean, standard deviation, median, minimum, and maximum. 
Additionally , the number and percentage of patients will be summarized by treatment group for 
duration c ategory . 
Concomitant medications will be summarized by therapeutic class, preferred term (PT), 
treatment group for the SAF population.
Additionally , all analy ses conducted above for Part 2 (Efficacy ) will be summarized by 
modified age group. 

Novartis                                                          Confidential                                                          Page 115
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
9.4 Analysis of the primary  variable(s)
9.4.1 Variable(s)
Part 1 (PK/PD)
The objective of Part 1 of the study  is to characterize PKand PDof LCZ696 in pediatric patients 
and compare PK, PD, and exposure -response with observed data in adult heart failure patients 
in order to d etermine the dose for Part 2 (Efficacy )of the stud y. In Part 1 (PK/PD) of the stud y, 
the pediatric patient population is divided into three age groups; Group 1: 6 to < 18 years old, 
Group 2: 1 to < 6 years old, and Group 3: 1 month to < 1 year old. 
Consi dering various factors including factors such as ontogen y of enzymes/transporters, the 
variability  in PKparameters is assumed to be similar between adult and pediatric HF patients 
(>3 months). Since LBQ657 is a metabolite, clearance and volume of distribu tion were not 
estimated in earlier clinical trials and coefficient of variation% (CV% )of total exposure was 
considered for sample size estimation. From previous clinical study  in adult HF patients, the 
observed CV% for body -weight normalized LBQ657 exposu re was 37.1% and the observed 
CV% for body -weight normalized clearance and volume of distribution of valsartan was 39.4% 
and 49.6%, respectivel y (CLCZ 696A2117). Therefore 49.6% of CV% was assumed for sample 
size estimations. The sample size is up to 12 observations per age group (except Group 3 where 
N= 8observations) to achieve 95% CI for geometric mean of PK parameters to fall between 
60% and 140% range (95% CI : 71 –141%) with 80% coverage probability . 
A popula tion PK model will be developed to describe incoming data from pediatric patients 
based on anestablished model developed for the adult HF population. The fidelity  of the 
developed PK model will be cross validated for its robustness and precision to the observed 
data. The stead y state population PK parameters including clearance, volume of distribution, 
Ka, T1/2, Cmax, Cmin, and AUC will be estimated. The impact of covariates such as eGFR, 
age, bod y weight, NYHA /Ross class, TBL, and AST levels will be eva luated.
Pharmacod ynamic evaluations will include analysis of change in plasma cGMP, plasma BNP, 
plasma NTproBNP and urine cGMP. Dose and exposure -response relationship will be 
evaluated based on changes in plasma cGMP levels (and also plasma NTproBNP, plasma BNP, 
urine cGMP).
PKPD modeling of Part 1 data may be carried out, depending on the robustness of both the PK 
and biomarkers to be used to inform the dose justification for Part 2.
Part 2 (Efficacy )
The global rank primary  endpoint is constructed throu gh 2 steps: 
Step 1: Patients are classified into the 5 ordinal categories based on the logic described in 
Table 6-3 in Section 6.4.1 .
Step 2: Within e ach category, patients are ranked from worst to best based firston the 
subcategory  if applicable, and then the ranking algorithm asexplained in Table 6-3.

Novartis                                                          Confidential                                                          Page 116
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
9.4.2 Statistical model, hypothesis, and method of analy sis
The primary  endpoint comparing the distributions for patients receiving LCZ696 and patients 
receiving enalapril will be assessed using a stratified Wilcoxon rank -sum analysis ( Kawaguchi 
2011), stratify ing by modified age group (Group 1: 6 to < 18 years; Group 2a: 2 to < 6 years; 
Group 3a: 1 month to < 2 years )and NYHA/Ross class group (Class I/II; Class III/IV) . The 
overall significance level (Type 1 error) of 0.05 (2-sided) will be used. In addition, the 
proportion of patients falling into each of the 5 ordered categories of the primary  endpoint will 
be presented by treatment group. These proportions will be provided both hierarchicall y (only 
worst category  counted for each patient), as the endpoint is defined, and overall, not accounting 
for whether a patient also had a worse event. Full anal ysis set will be used for these anal yses.
In addition, the number and percentage of patients in each category  will be provided by 
treatment group for each age group, e ach modified age group, and for overall.
Due to unresolvable technical reasons in study  drug supply , the unforeseen intercurrent events 
of the USM leading to study  treatment discontinuations are not related to disease progression, 
are not related to the assigned study  treatment, and donot reflect a real-world setting. The 
exposure to the study  treatment and study  follow -up are reasonably  long. Therefore, the on-
treatment approach is considered to be more appropriate for the handling of USM -impacted 
patient s in the primary  analysis, utilizing the relevant components of the global rank endpoint 
including Category  1 and Category  2 status at the time of treatment discontinuation.
9.4.3 Handling of missing values/censoring/discontinuations
Part 1 ( PK/PD)
All concentrations below the lowest limit of quantitation (LLOQ) or missing data will be labeled 
as such in the concentration data listings. Concentrations below the LLOQ will be treated as 
zero in summary  statistics and for the calculation of PK parameters.
The statistical anal ysis will include all subjects with valid PK parameters.
Part 2 (Efficacy )
All efforts should be made to collect all information including vital status for all patients at the 
52 week visit ,or the last on -treatment assessment visit for the USM impacted patients . 
For the primary  efficacy  endpoint, missing information will be handled as follows.
Patients will be classified into 
theworst possible category , based on available and retrievable 
infor mation for the patient. Within Categories 1 and 2, patients will be further ranked accordin g 
to the day  of the last reliable information (for example, last day  of contact). I fthe patient is not 
classified as Categories 1 or 2(e.g. patient is alive and is documented to not have any WHF 
events ), the same principle will be followed for ranking the patient.
If the 52 weeks measurements
, or the last on -treatment assessment visit for the USM impacted 
patients, of NYHA classification or Ross classification and the PGI S score are missing then the 
last-observation- carried -forward (LOCF) technique will be used to impute the missing post-
randomi zation values ( for patients who do not experience an y events in Category 1 or 2). Onl y 
post-
randomization values will be used for imputation.

Novartis                                                          Confidential                                                          Page 117
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Categories 3, 4, and 5 will be determined based on available information if the NYHA/Ross, 
PGIS, and PedsQL physical functioning domain are not complete .When ranking these patients, 
the ranking algorithm will place the patients at the median for the missing assessment 
component (s).
9.4.4 Sensitivity analy ses
In addition to the primary  analysis,the primary  efficacy  endpoint will also be analy zed using 
the same primary anal ysis model in the PP population.
For the USM -impacted patients, the full data, including the off-treatment part, from the 
impacted patients will be included as a sensitivity  analysis.
 
9.4.5 Supportive analy ses
To characterize the treatment difference between LCZ696 compared to enalapril, an ordered 
categorical endpoint with 5 categories, as used for deriving the primary  endpoint variables, will 
be analyzed using a stratified Wilcoxon rank-sum test. The number and percent of patients 
within each individual category  will be summarized by  treatment group.
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables 
Part 1 (PK/PD)
Theobjective of this part is to characterize the PK and PD of LC Z696 in pediatric patients w ith 
HF. Primary variables are described in Section 9.4.1. There are no specific secondary  variables
in Part 1. 
Part 2 ( Efficacy )
To determine whether LCZ696 is superior to e nalapril, Part 2 ( Efficacy ) variables include
Time to first Category  1 or 2 event
Change from baseline (random ization visit) for NYHA/Ross class
Change from baseline (randomization visit) for PGIS
Population PK of L CZ696 exposure in pediatric patients with HF , including an assessmen t 
of stead y
-state sparse PK data in a subset of Group 2 patients, t o further confirm the 
LCZ696 target dose for Group 2 .
The full anal ysis set will be used in anal yses for secondary endpoints.
With the same reasons described for the primary  analysis, for the USM -impacted patients, the 
relevant assessments at the time of treatment discontinuation will be utilized in the secondar y 
analyses (on -treatment approach).
For the USM -impacted patients, the full data, including the off-treatment part, from the 
impact ed patients will be included as the sensitivity  analy ses. 

Novartis                                                          Confidential                                                          Page 118
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
The time to event endpoints will be analy zed using Cox’s proportional hazards model with 
treatment as fixed -effect factor stratified by modified age group (Group 1: 6 to < 18 years; 
Group 2 a: 2 to < 6 years; Group 3a : 1 month to < 2 y ears).The estimated hazards ratio and the 
corresponding two- sided confidence interval will be provided. 
NYHA /Ross class and PGIS will be compared for LCZ696 and enalapril atweek 52,
respectivel y. Change from baseline at week 52 for these assessments will be analyzed based on 
a proportional cumulative odds model, stratified by modified age group (Group 1: 6 to < 18 
years; Group 2a: 2 to < 6 years; Group 3a: 1 month to < 2 years)in which treatment will be 
included asfixed -effect factors and baseline value as a covariate. The treatment comparison 
between LCZ696 and enalapril for the secondary objective is to be made at week 52. This 
model assumes that the treatment effect sizes across measurement categories are the same. The 
effect size estimates and their 95% confidence intervals will also be provided.
Part 2 A ge Group 2 (PK)
The population PK Model will be updated with sparse P Kdata from a subset of Part 2 Group 2 
patients for the purpose of 
further confirming thetarget dose for Age Group 2. This will be 
performed prior to database lock and requires unblinding, and as such will be done by an 
unblinded team who is not involved in the conduct of the study .  
9.5.2 Safety  variables 
Safety
 data from Part 1 (PK /PD) and Part 2 ( Efficacy ) will be presented separatel y.
The assessment of safety  will be based primarily  on the frequency  of AEs, SAEs, and laboratory 
abnormalities. Other safety  data, such as specific adverse events of interest (i.e. hypotension, 
hyperkalemia, renal impairment, angioedema) , will be summarized as appropriate. 
The incidence of treatment-emergent AEs (new or worsened) will be summarized by primar y 
system organ class , preferred term, severit y, and relationship to study  drug. In addition, the 
incidence of death, SAEs, and AEs leading to discontinuation will be summarized separately 
by primary  system organ class and preferred term.
Laboratory  data will be summarized by presenting shift tables using extended normal ranges 
(baseline to most extreme post-baseline value), by presenting summary  statistics of raw data 
and change from baseline values (mean, medians, standard deviations, ranges) and by the 
flagging of notable va lues in data listings.
Data from other tests (e.g. vital signs) will be descriptivel y summarized as appropriate by 
presenting absolute values and change from baseline at each assessment time point. Any  other 
information collected will be listed as appropri ate. 
Safety  analyses will be performed based on all patients who received study  drug during Part 1 
and the safet y population for Part 2 (Efficacy ). There will be no formal statistical inference 
analysis.

Novartis                                                          Confidential                                                          Page 119
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
9.5.3 Biomarkers
Data for each biomarker will be summari zed by treatment group and time point using 
descriptive statistics (n, mean, median, SD, min, max, n below LLOQ, n above ULOQ, 
geometric mean and 95% confidence interval around the geometric mean). Summary  statistics 
for change from baseline at each time p oint will also be presented.
 
 
 
 
 
 
 
 
 
 
 
 
In addition, as a supportive analysis, the same MMRM analy sis as above will be performed 
using data from all post-baseline scheduled visits (Week 4, Week 8, Week 12 and Week 52).
9.5.4 PK/PD
The relationship between LBQ657 exposure to changes in plasma BNP, plasma NTpr oBNP and 
plasma cGMP will be explored using exposure -response models . 
   
 
 
 
 
 
 
 
 

Novartis                                                          Confidential                                                          Page 120
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
 
 
9.6 Interim analy ses
An external DMC willmonitor patient safety  data during the course of the study. For this study , 
the DMC will review safety  data ona regular frequency , e.g.every  six months. DMC may 
request additional safet y data review. Such safet y anal yses do not inflate the type I error for the 
primary  efficacy  hypothesis testing and thus require no multiplicity  adjustments.
Part 1 (PK/PD )
The available PK, PD and safety data from each age group will be analyzed to confirm the dose 
for that age group in Part 2 and to start the next younger age group in Part 1. A sample size of 
up to 12 observations per age group for Groups 1 and 2is prospectivel y planned to evaluate 
the PKand PD of LC Z696 anal ytes following single dose administration of LCZ696 0.8 mg/kg 
(N=6 observations) and LCZ696 3.1 mg/kg (N=6 observations) .For Group 3a sample size of 
up to 8 observations is prospectivel y planned to evaluate the PKand PD of LCZ696 analy tes 
following single dose administration of LCZ696 0. 4mg/kg (N= approximately  4observations) 
and LCZ696 1.6mg/kg (N= approximately  4observations) . Since the pharmacokinetics of 
LCZ696 is demonstrated to be dose independent, dose-normalized PK parameters from both 
dose cohorts will be combined. If no age effect on PK is observed, then data from two different 
groups may  be pooled. 
Part 2 (Efficacy )
Interim effi cacy  analy sis of the global rank endpoint
It is planned to have aformal interim efficacy  analys is. The interim efficacy analysis is planned 
when at least 180patients (at least 36 patients from each age group) have completed the study
(i.e., reached a terminal endpoint or completed the 1 year study  visit), and at least 40 patients 
have had an event in Category  1 or 2 . Some adjustment to the time of interim analy sis may  be 
made to coincide with the regular DMC meetings. One-sided tests will be performed and
appropriate statistical adjustments for the interim efficacy  analysis actuall y performed will be 
made to ensure the overall one-sided type I error of 0.025 (Lan -DeMets spending function to 
match an O’Brien -Fleming stopping boundary ). For the interim efficacy analy sis, the analysis 
dataset will comprise all patients who completed the study  by the cut -off date.
The trial may only be concluded early for efficacy , if a significant difference between two 
treatment arms for the primary  efficacy  endpoint is achie ved by crossing the pre-specified 
boundary  at the interim efficacy  analysis and the overall risk/benefit profile is considered 
positive. A futility  analysis will also be incorporated into the interim analy sis plan, whereb y the 
study  can be stopped if there is evidence that the study  is unlikely  to have a positive outcome. 
Details of the stopping rules for the futility  analysis will be described in the interim analysis 
statistical plan.

Novartis                                                          Confidential                                                          Page 121
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
The interim analysis will be performed by an external independent statistician at an external 
data analysis center, who will not be involved in the study  conduct. The results will be reviewed 
by the independent DMC. I nvestigators and others who are involved in the conduct of the trial 
and in the anal ysis of the final trial res ults, or who have contact with stud y centers, will remain 
blinded to the treatment codes and interim analysis results until all monitoring decisions have 
been made and the database has been unblinded for final analysis. Additional details of the 
interim an alysis plan for efficacy  and safet y will be described in the [
DMC charter] .
If the study  is stopped early  at interim analy sis due to overwhelming efficacy , then the pre-
specified percentage of patients will be used for this analysis. Additional sensitivity analysis for
the primary  global rank endpoint (and components) will be performed at time point sof 30 days, 
90 day s, and 180 day s.For time to event endpoints, annualized event rateswill be calculated.
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7 Sample size calculation
Part 1 (PK/PD)
From a prior clinical study  in adult HF patients, the observed CV% for body -weight normalized 
LBQ657 exposure was 37.1%, and the observed CV% for body -weight normalized clearance 
and volume of distribution of valsartan was 39.4% and 49.6%, respectivel y (Study  
CLCZ696A2117 ). Therefore, 49.6% of CV% was assumed for sample size estimations. A 
sample size of 12 observations (except Group 3 where N=–approximately  8observations) is 
expected to have 80% probability that the 95% CI of the point estimate for the geometric mean 
estimates of clearance and volume of distribution will be between 60% and 140% range (95% 
CI: 71 –141%) .

Novartis                                                          Confidential                                                          Page 122
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Part 2 (Efficacy )
In the Carvedilol Pediatric HF study  (Shaddy  2007 ) for the subgroup of systemic left ventricle 
patients, the improvement rate of the placebo group was 51%, while the improvement rate in 
the carvedilol group was 64%. This was a 13% increase in absolute improvement rate over 8 
month treatment period. Most of the patients in the carvedilol and placebo groups received 
ACEI  treatment.
Table 9-1presents the assumed underl ying probabilities for each category  of the primary 
endpoint in Part 2 (Efficacy ) using data from the Carvedilol Pediatric HF study  data (Shaddy 
2007). It is assumed that the probability  for patients receiving LCZ696 and enalapril who will 
have an event of death, circulatory  and/or respiratory  mechanical support or UNOS 1A heart 
transplant listing (Category  1) is similar to what was observed for the carvedilol and placebo 
groups in the Carvedilol Pediatric HF study .It is also assumed that the probability  of patients 
experiencing Worsening HF (Category  2)is similar to Hospitalization for HFobserved in the 
Carvedilol Pediatric HF study . 
Thus, for Categories 1 and 2, the events percentages are based 
on the Carvedilol Pediatric HF study  (Shaddy  2007 ). The probability  of an improved outcome 
for enalapril patients is assumed to be the same as for the placebo group in the carvedilol study, 
and the probability  for the LCZ696 patients is assumed to be the same as observed for carvedilol 
patients in the Carvedilol Pediatric HFstudy . The probabilities for the worsened and unchanged 
categories are formed by splitting the remaining probability  approximately  equall y for these 
two categories. 
Table 9-1 Assumed percentage of patients in each category  of the primary  
efficacy  endpoint in Part 2 by  treatment group at Month 8 (Week 32)
Cate gory LCZ696 (%) Enalapril (%)
1. Clinical event –death / heart transplant listing / mech. support 6 9
2. Clinical event – WHF 10 13
3. Worsened functional class: NYHA/ Ross Classification or 
worsened PGIS9 14
4. Unchanged functional class: NYHA/ Ross Classification and 
unchanged PGIS11 13
5. Improved functional class: NYHA/ Ross Classification or 
Improved PGIS64 51
The projected event percentages presented in Table 9-1are based on the 8 mon th treatment 
period estimates. For a 52 weeks treatment period (Table 9-2) , for Categories 1 and 2, the 
anticipated events percentages are calculated based on an exponential distribution assumption, 
extending from Month 8 to Month 12; and the remaining percentages within each treatment 
group are shared b y Categories 3, 4, 5 according to their corresponding proportions at Month 8
(i.e. according to Table 9-1, 9 : 11 : 64 for the L CZ696 g roup, and 14 : 13 : 51 for the e nalapril 
group) . The treatment difference represented in Table 9-2 represents a Mann -Whitney -
Wilcoxon Odds of 0.753
.

Novartis                                                          Confidential                                                          Page 123
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Table 9-2 Assumed percentage of patients in each category  of the primary  
efficacy  endpoint in Part 2 by  treatment group at Month 12 (Week 52)
Category LCZ696 (%) Enalapril (%)
1. Clinical event –death / heart transplant list ing / 
mech. support9 13
2. Clinical event – WHF 15 19
3. Worsened functional class: NYHA/ Ross 
Classification or worsened PGIS8.1 12.2
4. Unchanged functional class: NYHA/ Ross 
Classification and unchanged PGIS10.0 11.3
5. Improved functional class: NYHA/ Ross 
Classification or Improved PGIS57.9 44.5
The primary  efficacy  analysis will be a stratified Wilcoxon rank-sum test with alpha level of 
0.05%, (two-sided). For the analysis of an ordered categorical endpoint with an underl ying 
distributi on as presented in Table 9-2, there is approximately  70% power with a sample size of 
177 patients per group (354 total patients). Sample size calculations for the ordered categorical 
test (ordered catego rical Mann -Whitney /Wilcoxon rank sum test) were determined using 
nQuery . Using a global ranked endpoint, the power under the same assumptions is expected to 
increase. While the exact increase in power is dependent on the distribution of the ranking 
within each category , simulation studies have demonstrated that the power for the global rank 
endpoint increases 10- 20% more than with the ordered categorical anal ysis when the power of 
the ordered categorical endpoint is more than 50% (Sun 2012). Based on the assumptions stated, 
the power is estimated to be at least 80% for this study . 
The sample size is further increased to account for a single planned interim analysis to be 
performed when approximately  50% 
of the patients (and at least 36 patients from each age 
group) have completed the study  (50% information fraction). This interim analysis will be done 
to allow for early stopping of the study  in the event that overwhelming positive efficacy  is 
observed at the time of the interim anal ysis. Using the Lan- DeMets alpha spending function of 
the O’Brien- Fleming stopping boundary , a sample s ize of 180 patients per group (360 patients 
total) will provide at least 80% power for a test of the primary  endpoint including a planned 
interim analy sis. Further simulations will be performed to ensure that the estimated sample size 
maintains the targete d power when accounting for the interim anal ysis.
10 Ethical considerations
10.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese 
Ministry  of Health, Labor, and Welfare), and with the ethical principles laid down in the 
Declaration of Helsinki.

Novartis                                                          Confidential                                                          Page 124
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
10.2 Informed consent proc edures
Eligible patients/subjects may  only be included in the study after providing written (witnessed, 
where required by law or regulation), IRB/IEC -approved informed consent, or, if incapable of 
doing so, after such consent has been provided by a legally acceptable representative(s) of the 
patient. In cases where the patient’s representative gives consent, the patient must be informed 
about the study  to the extent possible given his/her understanding. If the patient is capable of 
doing so, he/she must indicate assent by personally  signing and dating the written informed 
consent document or a separate assent form. Informed consent must be obtained before 
conducting an y study -specific procedures (e.g. all of the procedures described in the protocol). 
The pro cess of obtaining informed consent and child assent where applicable must be 
documented in the patient source documents. 
Novartis will provide to Investigator s in a separate document a proposed informed consent form 
and age appropriate assent forms that comply  with the ICH GCP guideline and regulatory 
requirements and is considered appropriate for this study . Any changes to the proposed consent 
form suggested by the Investigator must be agreed to by Novartis before submission to the 
IRB/IEC, and a copy of the approved version must be provided to the Novartis monitor after 
IRB/IEC approval.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirement for the duration of 
the study and for 7 days after study  drug discontinuation . If there is any question that the patient 
will not reliably  compl y, they must no t be entered in the study .
10.3 Responsibilities of the Investigator and IRB/IEC
Before initiating a trial, the Investigator /institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subje ct recruitment procedures (e.g.
advertisements) and any other written information to be provided to patients/subjects. Prior to 
study  start, the Investigator is required to sign a protocol signature page confirming his/her 
agreement to conduct the study  in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
Novarti s monitors, auditors, Novartis Qualit y Assurance representatives, designated agents of 
Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site 
is requested by a regulatory  authority , the Investigator must inform Novartis immediately  that 
this request has been made.
10.4 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study report the 
results of this trial will be either submitted for publication and/or posted in a publicly  accessible 
database of clinical trial results.

Novartis                                                          Confidential                                                          Page 125
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
11 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be col lected on 
study  participants. Additional assessments required to ensure safet y of patients/subjects should 
be administered as deemed necessary  on a case by case basis. Under no circumstances is an 
Investigator allowed to collect additional data or conduct any additional procedures for any 
research related purpose involving an y investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
Investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IR B/IEC and health authorities, where required, it cannot be implemented. 
11.1 Protocol a mendments 
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediat e hazard 
to patients/subjects may be implemented immediately  provided the health authorities are 
subsequently  notified by protocol amendment and the reviewing IRB/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the Investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 7 Safety  Monitoring must be followed.
12 References 
(References available upon request).
Andrews RE, Fenton MJ, Ridout A, et al. (2008) New onset heart failure due to hear t muscle 
disease in childhood: A prospective study  in the United Kingdom and Ireland. Circulation; 
117:79 -84.
Anker SD , Ponikowski P , Mitrovic V, et al.(2015) Ularitide for the treatment of acut e 
decompensated heart failure: F rom preclinical to clinical studies. Eur Heart J; 36(12):715
-23.
Bengur AR, Beekman RH, Rocchini AP, et al. (1991) Acute hemod ynamic effects of 
captopril in children with a congestive or restrictive cardiom yopath y. Circulation; 83:523.
Blumer J, Batisky  DL, Wells T, et al. (2009) Pharmacokinetics of valsartan in ped iatric and 
adolescent subjects with hy pertension. J Clin Pharmacol; 49:235-241.
Chang S, Davids on PM, Newton PJ, et al. (2015) Composite outcome measures in a 
pragmatic clinical trial of chronic heart failure management: A comparative assessment.
Internati onal Journal of Cardiology ; 185: 62 –68.
Chaturvedi V, Saxena A (20 09) Heart failure in children: C linical aspect and management. 
Indian Journal of Pediatrics; 76:195
-205.
ClinicalTrials.gov (2008) Quality  of life in pediatric t ransplant r ecipients.
[STUDY_ID_REMOVED].Medical College of Wisconsin.

Novartis                                                          Confidential                                                          Page 126
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Committee for human medicinal products (CHMP), European Medicines Agency  (EMA). 
(2004) ICH Topic E 2 D :Post approval safet y data management, L ondon, UK.
Criteria Committee of the New York Heart A ssociation (1994) Functional capacity  and 
objective assessment. In: Dolgin, M ed. Nomenclature and criteria for diagnosis of diseases of 
the heart and great vessels. 9th ed ; Boston: L ittle, Brown & Co. 253-255
CLCZ696A2117 (2009) An open label, non -randomised study  to expl ore safety /tolerability , 
pharmacokinetics and pharmacod ynamics of LCZ696 in patients with stable heart failure. 
Novartis Internal Document.
CVAL  489K2304 (2011) Physician survey  of clinical management and uses of medicinal 
products in paediatric patients w ith heart failure survey  protocol. Diovan pediatric heart 
failure s urvey .Novartis Internal Document.
Desai AD, Zhou C, Stanford S, et al. (2014) Validity  and responsiveness of the 
pediatric 
quality  of life inventory  (Peds QL) 4.0 generic core scales in the pediatric inpatient setting. 
JAMA Pediatrics; 168:1114-21.
Dore A, Houde C, Chan KL ,et al. (2005) Angiotensin receptor blockade and exercise 
capacity  in adults w ith systemic right ventricles: Amulticenter, randomized, placebo -
controlled clinical trial. Circulation; 112:2411–2416.
Duboc D, Meune C, Lerebours G, et al. (2005) Effect of perindopril on the onset and 
progression of left ventricular d ysfunction in Duchenne muscular d ystrophy . J Am Co ll 
Cardiol; 45:855.
Duboc D, Meune C, Pierre B, et a l. (2007) Perindopril preventive treatment on mortality  in 
Duchenne muscular d ystrophy : 10 y ears' follow -up. Am Heart J; 154:596.
Eagleson KJ, Justo RN, Ware RS, et al. 
(2013) Health -related quality  of life and congenital 
heart disease in Australia: Journal of Paediatrics and Child H ealth; 49:856-64.
European Medicines Agency  (EMA). (2010) Report on the expert group meeting of pediatric
heart failure, London, UK.
Europ ean Commission . ENTR/CT3 (2006) Detail ed guidance on the collection, verification 
and presentation of adverse reaction reports arising from clinical trials on medicinal products 
for human use .
Favilli S, Fres nos S, Lasagni D, et al. (2009) The use of B- type natriuretic peptide in pediatric
patients: A review of the literature. J Cardiovasc Med; 10: 298 -302.
FDA (2012) Guidance for Industry  and Investigators: Safet y reporting requirements for INDs 
and BA/BE studies.
Felker GM ,Maisel AS (2010) A global rank end point for clinical trials in a cute heart failure. 
Circ Heart Fail; 3:643 -646.
FDA (2016) Guidance for Industry  and Food and Drug Administration Staff : Collection of 
Race and Et hnicit y Data in Clinical Trials .Document issued on October 26, 2016.
Hartland AJ, Neary  RH (1999) Serum potas sium is unreliable as an estimate of in vivo plasma 
potassium. Clin Chem; 45:1091 -1092.
Hechter SJ, Fredriksen PM, L iu P, Veldtman G, et.al. (2001) Angiotensin- converting enzy me 
inhibitors in adults after the mustard procedure. Am J Cardiol ;87: 660–663, A11.

Novartis                                                          Confidential                                                          Page 127
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Howie SR (2011) Blood sample volumes in child health research: review of safe limits. Bull 
World Health Organ; 89:46-53.
Hsu DT, Pearson GD (2009a) Hea rt failure in children Part I: H istory , etiology  and 
pathophy siology . Circulation Heart Failure; 2:63-70.
Hsu DT
,Pearson GD (2009b) Hear t failure in children Part II: D iagnosis, treatment, and 
future directions. Circulation Heart Failure; 2:490-498.
Hsu DT, Zak, V, Mahony  L, et al. (2010) Enalapril in infants with single ventricle :results of a 
multicenter randomized trial. Circulation ;122:333
-340.
International Conference on Harmonisation (I CH)(2000) Tripartite g uideline E11 Clinical 
investigation of medicinal products in the pediatric p opulation. 
[http://www.ich.org/fileadmin/Pub lic_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step
4/E11_Guideline.pdf ].
Interagency  registry  for mechanically  assisted circulatory  support (INTERMACS): Protocol.
[http://www.uab.edu/medicine/intermacs/images/Opening_page_4.0_info/Intermacs_Protocol
_4.0_2-27-14.pdf].
Kantor PF, Mertens LL (2010) Clinical practice :Heart failure in children. P art II : current 
maintenance therap y and new therapeutic approaches. Eur J Pediatr; 169:403 -
410.
Kawaguc hi, A, Koch, GG, Wang, X (2011) Stratified multivariate Mann–W hitney  estimators 
for the comparison of two treatments with randomization based covariance adjustment. 
Statistics in Biopharmaceutical Research ; 3:217 -231. 
Kay JD, Colan SD, Graham TP Jr, et al. (2001) Congestive heart failure in pediatric patients. 
Am Heart J; 142:923 -928.
Kirk R, Dipchand AI, Rosenthal DN, et al. (2014) The international societ y for heart and lung 
transplantation guidelines for the manageme nt of pediatric heart failure: E xecutive summary . 
J Heart L ung Transplant; 33:888 -909.
Kleinman ME, Chameides L ,Schexnay der SM, et al .(2010) Part 14: PALS (Pediatric 
Advance d Life Support): 2010 American Heart A ssociation guidelines for cardiopulmonary  
resuscitation and emergency  cardiovascular care. Circulation; 122:S876 -S908.
LENA: Label ing of enalapril from neonates up to adolescents stud y. [http://www.lena -
med.eu] .
Leversha AM, Wilson NJ, Clarkson PA et al. (1994) Efficacy  and dosage of enalapril in 
congenital and acquire heart disease. Arch Dis Child; 70:35 -9.
Lewis AB, Chabot M (1993) The effect of treatment with angiotensin -converting enzy me 
inhibitors on survival of pediatric patients with dilated cardiomy opathy . Pediatr Cardiol; 
14(1) :9- 12 .
Lin DY, Wei LJ, Yang I, et al. (2000) Semiparametric regression for the mean and rate
functions of re current events. J R Stat Soc B; 62(Pt 4):711-30.
Lipshultz SE, Sleeper LA, et al. (2003) The incidence of pediatric cardiomy opathy  in two 
regions of the United States. N Engl J Med; 348:1647-1655.

Novartis                                                          Confidential                                                          Page 128
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Madsen BK, Hansen JF, Stokholm KH, et al. (1994) Chronic congestive heart failure: 
description and survival of 190 consecutive patients with a diagnosis of chronic congestive 
heart failure based on clinical signs and s ymptoms. Eur Heart J; 15:303 -10.
Mah D, Singh TP, Thiagarajan RR, et al. (2009) Incidence and risk factors for mortality  in 
infants awaiting heart transplantation in the USA. J Heart L ung Transplant; 12: 1292 -8.
McMurray  JJV, Packer M, Akshay  S, et al. (2014) Angiotensin -nepril ysin inhibition versus 
enalapril in heart fail ure. NEJM; 371(11):993-1004.
Momma K. (2006) ACE Inhibitors in pediatric patients with heart failure. Pediatr Drugs; 
8:55-69.
Nugent AW, Daubeney  PEF, Chondros P, et al. (2003) The epidemiology of childhood 
cardiom yopath y in Australia. N Engl. J Med; 348:1 639-1646.
Packer M (2001) Proposal for a new clinical end point to evaluate the efficacy  of drugs and 
devices in the treatment of chronic heart failure. J Card Fail; 7: 176–82.
Peters A, Gordon I (1999) Quantitative Assessment of the Urinary  Tract with Radi onuclides. 
In Barratt T. M, Avner E, Harmon W (eds), Pediatric Nephrology , fourth edition, pp 365-735. 
Lippincott Williams & Wilkins, Mary land.
Rosenthal D, Chrisant MRK, Edens E, et al . (2004) International societ y for heart and lung 
transplantation: prac tice guidelines for management of heart failure in children. J Heart Lung 
Transplant; 23:1313 -33.
Ross RD, Bollinger RO, Pinsky  WW (1992) Grading the severit y of congestive heart failure 
in infants. Pediatr Cardiol; 13:72 –75.
Ryman DC, Acost -
Baena N, Aise n PS, et al. (2014) Sy mptom onset in autos omal dominant 
Alzheimer disease. Neurology ; 83:253-60.
Sand P, Kljajic M, Sunnegardh J (2013) The reliability  of the Pediatric Quality  of Life 
Inventory  3.0 Cardiac ModuleTMfor Swedish children with congenital heart defects; Nordic 
Psychology ; 65: 210 -
23.
Schupf N, Sergievsk y GH (2002) Genetic and host factors for dementia in Down's s yndrome. 
Br J Psy chiatry ; 180:405 -10.
Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and 
adolescents. C lin J Am Soc Nephrol; 4:1832–1843.
Shaddy  RE, Boucek MM, 
Hsu DT, et al. (2007) Carvedilol for children and adolescents with 
heart failure: Arandomized controlled trial. JAMA; 298:1171-1179.
Sharma M, Nair M, Jatana SK ,et al. (2003) Congestive heart failure in infants and children. 
MJAFI ; 59:228 -233.
Spertus J, Peterson E , Conard MW ,et al. (2005) Monitoring clinical changes in patients with 
heart failure: a comparison of methods. Am Heart J; 150(4):707-15.
Sun H, Davi son BA, Cotter G , et al. (2012) Evaluating treatment efficacy  by multiple end 
points in phase II acute heart failure clinical trials: A nalyzing data using a global method. 
Circulation Heart Failure; 5:742 -9.

Novartis                                                          Confidential                                                          Page 129
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Uzark K, Jones K, Slusher J ,et al. (2008) Quali ty of life in children with heart disease as 
perceived b y children and parents. Pediatrics; 121:e1060 -7.
Uzark K, Griffin L, Rodriguez R, et al. (2012) Quality  of life in pediatric heart transplant 
recipients: A comparison with children with and without heart disease. J Heart Lung 
Transplant; 31:571 -8.
Uzark K, King E, Spicer R et al. (2013) The clinical utility  of health- related quality  of life 
assessment in pediatric cardiology  outpatient practice. Congenit Heart Dis; 8:211-8.
van der Bom T, Winter MM, Bouma BJ, et.al. (2013) Effect of valsartan on sy stem ic right 
ventricular function: A double -blind, randomized, placebo -controlled pilot trial. Circulation; 
127:322–330.
Varni JW, Burwinkle TM, Seid M, et al. (2003) The PedsQL 4.0 as a pediat ric population
health measure: F easibility , reliabilit y, and validity. Ambul Pediatr; 3:329 -41.
Varni JW , Limbers CA , Neighbors K et al. (20 11) The PedsQL™ infant scales: F easibility , 
internal consistency  reliability , and validity  in healthy  and ill infants. Qual Life Res; 20:45-55.
Wang DS, Dickson DW, Malter JS (2006) β -Amy loid degradation and Alzheimer's disease. J 
Biomed Biotechnol; 3:58406.
Zoetis T
, Tassinari MS , Bagi C et al. (2003) Species comparison of postnatal bone growth and 
development. Birth Defects Res B Dev Reprod Toxicol; 68(2):86-110.
13 Appendix 1: Clinically  notable laboratory  values and vital 
signs
Table 13-1 Clinically  notable laboratory  values
Parameter Conventional
Alert ValueConventional
UnitsSI Alert
ValueSI
Units
Hematology
Red Blood Cell 
Count >50% 
increase, >30% 
decreasex10E6/uL >50% 
increase, >30% 
decreasex10E12/L
Hemoglobin >50% 
increase, >30% 
decrease, or any 
value <7g/dL >50% 
increase, >30% 
decrease, or any 
value <70g/L
Hematocrit >50% 
increase, >30% 
decrease% >50% 
increase, >30% 
decreaseL/L
White Blood Cell 
Count >50% 
increase, >50% 
decreasex10E3/uL >50% 
increase, >50% 
decreasex10E9/L
Platelet Count >75% 
increase, >50% 
decreasex10E3/uL >75% 
increase, >50% 
decreasex10E9/L
Chemistry
BUN >50% increase mg/dL >50% increase mmol/L

Novartis                                                          Confidential                                                          Page 130
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Parameter Conventional
Alert ValueConventional
UnitsSI Alert
ValueSI
Units
Creatinine >50% increase mg/dL >50% increase umol/L
Albumin <2 g/dL <20 g/L
Glucose >50% 
increase, >50% 
decrease, or any 
value <60mg/dL >50% 
increase, >50% 
decrease, or any 
value <3.3mmol/L
Total Bilirubin >100% increase mg/dL >100% increase umol/L
AST (SGOT) >150% increase U/L >150% increase U/L
ALT (SGPT) >150% increase U/L >150% increase U/L
Sodium >5% increase, or 
any value >150mEq/L >5% increase, or 
any value >150mmol/L
Potassium >20% 
increase, >20% 
decrease, or any 
value >5.3 mEq/L >20% 
increase, >20% 
decrease, or any 
value >5.3 mmol/L
Chloride >10% 
increase, >10% 
decreasemEq/L >10% 
increase, >10% 
decreasemmol/L
Calcium >10% 
increase, >10% 
decreasemg/dL >10% 
increase, >10% 
decreasemmol/L
Uric Acid >50% increase mg/dL >50% increase mmol/L
Table 13-2 Criteria for clinically  notable vital signs
Age HR [min-1] SBP [mmHg] DBP [mmHg] RR [min-1]
1-<3 months <90, >160 <60, >95 <40, >50 <25, >60
3-<6 months <80, >130 <60, >100 <40, >60 <20, >50
6-<12 months <70, >130 <60, >110 <45, >70 <15, >45
1-<3 years <60, >120 <76, >115 <45, >75 <14, >35
3-<6 years <55, >120 <82, >120 <50, >80 <12, >30
6-<12 years <50, >105 <90, >130 <50, >80 <10, >27
≥12 years <45, >95 <90, >145 <55, >90 <8, >23

Novartis                                                          Confidential                                                          Page 131
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
14 Appendix 2: Liver event and laborator y trigger definitions 
and follow-up r equirements
Table 14-1 Liver e vent and laboratory  trigger d efinitions
Definition/ threshold
LIVER LABORATORY TRIGGERS 3 x ULN < ALT / AST 5 x ULN
1.5 x ULN < TBL 2 x ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN [mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vomiting, or rash with 
eosinophili a
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
TBL: total bilirubin; ULN: upper limit of normal 
Table 14-2 Follo w up requirements for liver events and laboratory  triggers
Criteria Action s required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study treatment 
immediately
Hospitalize, if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
Investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study treatment 
immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
Investigator discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study treatment 
immediately
Hospitalize, if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
Investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -up 
monitoring
If elevation persists for more than 2 
weeks, discontinue the study drug
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
Investigator discretion)

Novartis                                                          Confidential                                                          Page 132
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Criteria Action s required Follow -up monitoring
> 3 × ULN 
accompanied by 
symptomsbDiscontinue the study treatment 
immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
Investigator discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the 
study drug immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT unt il resolutionc(frequency at 
Investigator discretion)
Test for hemolysis (e.g. reticulocytes, 
haptoglobin, unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patient Investigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
Jaundice Discontinue the study treatment 
immediately
Hospitalize the patient
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP and 
γGT until resolutionc(frequency at 
Investigator discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consider study treatment interruption or 
discontinuation 
Hospitalization if clinically appropriate
Establish causality
Complete liver CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 
months, (4) liver transplantation, an d (5) death.

Novartis                                                          Confidential                                                          Page 133
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
15 Appendix 3: Specific renal alert criteria and a ctions
Table 15-1 Specific renal alert criteria and a ctions
Serum event
Estimated GFR* decrease
≥25% compared to baseline AND eGFR 
<90mL/min/1.73m2 Confirm ≥25% decrease AND eGFR*
<90mL/min/1.73m2after 24 -48hours (h) . 
If it persists follow up with repeat, if possible, 
within 2 -5 days. 
Then do some frequent monitoring (preferably 
weekly ) until event resolves or stabilizes. 
If event does not resolve or stabilize consider 
consulting nephrologist and/or drug interruption.
Acute Kidney Injury: Serum estimated GFR* 
decrease 50 % compared to baselineFollow up within 24 -48h if possible.
If value persists, consider consulting nephrologist 
and/or drug interruption.
Urine event Confirm by  urinar y protein creatinine ratio. 
If it persists, consider consulting nephrologist 
and/or drug interruption.
New dipstick proteinuria ≥ 1+ Confirm value after 24- 48h, if possible.
If dipstick value confirmed: 
a) perform urinary protein creatinine ratio (PCR) 
within 2 -5 days, if possible. If PCR > 0.2 then:
b) perform urine microscop y and evaluate .
If PCR > 0.2 and /or urine microscopy has 
findings (e.g. crystals, casts , dysmorphic RBC, 
leukocytes) ,consider consulting nephrologist or 
drug interruption or discontinuation
New dipstick glucosuria ≥ 1+ not due to diabetes Confirm value after 24 -48h, if possible .
If it persists: 
a) perform, blood glucose (fasting)
b) perform urinary protein/creatinine ratio. 
If PCR ratio > 0.2 and blood glucose abnormal 
consider consulting nephrologist and /or drug 
interruption or discontinuation
New dipstick hematuria ≥ 1+ not due to trauma Confirm value after 24- 48h, if possible .
If it persists:
a) perform urinary protein creatinine ratio (PCR) 
within 2 -5 days on a first morning urine collection 
b) perform urine microscopy and evaluate .
If PCR > 0.2 and /or urine microscopy has 
findings (e.g. crystals, casts , dysmorphic RBC, 
leukocytes) consider consulting nephrologist or 
drug interruption or discontinuation
* eGFR is calculated using a modified Schwartz formula 
Urine samples for testing for renal monitoring, and particularly those for the PCR ratio determination, 
must be collected at the first morning void.
Document contributing factors in the CRF: co -medication, other co -morbid conditions, and additional 
diagnostic procedures perform ed.

Novartis                                                          Confidential                                                          Page 134
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Monitor patient regularly (frequency at investigator’s discretion) until either: 
Event resolution: estimated GFR within 20% of baseline and > 90mL/min/1.73m2or PCR < 0.2;
Event stabilization: estimate d GFR within 20% of baseline OR >90mL/min/1.73m2or PCR < 0.3.
15.1 Guidelines for the management of renal dy sfunction
General principles:
Glomerular filtration rate in HF patients depends on intrinsic renal function and on a balance
between afferent and efferent glomerular arterial tonicity . This tonicity  is partly  regulated by  a 
stimulation of angiotensin II and could be affected by  either study medication. Moreover, renal 
dysfunction may develop or may deteriorate in some patients a fter study  drug administration. 
These recommendations have been developed to guide the Investigator s in managing patients 
with renal d ysfunction after randomization.
Two ty pes of response to serum creatinine increase are described:
1.Surveillance situation
If, at any  time after randomization, eGFR%* decreases by  ≥ 50% from baseline (Visit 301 for 
Part 2), the Investigator will check for potentiall y reversible causes of renal dysfunction such 
as:
non-steroidal anti - inflammatory  drug intake, antibiotics, or oth er treatments known to 
cause creatininemia
volume decrease, including that resulting from excessive dosing of diuretics
urinary  infection
urinary  tract obstruction
study  medication .
2. Action situation
If a patient eGFR* decreases by ≥ 50% from baseline (Visit 301 for Part 2) (or if serum 
creatinine concentration rises above 3 mg/dL  (265 μmol/L ), the Investigator will check for 
potentially  reversible causes of renal dysfunction (see above). If the Invest igator judges that 
study  medication has to be stopped, he/she will have to contact the Novartis medical monitor 
or his/her designee. Thereafter, serum creatinine assessments will have to be repeated at least 
each week until levels return to acceptable values. If study  medication was stopped, every  effort 
will be done to restart it again, according to clinical conditions.
*eGFR is calculated using a modified Schwartz formula

Novartis                                                          Confidential                                                          Page 135
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
16 Appendix 4: American heart association ( AHA)pediatric 
advanced life support (PALS) g uidelines 
Table 16-1 5thpercentile sy stolic blood pressure table
Age SBP percentile SBP (mmHg)
1 month to < 1 year 5th70
1 year 5th72
2 years 5th74
3 years 5th76
4 years 5th78
5 years 5th80
6 years 5th82
7 years 5th84
8 years 5th86
9 years 5th88
10 years 5th90
11 years 5th90
12 years 5th90
13 years 5th90
14 years 5th90
15 years 5th90

Novartis                                                          Confidential                                                          Page 136
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
16 years 5th90
17 years 5th90
* AHA PALS guidelines 2010 (Kleinman 2010 ) are widely used criteria for hypotension in acute HF
patients. The formula (for 1 yearand older: 70 mmHg + 2 x Age, up to age 10) is understood to provide 
the 5th BP percentile up to 10 y ears. For children 
1 month to < 1 year and >10 y ears, the AHA PALS 
guidelines 2010 5th percentile is set at 70 mmHg and 90 mmHg respectively . NOTE: This formula 
approximates the population -based 5th percentile BP data; however, the margin of error increases 
with increasing age, with the PALS formula value generally providing a lower value.
16.1 Guidelines for the management of blood pressure
1.Investigator should monitor blood pressure closely.
2.If symptomatic hy potension occurs:
 Correct an y treatable cause, e.g. h ypovolemia
 If hypotension persists, any antih ypertensive drug and non -disease -modify ing 
drugs, such as diuretics, calcium channel blockers (CCBs), nitrates, and α -
blockers, should be down -titrated or stopped first before down- titration of the 
study  drug is considered
 If hypotension persists, the study drug should be down -titrated or even temporarily  
withdrawn. The dose re -challenge and medications ad just guidelines described in 
Section 5.5.5 should be adhered to as much as possible .

Novartis                                                          Confidential                                                          Page 137
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
17 Appendix 5: Treatment guidelines for elevated potassium 
and hyperkalemia (serum potassium greater than or equal to 
5.3mmol/L)
General principles
Elevation of potassium levels on a non-hemolyzed specimen above the predefined values 
should be repeated and confirmed before any action if appropriate based on Investigator’s 
medical judgment.
For assessment of potassium, no 
blood sample should be drawn by finger or heel stick. Also 
note that pH can affect potassium values, and that abnormal potassium values should include 
assessment of pH. Each 0.1 increase in pH represents a 0.6 mEq/L  change in the opposite 
direction of the p H change.
Patients with elevated potassium value will be managed according to the corrective actions 
outlined below. Hyperkalemia should be followed until resolution.
Corrective action for management of elevated potassium andhyperkalemia
Serum potassium > 5.2 and less than or equal to 5.4 mmol/L
Confirm potassium concentration in a non -hemoly zed sample .
Reinforce low potassium diet and restriction of food/drinks with high potassium content (e.g. 
orange juice, melon, bananas, low- salt substitutes etc.) .
Review medical regimen (including dietary supplements and over -the-counter medications) for 
agents known to cause hyperkalemia. Consider reduction in dose or discontinuation of these 
agents:
Aldosterone antagonists (if they  are believed to be the most likely  cause of hyperkalemia)
Potassium -sparing diuretics ( e.g. amiloride and triam terene) including in combination 
products with thiazide or loop diuretics
Potassium supplements, e.g.potassium chloride
Salt substitutes
Non-steroidal anti -inflammatory  drugs (NSAIDs)
Cyclo-oxygenase -2 (COX -2) inhibitors
Trimethoprim and trimethoprim -containing combination products, such as Bactrim® and 
Septra® (trimethoprim/sulfamethoxazole fixed combination)
Herbal Supplements: For example, Noni juice, alfalfa ( Medicago sativ a), dandelion 
(Taraxacum officinale ), horsetail ( Equisetum arvense ), nettle ( Urtica dioica ), milkweed, 
lilyof the valley , Siberian ginseng, hawthorn berries .
Repeat serum potassium measurement within 3 to 5 days. If serum potassium remains > 5.2 and 
≤ 5.4mmol/L , regularl y monitor serum potassium levels to ensure stability  suggested once 
monthly .
Consider down
-titration of study  medication, according to Investigator ’s medical judgment .

Novartis                                                          Confidential                                                          Page 138
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
Serum potassium > 5.4 and < 6.0 mmol/L
Confirm potassium concentration in a non -hemoly zed sample .
Consider down -titration or temporarily  discontinue study  drug according to Investigator
medical judgment.
Apply  all measures outlined for serum potassium > 5.2 and ≤ 5.4 mmol/L .
Repeat serum potassium measurement after 2 -3 day s.
If serum potassium < 5.4 mmol/L , consider resumption of study  drug at lower dose with
repeat potassium within 5 days.
Serum potassium greater than or equal to 6.0 mmol/L
Confirm potassium concentration in a non -hemoly zed sample .
Urgently  evaluate patient a nd treat h yperkalemia as clinically  indicated .
Apply  all measures outlined for serum potassium > 5.4 and < 6.0 mmol/L .
Study  drug should be immediately interrupted or discontinued if the serum potassium is greater 
than or equal to 6.0 mmol/L .
No resumption of study  drug without individualized case discussion with and permission from 
Novartis medical monitor or his/her designee .

Novartis                                                          Confidential                                                          Page 139
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
18 Appendix 6: Reference t able - blood volume by weight
Table 18-1 Reference table –blood collection volumes by body weight (kg)
2.5% and 5% Blood v olume table by weight (up to 35kg)1
Body
Weight
(Kg)Total blood volum e 
of the patient (mL)Maximum allowable volume
(mL) in on e blood draw
(=2.5% of to tal blood volum e 
of the patient)Total maximum volume (mL) 
drawn in a 28-day period
(= 5% of tota l blood volum e 
of the patient)
2.5 200 5 10
3 240 6 12
3.5 280 7 14
4 320 8 16
4.5 360 9 18
5 400 10 20
5.5 440 11 22
6 480 12 24
6.5 520 13 26
7 560 14 28
7.5 600 15 30
8 640 16 32
8.5 680 17 34
9 720 18 36
9.5 760 19 38
10 800 20 40
10.5 840 21 42
11 880 22 44
11.5 920 23 46
12 960 24 48
12.5 1000 25 50
13 1040 26 52
13.5 1080 27 54
14 1120 28 56
14.5 1160 29 58
15 1200 30 60
15.5 1240 31 62
16 1280 32 64
16.5 1320 33 66
17 1360 34 68
17.5 1400 35 70
18 1440 36 72
18.5 1480 37 74
19 1520 38 76
19.5 1560 39 78
20 1600 40 80
20.5 1640 41 82
21 1680 42 84

Novartis                                                          Confidential                                                          Page 140
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
2.5% and 5% Blood v olume table by weight (up to 35kg)1
Body
Weight
(Kg)Total blood volum e 
of the patient (mL)Maximum allowable volume
(mL) in on e blood draw
(=2.5% of to tal blood volum e 
of the patient)Total maximum volume (mL) 
drawn in a 28-day period
(= 5% of tota l blood volum e 
of the patient)
21.5 1720 43 86
22 1760 44 88
22.5 1800 45 90
23 1840 46 92
23.5 1880 47 94
24 1920 48 96
24.5 1960 49 98
25 2000 50 100
25.5 2040 51 102
26 2080 52 104
26.5 2120 53 106
27 2160 54 108
27.5 2200 55 110
28 2240 56 112
28.5 2280 57 114
29 2320 58 116
29.5 2360 59 118
30 2400 60 120
30.5 2440 61 122
31 2480 62 124
31.5 2520 63 126
32 2560 64 128
32.5 2600 65 130
33 2640 66 132
33.5 2680 67 134
34 2720 68 136
34.5 2760 69 138
35 2800 70 140
Blood volume drawn for the purpose of this study  is limited to a maximum of 2.5% of the circulating blood 
volume per sampling session and to a maximum of 5% over a 4 week period (Howie 2011 ). Investigators 
may furt
her limit the volume of blood withdrawn based on local institutional guidelines and if the clinical 
condition of the patient may be adversely affected by removal of the blood volumes stated above. Details 
about blood volume requirement for PK, biomarker and safety samples are provide in the laborator y 
manual.
1For body weights >35 kg, use the following formulas to calculate 2.5% and 5% of total blood volume:
2.5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 2
5% of total blood volume = body weight (in kg to the closest 0.5 kg) X 4

Novartis                                                          Confidential                                                          Page 141
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
19 Appendix 7: NYHA /Ross c lassification
For older children 6 to less than 18 years old, the Investigator will determine the appropriate 
NYHA class of heart failure. Classification criteria are as follows:
NYHA Class I: No limitation - ordinary  physical activity  does not cause undue fatigue, 
dyspnea, or palpitation
NYHA Class II: Slight limitation of phy sical activity  -comfortable at rest, ordinary  
physical activity  results in fatigue, palpitation, dyspnea, or angina
NYHA Class III: Marked limitation of phy sical activity  
- comfortable at rest, less than 
ordinary  activity  will lead to sy mptoms
NYHA Class IV: Inability  to carry  on any  physical activity  without discomfort -
symptoms of congestive failure present even at rest; with any  physical activity , increased 
discomfort is experienced
For younger children less than 6 years old, the Investigator will determine the appropriate Ross 
class of heart failure. Classification criteria are as follows:
Ross Class I: No limitation or sy mptoms.
Ross Class II: No growth failure.  
Mild tachy pnea with feeds in infants and/or
Mild diaphoresis with feeds in infants and/or
Dyspnea on exertion in older children.
Ross Class III: Growth failure. Prolonged feeding time in infants.
Marked tach ypnea with exertion or with feeding.
Marked diaphoresis with exertion or with feeding.
Ross Class I V: Symptomatic at rest with the following sign/s ymptom(s):
Tach ypnea and/or
Retractions and/or
Grunting a nd/or
Diaphoresis.

Novartis                                                          Confidential                                                          Page 142
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
20 Appendix 8: Patient global i mpressio n of s everity (PGIS)
For patients 7 to < 18 years old :
How would y ou describe the severit y of your heart failure s ymptoms over the past 7 
days ? (None / Mild / Moderate / Severe / Very  Severe)
For parents /caregivers of patients < 5 years of age :
How would y ou describe the severit y of your child’s heart failure s ymptoms over the past 
7 days ?
(None / Mild / Moderate / Severe / Very Severe)
For patients 5 to < 7 years old :
Point to the one face th at best shows how y our heart problems have been over the past 7 
days ?

Novartis                                                          Confidential                                                          Page 143
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
 
 
 
 
21.1 Teen report (ages 13 - 18)

Novartis                                                          Confidential                                                          Page 144
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 145
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 146
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 147
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
21.3 Child r eport (ages 8 - 12)

Novartis                                                          Confidential                                                          Page 148
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 149
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 150
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 151
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
21.5 Young child r eport (ages 5 -7)

Novartis                                                          Confidential                                                          Page 152
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 153
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 154
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 155
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 156
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 157
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 158
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 159
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 160
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 161
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 162
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 163
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
22 Appendix 10: GFR by  age
Table 22-1 GFR by  age for initiation/up -titration and exclusion criteria
Age range* ≥30% mean GFR for 
age ( mL/min/1.73m2)**< 30% mean GFR for 
age ( mL/min/1.73m2)***
1 month to < 3 months ≥14 < 14
3 months to < 6 months ≥17 < 17
6 months to < 12 months ≥23 < 23
12 months to < 19 months (1 year, 7 
months) ≥31 < 31
19 months to < 18 years ≥38 < 38
* Age rounded to nearest whole number
** Initiation/up -titration criteria
*** Exclusion criteria
Source: ( Peters 1999 )

Novartis                                                          Confidential                                                          Page 164
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
 
 
 

Novartis                                                          Confidential                                                          Page 165
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Novartis                                                          Confidential                                                          Page 166
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Novartis                                                          Confidential                                                          Page 167
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
 
 
 
 
 
     
 

Novartis                                                          Confidential                                                          Page 168
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
 
 
 
   
 

Novartis                                                          Confidential                                                          Page 169
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9

Novartis                                                          Confidential                                                          Page 170
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
25 Appendix 13: Safet y Monitoring for Age Group 3 patients 
This Appendix applies only to Part 2 Age Group 3 patients (i.e. patients who are 1 month to <1 
year old at randomization) and provides Safety  Monitoring requirements for the initial up-
titration portion of the study  for Part 2 Age Group 3 patients
.
25.1 Safet y Monitoring for A ge Group 3 patients:
Starting with the first dose of study  medication, vital signs must be checked for up to 4 hours 
after the initial dose at each study  drug dose level (i.e. dose levels 1x through 4x, as applicable). 
(Note: This does not apply  for up-titrations following study drug interruptions or down -
titrations
,up to the prior achieved maximal dose level.) Patients are to remain in the study  site 
clinic for this 4-hour post-dose Vital Sign monitoring period. Vital signs (i.e. blood pressure 
and heart rate) are to be measu red pre-dose (time 0), and post-dose at 0.5, 1, 2, 
3 and 4 hours.
These data are to be recorded on the CRFs as well as in the source documentation.
The Investigator is to follow up with the parents of the Part 2 Group 3 patient by phone, 3 days 
(+/- 1 day)after the initial dose of the study  medication at each dose level, checking for 
symptoms of hypotension. This does not apply  for up-titrations following study  drug 
interruptions or down -titrations .up to the prior achieved maximal dose level .
Examples of signs and/or symptoms of hypotension in infants: 
•Not feeding or eating as they  usually  do
•Not breast -feeding or drinking milk from a bottle (as it applies) as they usually 
do
•Acting more fuss y or tired than usual
•More difficult than usual to arouse from a nap or sleep
•Breathing faster than normal 
•Unusually  cold arms, legs, hands and/or feet: change from how they usuall y are
•Change in appearance of skin: pale or mottled 
skin (spotted, blotchy , varicolored 
skin)
•Decrease in amount of urine made; producing very little urine or not at all
If any signs and/or symptoms of hypotension are reported by the parents/guardians, the 
parents/guardians should be instructed to have their child seen by  their local provider or at the 
study  site as quickl y as possible, so their vital signs can be assessed.

Novartis                                                          Confidential                                                          Page 171
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
26 Appendix 14: Up-titration dosing instructions for patients in 
Age Group 3 (1 month to <1 y ear at randomization) who turn 
1 year old during Part 2
This Appendix applies only to Part 2 Age Group 3 patients (i.e. patients wh o are 1 month to <1 
year old at randomization) and provides Up-titration instructions for patients randomized into 
Age Group 3. who turn 1 year old during Part 2 of the stud y.
26.1 Up-titration instructions for Age Group 3 patients who turn one 
year old during Part 2
Randomized, ongoing, Part 2 Age Group 3 patients who are safel y tolerating Age Group 3 Dose 
Level 4x(i.e. LCZ696/Placebo, 2.3mg/kg bid / Enalapril/Placebo 0.1 5mg/kg bid) for at least 
2 weeks , and who turn 1 year old during the study ,may be up -ti
trated, if it is the patient’s best 
interest to be up-titrated based on the medical judgement of the investigator. Under these 
circumstances, the patient may be further up
-titrated to Age Group 3 Dose Level 5x(i.e. 
LCZ696/Placebo, 3.1 mg/kg bid / Enalapril/Placebo 0.2 mg/kg bid) .
See Table 26-1 for dose level up-titration information for Age Group 3 patients who have turned 
1 year old during Part 2 of the study .
Table 26
-1 Part 2 (Efficacy ): Study drug dose level for double -blind enalapril and 
LCZ696 for Age Group 3 patients who tu rn 1 year old during the study
Dose levels for pediatric formulation Enalapril dose ^ LCZ696 dose ^
Dose Level 5xfor Age Group 3 patient s who turn 
1year old during the study0.2 mg/kg bid. 3.1 mg/kg bid.
^Note: The maximum LCZ696 dose and enalap ril dose allowed for patients who turn 1 year old during 
the Part 2 study ,is Dose L evel 5x (3.1 mg/kg bid and 0.2 mg/kg bid ,respectiv ely).
A subsequent planned study  visit or an unscheduled visit (see Table 6-2Part 2 Assessment 
Schedule) can be utilized for theadditional up-titration visit for the Age Group 3 patients that 
turn 1 year old durin g the study. The timing of the up-titration visit, where applicable, will var y 
from patient to patient.
Abbreviated safety labs: For Age Group 3 patients who are ≥1 year old and who are further up-
titrated to Dose L evel 5x
,at a scheduled visit or at an unscheduled visit, abbreviated safet y labs 
are to be done at this up -titration visit for Dose L evel 5x .
All safet y requirements for dose up-titration (and down titration), that are outlined in the
protocol in Section 5.5.5, Permitted dose adjustments and interruptions of study  treatment ,
apply  to the above described dose up-titration for patients that have turned 1 year old during 
part 2.

Novartis                                                          Confidential                                                          Page 172
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
27 Appendix 15: Urgent safety  measure (USM) 
This appendix describes the USM implemented in consideration of a quality event affecting the 
active comparator used in this study , effective 26 October 2021. An out of specification (OOS) 
result for an unspecified degradation product (observed: 0.3% vs. requirement: ≤ 0.2%) for both 
enalapril maleate 5 mg and 10 mg, packaged in alu-alu blisters by Novartis for this clinical trial, 
was observed in representative batches during supportive stability  testing. As a result, the 
assigned shelf -life of 24 months of enalapril 5 mg and 10 mg in alu-alu blisters can no longer 
be supported for the current batches in use in the study  and only a shelf-life of 12 months and 
18 months, respectively, is supported. This finding impac ts the batches currentl y in use in the 
trial of enalapril 5 mg and 10 mg as well as one batch of enalapril 5 mg and 10 mg used earlier 
in the study . The current clinical trial suppl y of enalapril 5 mg is bey ond the revised supported 
12-month shelf -life (expiry date was 31 March 2021). The current suppl y of enalapril 10 mg 
has a revised supported expiry  date of 18 months lasting up to 31 October 2021. The finding 
only relates to enalapril 5 mg and 10 mg in alu -alu blister packs. The placebo of enalapril 5 mg
and 10 mg ,
as well as all LCZ696/placebo and Enalapril/placebo 2.5 mg, are not impacted.
What follows outlines the safet y measures that have been implemented for the 31 patients who 
were ongoing and receiving stud y medication at the time the USM was initi ated.
The USM include s the following:
Investigational medicinal product (IMP) dispensation was blocked in the IRT system by 
Novartis
All patients who were receiving study  medication at the time the USM was initiated, 
had to discontinue study  treatment by  31October 2021 and change to local standard of 
care, respecting any required washout periods. These patients were to attend an 
unscheduled visit at the site by 31October 2021, or as soon as possible thereafter, for 
safet y and efficacy assessments (see Section 27.1 for additional details).
It was requested for all patients to return IMP in their possession by  31October 2021.
All IMP is to be removed from the sites for destruction per local practices.
27.1 Instructions for patients impacted by  the USM 
For patients who discontinued study  treatment for other reasons before the USM was 
implemented but were being followed in the study at the time the USM was initiated ,
instructions are as follows
:
oPatients to remain off study  medication permanently  and continue to be treated with 
SOC
oPatients t o be followed to their originally  planned EOS visit (week 52 ±2 weeks).
For patients who were receiving study  medication, with an EOS visit originally  planned for a 
date up to and including 14November 2021, instructions are as follows :
oPatients t
ohave anEOS visit by31October 2021 enabling visit tobe within 2weeks 
of their originally  planned E OS visit. 

Novartis                                                          Confidential                                                          Page 173
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
For patients who were receiving study  medication with an EOS visit originally  planned for after
14November 2021, instructions are as follows : 
oPatients tocome to the study  site for an unscheduled visit (or regularl y scheduled 
visit)by31October 2021 and perform the following : 
Discontinue study  medication
Transition to local SOC , respecting the required washout period
Complete the following additional assessments with all data maintained 
in source documentation (see Table 6-2Part2 Assessment schedule, 
visits UNS/TD and UNS and footnotes 18 and 19 for details):
 
•Unscheduled PK
•Unscheduled abbreviated labs 
•NYHA/ROSS class evaluation 
•PGIS patients or parent/caregiver 
 
 
oThese patients should continue to be followed in the trial until the planned EOS
visit ( week 52 ± 2 weeks).
oFull E
OS visit assessments (with the exception of PK) are to be conducted atthe 
planned E OS visit (week 52 ± 2 weeks)
27.2 USM implications regarding data collection and stud y results 
As described in the sections above, d ue to unresolvable technical reasons regarding study  drug 
supply , all patients on study  medication at the initiation of the USM will have to discontinue
study  drug treatment by 31October 2021, which is up to twomonths prior to the scheduled study  
endfor the last patient . This early  study drug discontinuation is not expected to compromise the 
scientific integrity  of the study due to the limited number of patients i mpacted . 
The early stud y drug discontinuation affects a maximum of 31 patients, who were on
-treatment 
as of 26October 2021, with a current follow - up between 297 days to 395 days. The total on-
treatment follow -up time lost is expected to be <1%.
Regarding CRF documentation, the reason for the treatment discontinuation is to be reported
on the End of Treatment (EOT) 
CRF as ‘Technical problems’. If a patient withdraws from study  
participation after the study  drug discontinuation due to the USM and before they have 
completed 52 weeks (± 2 weeks) of follow up, the reason for the study  phase discontinuation 
on the EOS CRF, is also be documented as ‘ Technical problems’. 
Every  effort is to be made to keep patients in the study  until the planned 52-week follow up and 
to ensure study  integrit y. While the current statistical analysis plan (SAP) includes off-treatment 

Novartis                                                          Confidential                                                          Page 174
Amended Clinical Trial Protocol Version 07 (Clean) Protocol No. CLCZ696B231 9
data after treatment discontinuations in the primary  analysis (reflecting a real-world setting), 
this does not seem appropriate for the s tudy drug discontinuations in the context of this USM. 
The unforeseen intercurrent events of the USM leading to study  treatment discontinuations are 
not related to disease progression, are not related to the assigned study  treatment and donot 
reflect a real-world setting. The exposure to the study  treatment and study  follow -up are 
reasonabl y long. Therefore , an on -treatment approach is considered to be more appropriate for 
the handling of USM -impacted patients in the primary  analysis, utilizing the relevan t 
components of the global rank endpoint including Category  1  and 2 status at the time of 
treatment discontinuation. The full data, including the portion off -treatment from the impacted 
patients, will be included in a sensitivity  anal ysis. The SAP will be amended to reflect this .
